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Summary 
 
Acute myeloid leukaemia (AML) affects about 3000 people in the UK each year.  
Chemotherapy leads to complete remission in most patients but, up to 70% relapse. 
The success of allogeneic stem cell transplant (SCT) demonstrates that donor T cells 
can eliminate residual tumour through a graft-versus-leukaemia effect however, 
SCT is only viable in a minority of patients. Responses seen with alternative 
approaches, such as adoptive immunotherapy with tumour specific T cells or 
inducing T cells by vaccination, have been disappointing, highlighting a clear need 
for new immunotherapeutic approaches. Immune responses against leukaemia are 
inhibited by a range of suppressive mechanisms. Identification of novel therapeutic 
targets capable of unleashing natural and effective immune responses is critical.  
The complement system is an enzyme cascade with diverse effector functions 
instituted by both the innate and adaptive immune systems. Recent evidence 
suggests that complement promotes the progression of malignancy. The role of 
complement in AML is largely unexplored but the limited data available implies that 
complement could have a critical role in both the initiation and progression of AML.   
 
Sub-lytic complement protects cells against further attack by both lytic doses of 
complement and other pore-formers including perforin, the cytolytic protein used 
by both NK and CD8+ T cells. This phenomenon termed complement-induced 
protection (CIP). Thus cancer cells exposed to sub-lytic complement may be 
protected from lysis by NK and CD8+ T cells with significant consequences for 
immune escape. When this hypothesis was tested using an in vitro model of NK cell 
killing, no evidence of protection against NK cell killing was observed despite clear 
CIP against further complement attack. Despite a strongly protective phenotype, 
subsequent microarray analysis revealed no genetic signature for CIP indicating that 
mechanisms underpinning CIP require no changes in gene expression.  
 
A mouse model was then used to test the hypothesis that complement promotes 
progression of AML. The use of both genetically modified mice lacking various 
complement components and complement inhibitors in wild-type animals, revealed 
that complement promotes AML progression. CIP was a potential mechanism by 
which tumours might escape immune elimination in vivo, however, this was only a 
small component of the almost complete protection observed in C3 deficient mice. 
Putative mechanisms include inhibition of CD8+ T cells and promoting AML seeding.  
 
Should complement prove to have a key role in human AML, available complement 
therapeutics could progress rapidly into human studies. These might not only have 
an independent role in improving spontaneous immune responses, but might also 
impact on all available or novel immune mediated therapies for AML.     
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Chapter 1- Introduction 
 
1.1 The Immune System and Cancer 
 
1.1.1 The Development of Cancer 
 
The transformation of normal cells into a cancerous growth involves both genetic 
mutations and epigenetic modifications which lead to the sequential acquisition of 
biological capabilities ultimately resulting in malignancy. In their seminal review 
Hannahan and Weinberg described six ‘Hallmarks of Cancer’ which malignant cells 
need to acquire during their multi-step development (Hanahan and Weinberg 
2000): 
 
- Sustaining proliferative signalling 
- Evading growth suppressors 
- Resisting cell death 
- Enabling replicative immortality 
- Inducing angiogenesis 
- Activating invasion and metastasis 
 
A recent review of these ‘Hallmarks’ focused on the developing understanding that 
tumours are not isolated masses of proliferating cancer cells but evolve within a 
microenvironment which plays a critical role in tumorigenesis (Hanahan and 
Weinberg 2011). It was proposed that evading immune destruction should be 
included as a ‘Hallmark of Cancer’ (Hanahan and Weinberg 2011). The review also 
acknowledged two processes underlying the development of biological capabilities 
i) genomic instability which expedites their acquisition and ii) inflammation which 
fosters the development of multiple hallmark features (Hanahan and Weinberg 
2011). Thus the ‘Hallmarks of Cancer’ now recognize the dual function of the 
immune system in both protecting against and promoting cancer development.  
 
1.1.2 The Dual Role of the Immune System in Cancer 
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Rudolf Virchow first noted the presence leukocytes in neoplastic tissue in 1863 and 
went on suggest a link between inflammation and cancer (Balkwill and Mantovani 
2001). Despite this early insight, it is only in the last 20 to 30 years that our 
understanding of the role of inflammation in cancer has reached a level where it has 
begun to have an impact on the prevention and treatment of cancer (Balkwill and 
Mantovani 2001). Inflammation both promotes initial malignant transformation and 
subsequent progression of cancer. During chronic inflammation a range of factors 
are produced which promote malignant growth. These include growth factors, 
which promote proliferation, survival factors which inhibit cell death, proangiogenic 
factors which enhance neovascularisation and extracellular matrix-modifying 
enzymes which facilitate invasion (reviewed in (Grivennikov, Greten et al. 2010). 
Malignant cells elicit a chronic, lingering immune response that promotes the 
neoplastic process whilst failing to trigger appropriate danger signals that would 
result in immune clearance (Balkwill and Mantovani 2001; Coussens and Werb 
2002; Bhardwaj 2007; Lin and Karin 2007).  
 
Pathogens trigger danger signals which lead to the clearance of infected cells. In a 
similar way, acute and brisk inflammation can induce spontaneous or treatment-
induced tumour regression (reviewed in (Schreiber, Old et al. 2011)). William Coley 
first recognized the ability of infection to trigger tumour regression over 100 years 
ago, this led him to develop the bacterial based ‘Coley’s toxin’ which met with some 
sporadic success. A refined form of ‘Coley’s toxin’, was still in use until the advent of 
cytotoxic chemotherapy in the 1940s (Nauts and McLaren 1990).  
 
1.1.3 Cancer Immunosurveillance 
 
Studies of both carcinogen-induced and spontaneous tumours in cancer-prone mice 
demonstrate that immune effector cells can eliminate malignant cells. Tumours 
develop more rapidly and occur more frequently in mice lacking a variety of 
immune cells/ functions (Smyth, Dunn et al. 2006). In humans, data derived from 
patients undergoing transplant who receive immunosuppressants in order to 
prevent graft rejection have a 3-fold increased risk of cancer (Vajdic and van 
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Leeuwen 2009) with similar findings in patients with HIV/AIDS supporting this being 
due to immune deficiency as opposed to any confounding risk factor (Grulich, van 
Leeuwen et al. 2007). Many of the cancers observed at higher frequencies in 
immunocompromised patients, such as Kaposi’s sarcoma and non-Hodgkin’s 
lymphoma, have recognised, usually viral, infectious causes. This raises the 
possibility that the immune system is only capable of controlling cancers via an anti-
viral immune response. Whilst other cancers which have no recognised infectious 
aetiology are also observed at increased frequencies in immunocompromised 
patients, incidence of all cancer is not increased to a similar degree across the board 
(Vajdic and van Leeuwen 2009). Whilst this might reflect variability in 
immunogenicity between different types of malignancy, it could arguably be the 
result of thus far unrecognised infectious stimuli. There are therefore still some 
doubts about the validity of the immunosurveilance hypothesis. Even if you accept 
that the immune system offers a degree of protection against the development of 
cancer (Dunn, Bruce et al. 2002; Swann and Smyth 2007), the existence of cancer as 
an identifiable disease, in patients with apparently intact immune systems, 
demonstrates that tumours are able to overcome this defence.  
 
1.1.4 Cancer Immunoediting 
 
The cancer immunoediting hypothesis describes three distinct phases, elimination, 
equilibrium and escape (Dunn, Bruce et al. 2002). Whilst immune effectors might be 
able to eliminate malignant cells, if this process is incomplete a period of 
equilibrium can occur where disease progression is balanced by the hosts immune 
response, the inherent genetic instability of malignant cells may result in a mutation 
which edits the cancers phenotype in a way that allows it to evolve and escape from 
immune control (Dunn, Old et al. 2004).  Escape can be via a range of mechanisms 
such as the down-regulation of immunogenic antigens (Ags), the release of 
immunosuppressive cytokines or expression of anti-apoptotic molecules (reviewed 
in (Khong and Restifo 2002)). The intimate and dynamic interaction between 
emerging tumours and the host stroma means malignancy evolves under the 
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constraints of whatever selective pressure is imposed on it by the environment 
(Loveland and Cebon 2008).    
 
Experimental systems used to demonstrate the role of immunoediting in cancer 
progression have identified both Natural Killer (NK) cells and T cells as being 
important in both controlling and sculpting the phenotype of developing tumours.  
 
1.1.5 Natural Killer Cells 
 
NK cells are lymphocytes originally identified by their ability to lyse tumour cells 
without prior sensitization (Herberman, Nunn et al. 1975; Kiessling, Klein et al. 
1975). Although named for this natural ability to kill cells in vitro, their activity is 
also increased by exposure to a range of cytokines. As opposed to B and T cells, 
which have Ag-specific receptors, NK cells target tumour cells via a range of 
activating and inhibitory cell surface receptors. Although NK cells have long been 
considered an important effector arm of the innate immune response, more recent 
data has shown that some NK subsets can be long-lived and even exhibit recall 
responses (Foley, Cooley et al. 2012; Foley, Cooley et al. 2012).  
 
NK cells mediate cytotoxicity via several mechanisms, the most studied of which is 
degranulation.  NK cells have large amounts of perforin and granzyme stored in 
cytotoxic granules which means that, when activated, they are able to rapidly lyse 
target cells (Bryceson, March et al. 2006).  
 
NK cell degranulation can occur following the interaction of activating cell surface 
receptors, such as NKG2D, DNAM1 and 2B4, and natural cytotoxicity receptors, 
NKp30, NKp44 and NKp46, which are counterbalanced against signals from 
inhibitory receptors all of which bind to major histocompatibility complex (MHC) 
class 1 molecules on target cells (Bryceson and Long 2008). Degranulation can also 
be triggered following NK cell activation by Abs bound to target cells. This is 
mediated through cell surface Fc receptors such as FcγRIIIA and/ or FcγIIC expressed 
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on NK cells, binding to the Fc portion of immunoglobulin on the surface of target 
cells (Lanier, Ruitenberg et al. 1988; Morel, Ernst et al. 1999).  
 
In addition to degranulation, NK cell activation can result in target cell lysis by 
triggering death receptor pathways such as TNF-related apoptosis-inducing ligand 
(TRAIL) and Fas which induce apoptosis via caspase activation. 
 
NK cells are also a major source of a range of cytokines such as Interferon (IFN)-γ, 
Tumour necrosis factor (TNF)-α and Granulocyte macrophage colony-stimulating 
factor (GM-CSF) (Fauriat, Long et al. 2010).  The mRNA for these cytokines is present 
in NK cells and can be readily transcribed upon NK cell activation (Bryceson, March 
et al. 2006). Cytokine release leads to the recruitment and activation of other 
immune cells resulting in increased antigen presentation and an improved adaptive 
immune response (Srivastava, Lee et al. 2013).   
 
NK cells are able to control tumour development in experimental mice (Kim, Iizuka 
et al. 2000). Tumour infiltration by NK cells is also associated with a favourable 
prognosis in several human cancers (Coca, Perez-Piqueras et al. 1997). There is 
however evidence that tumours evolve to escape elimination by NK cells (Groh, Wu 
et al. 2002) with some having been shown to reversibly down-regulate the activity 
of NK cells (Fauriat, Just-Landi et al. 2007).  
1.1.6 Adaptive Immune Response 
 
The adaptive immune system consists of both B and T cells and is able to recognize 
Ags and generate both effector responses, capable of eliminating target cells, and 
specific memory responses that protect against future exposure to the same 
pathogens. 
1.1.6.1 T cells 
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Many subsets of T cells exist which have distinct functions in both promoting and 
regulating this immune response. T cells which express the co-receptor CD8 (CD8+ T 
cells) kill cells recognised to be infected or transformed via the production of the 
cytolytic protein perforin which forms pores through which inducers of cell death, 
such as granzymes, are introduced into the target cell.  
 
T cells which express CD4 (CD4+ T cells) can differentiate to either help this cytotoxic 
response by producing interleukin (IL)-2 and IFN-γ or dampen down the response 
via the production of IL-10 and transforming growth factor-beta (TGF-β).  
 
Whilst Ag-specific lymphocytes are thought to play an important role in tumour 
immune surveillance (Galon, Costes et al. 2006), tumour-infiltrating lymphocytes 
(TILs) are often hypo-functional with T cells specific for tumour Ag co-existing with 
the tumour rather than eliminating it (reviewed in (Rosenberg 2004)). Tumour 
specific cytotoxic T lymphocytes (CTLs) can be activated and expanded however, the 
full effector function seen when they are exposed to tumour Ag in vitro is 
progressively lost in vivo (Rosenberg 2004). In a similar way, tumour vaccines are 
able to induce T cells at high frequencies yet these fail to achieve significant tumour 
elimination (Rosenberg 2004).  
1.1.6.2 Antigen Presenting Cells 
 
The efficacy of the immune response depends on the ability of professional antigen 
presenting cells (APCs) such as dendritic cells (DCs) to process Ags and present them 
to CD4+ and CD8+ T cells. There has been a significant drive to use the antigen-
presenting properties of DCs in order to elicit potent tumour antigen-specific T-cell-
driven immune responses (Anguille, Smits et al. 2014; Datta, Terhune et al. 2014). It 
is believed that  DC therapy has the advantage over more passive immunotherapy 
strategies in that it aims to ‘train’  the hosts immune system and hence generate an 
immunological memory for the cancer (Rescigno, Avogadri et al. 2007; Melero, 
Gaudernack et al. 2014).  
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1.1.6.3 B cells 
 
Upon antigen binding to receptor, B cells are triggered to proliferate and 
differentiate into their effector form, plasma cells. Plasma cells produce and secrete 
antigen specific antibodies which are essentially soluble forms of the original 
surface receptor (Murphy, Travers et al.). Whilst both naturally occurring anticancer 
immune responses and many forms of cancer immunotherapy depend on the 
activity of T cells, the evidence is scarce for an anticancer role for antibody 
producing B cells (Hannani, Locher et al. 2014). However a recent paper has 
demonstrated a role for B cells in allogeneic tumour rejection by triggering the 
crucial first step in the cellular immune response (Carmi, Spitzer et al. 2015). This 
response was initiated by naturally occurring Abs binding to tumour Ags and 
interacting with DCs leading to engulfment and antigen presentation which 
triggered T cell mediated tumour clearance (Carmi, Spitzer et al. 2015).  
 
1.1.7 Immunosuppressive mechanisms 
 
The adaptive immune system mounts robust responses to non-self Ags however, it 
also responds to self-Ags which can result in the development of autoimmune 
disease. The immune system has developed several mechanisms to avoid 
recognition of self-Ags including clonal deletion during thymic selection and 
functional inactivation of self-reactive lymphocytes. Despite this, autoreactive T 
cells are a common occurrence, even in the absence of autoimmune conditions, but 
are kept in check by peripheral tolerance mechanisms. These are mediated by a 
range of immunosuppressive cells derived from both the CD4+ T cell and myeloid 
cell populations which play an important role in down-modulating excessive or 
inappropriate immune responses, thereby preventing immunopathology and 
autoimmune disease. Many immune responses to tumour are mediated via self-Ags 
and the success of these responses are hampered by tumours utilising a range of 
immune tolerance mechanisms in order to  avoid immune mediated clearance 
(Swann and Smyth 2007).   
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1.1.7.1 Regulatory T cells 
 
Regulatory T cells (Tregs) are suppressive cells which have a key role in maintaining 
immune homeostasis and immune tolerance and are also critical to limiting 
excessive and harmful immune responses (Sakaguchi, Yamaguchi et al. 2008).  Tregs 
act in a range of locations, in multiple disease situations in order to suppress or 
modulate the function of a wide range of cells (Tang and Bluestone 2008). The 
suppressive capacity of Tregs utilises multiple contact-dependent and contact-
independent mechanisms (Shevach 2006; Vignali 2008).   
 
Tregs account for approximately 10% of peripheral T cells and can be produced in 
the thymus as a functionally mature suppressive T cell subpopulation or induced in 
the periphery from naive T cells following Ag exposure (Yamaguchi, Wing et al. 
2011). The nomenclature for Tregs has recently changed with tTregs denoting 
thymus derived Tregs and pTregs implying peripherally-induced Tregs (Abbas, 
Benoist et al. 2013). Most tTregs express the forkhead/ winged helix transcription 
factor, Foxp3, which is critical to both their development and their functional 
capacity (Fontenot, Gavin et al. 2003; Hori, Nomura et al. 2003). FoxP3 whilst 
reliable in mice, is less so in humans being both absent from some Treg sub-sets and 
present on non-Tregs (deLeeuw, Kost et al. 2012; Devaud, Darcy et al. 2014). Most 
FoxP3+CD4+ Tregs express CD25 (IL-2 receptor α-chain (IL-2Rα)) at a high level 
however, CD25 is also expressed on activated conventional T cells. The phenotype 
of human Tregs has recently undergone a collaborative review (Santegoets, 
Dijkgraaf et al. 2015). There are however significant differences in Treg phenotype 
between both healthy controls and cancer patients and between circulating Tregs 
and those present within the tumour microenvironment (Bergmann, Strauss et al. 
2008; Whiteside, Schuler et al. 2012; Adeegbe and Nishikawa 2013).   
 
Tregs have positive roles in maintaining peripheral tolerance, preventing 
autoimmune disease and limiting chronic inflammatory disease (Vignali 2008). They 
also appear to play an important, though perhaps controversial, role in cancer. 
Studies in most mouse tumour models and many human cancers have revealed an 
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increased frequency and enhanced suppressive capacity of Tregs (Wolf, Wolf et al. 
2003; Strauss, Bergmann et al. 2007; Mougiakakos, Choudhury et al. 2010). 
Conflicting studies have demonstrated the accumulation of Tregs to be associated 
with both worse (Curiel, Coukos et al. 2004; Wolf, Wolf et al. 2005; Deng, Zhang et 
al. 2010) and improved prognosis (Badoual, Hans et al. 2006; Carreras, Lopez-
Guillermo et al. 2006; Tzankov, Meier et al. 2008; Farinha, Al-Tourah et al. 2010; 
Droeser, Zlobec et al. 2012). Despite this apparently contradictory evidence, there 
remains clear experimental and clinical evidence to support a role for Tregs in 
suppressing anti-tumour immune responses and thus avoiding immune clearance 
(Whiteside 2012).  
 
The release of chemokines in the tumour microenvironment results in Treg 
recruitment to tumour sites (Ondondo, Jones et al. 2013). Whilst Tregs appear to 
have a role in promoting immune escape via the suppression of immune effector 
cells, they might also have a critical role in limiting tumour progression associated 
with inflammation. Tregs alter their phenotype depending on the concomitant 
inflammatory response (Yamaguchi, Wing et al. 2011). Tregs might thus limit 
tumour development in cancers associated with increased inflammatory infiltrates 
by controlling chronic inflammation (Rech, Mick et al. 2010; Ladoire, Martin et al. 
2011) resulting in a better prognosis (Salama, Phillips et al. 2009; Frey, Droeser et al. 
2010; Ladoire, Martin et al. 2011; Droeser, Zlobec et al. 2012). The diverse 
phenotype and functional role of Tregs could thus be dependent on both the 
tumour type and the ‘immune signature’ it provokes. Therapies which target 
mechanisms underlying Tregs diverse roles might thus prove more effective than 
therapy aimed at Treg ablation.  
 
1.1.7.2 Myeloid-derived suppressor cells  
 
Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells that have a 
remarkable ability to suppress T-cell responses (Gabrilovich and Nagaraj 2009). They 
are a heterogenous population of cells which regulate immune responses in both 
healthy individuals and in the context of disease. Although first described in the 
24 
 
setting of cancer (Buessow, Paul et al. 1984; Young, Newby et al. 1987), MDSCs also 
expand during inflammation and infection (Gabrilovich and Nagaraj 2009).  
 
MDSCs are produced in increased numbers by the bone marrow (BM) and spleen of 
tumour-bearing mice and suppress anti-tumour responses (Gabrilovich and Nagaraj 
2009). Increased levels are also found in the peripheral blood of patients with 
cancer (Almand, Clark et al. 2001). MDSCs suppress CD8+ T cell activity and are one 
of the mechanisms utilised by tumours to evade immune control, they have also 
been shown to limit the efficacy of cancer immunotherapy (Serafini, De Santo et al. 
2004; Kusmartsev, Nagaraj et al. 2005; Serafini, Borrello et al. 2006; Sica and Bronte 
2007; Gabrilovich and Nagaraj 2009). Their activated state is characterized by the 
production of reactive oxygen and nitrogen species (RONS) and arginase 
(Gabrilovich and Nagaraj 2009). In addition to suppressing adaptive immune 
responses they can also act on innate immune responses by modulating cytokine 
production by macrophages (Sinha, Clements et al. 2007). In addition, MDSCs have 
a range of non-immunological functions including promoting tumour angiogenesis, 
invasion and metastasis (reviewed in (Murdoch, Muthana et al. 2008)).   
 
1.2 Acute Myeloid Leukaemia 
 
1.2.1 Incidence, Presentation and Classification 
 
Acute myeloid leukaemia  (AML) is a haematological malignancy which affects the 
myeloid compartment of the haematopoietic system resulting in an excess of 
immature cells, or ‘blasts’, which infiltrate the BM resulting in deficiencies of other 
blood components. AML is the commonest acute leukaemia in adults with an 
overall incidence of approximately 8 cases per 100,000 population (Statistics 2013). 
Incidence increases with age meaning that the 1-2 cases per 100,000 adults aged 
between 20 and 35 years rises to approximately 25 cases per 100,000 adults over 70 
years of age, resulting in a median age of onset of 69 years (Statistics 2013).  
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Patients generally present with symptoms resulting from cytopenias such as fatigue, 
infection or bleeding. An abnormal full blood count results in the examination of a 
blood film and the patient undergoing a BM examination in order to confirm the 
diagnosis. A range of additional investigations such as immunophenotyping, 
cytogenetics and molecular genetics allow full characterisation of the disease both 
aiding diagnosis and allowing patients to be designated a risk category.  
 
The World Health Organisation (WHO) classification incorporates clinical features, 
morphology, immunophenotyping, cytogenetics and molecular genetics in order to 
divides cases of AML into prognostically valid groups (Swerdlow 2008). Good risk 
patients are those found to have balanced translocation/inversion such as t(8:21) or 
inv(16) or normal cytogenetics with a mutated nucleoplasmin 1 (NPM1) gene (but 
lacking a Flt3-ITD mutation). The adverse risk groups includes those with t(9;11), 
inv(3) or complex cytogenetics as well as secondary AML (therapy related or post 
myelodysplasia) (Swerdlow 2008).  
 
A large proportion of patients fall into an intermediate risk group and their outcome 
is hardest to predict. Being able to risk stratify these patients is an important area of 
investigation as it might result in major implications to their management by 
identifying those that are likely to do well from conventional therapy and those who 
require a more aggressive course of action. There has been significant progress in 
this area with the discovery of molecular genetic lesions such as FLT3-ITD, NPM1 
and CEBPA being found to significantly affect outcome and therefore being included 
in the WHO classification (Swerdlow 2008).  
 
1.2.2 Management of AML 
 
Despite continuous, large, ongoing clinical trials, the current optimal treatment for 
AML has not altered substantially over the last 40 years and still involves intensive 
induction combination chemotherapy followed by further consolidation therapy 
(Yates, Wallace et al. 1973). Induction chemotherapy results in up to 85% of 
patients under 60 years of age achieving a complete remission falling to 
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approximately 50% in patients over 60 years of age. Consolidation therapy with 
either further chemotherapy or an allogeneic haematopoietic stem cell transplant 
(HSCT), leads to an overall survival (OS) of 40% in patients under 60 years of age 
falling to less than 15% in those aged over 60.  
 
Whilst survival rates in patients over 65 years of age have remained unchanged, 
outcome for patients aged between 25-64 years has improved from around 30% to 
nearly 40% over the last 10 years (2015). This is likely due to involvement in clinical 
trials, the ability to identify patients who will benefit from an intensive approach 
(and those who will not) and improved outcomes from allogeneic transplantation. It 
is also the case that the aim of therapy can be different in older patients. The best 
approach in this patients group might involve less toxic treatment that, whilst not 
curing their leukaemia, may prolong survival and achieve a better quality of life, but 
which may not impact on 5-year survival rates. There is therefore a need for the 
development of alternative, more effective, biologically inspired and better 
tolerated treatment strategies (Rashidi and DiPersio 2016).    
 
Therapy in AML is a dynamic process with patients who fail to achieve an adequate 
response being considered for a more intensive approach. The ability to measure 
minimal residual disease (MRD) in AML is an evolving field. However, whilst the 
value of MRD monitoring in acute promyelocytic leukaemia (APL) is proven and has 
thus been accepted as standard practise (Grimwade, Jovanovic et al. 2014), its value 
has yet to be determined for AML. Advances in the ability to detect leukaemia-
associated aberrant phenotypes by multiparameter flow cytometry or leukaemia-
specific genetic target by quantitative reverse-transcriptase-polymerase-chain-
reaction (RT-PCR) has made the detection of MRD possible in the majority of cases 
of AML. Whilst this is highly predictive of outcome, conclusive evidence of the value 
of MRD in risk-stratifying treatment in AML is not yet available (Kayser, Schlenk et 
al. 2015). The current NCRI AML 17 trial aims to determine the impact of MRD 
monitoring on survival, quality of life and utilisation of resources. The ability of MRD 
detection to improve outcomes is largely determined by the availability of 
alternative treatment options for patients found to be MRD positive. Whilst further 
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intensive chemotherapy or standard allogeneic HSCT remain the only viable 
treatment options, MRD is perhaps unlikely to live up to its full potential. 
 
Alternative therapies are essential in order to capitalise on these ‘early warning’ 
tests and although targeted therapy directed at underlying genetic or epigenetic 
aberration is an active area of research, it is yet to reap any large benefits. Whilst 
targeting a mutation might eliminate that clone or sub-clone, the genetic 
heterogeneity that exists both within an individual patient and between cases of 
AML limits this approach (Rashidi and DiPersio 2016). Other research aims to 
circumvent the heterogeneity of AML by targeting AML-niche interactions which 
have a key role in development, progression, chemotherapy resistance and relapse 
in AML (Rashidi and DiPersio 2016). A second key area of research which could have 
a major impact on all patients and all disease subgroups is the development of 
alternative immunotherapies for AML. 
 
AML is known to affect normal immune function and allogeneic HSCT is a successful 
and widely used form of immunotherapy however, its high level of toxicity has led 
to a quest for alternative immune based therapies which offer the activity of HSCT 
with less toxicity. The use of cytokines, monoclonal antibodies, vaccines and cell 
therapy are potentially attractive options especially since levels of resistant or 
recurrent disease can now be identified in most patients before a frank relapse 
occurs. 
 
1.2.2.1 Allogeneic haematopoeitic stem cell transplantation 
 
AML is the commonest indication for adults undergoing an allogeneic HSCT, where 
practically all patients, except those in a good risk category, should be offered a 
transplant in their first complete remission (Sureda, Bader et al. 2015). There is 
evidence that in older patients, age may be a more important prognostic factor 
than standard cytogenetic risk so it is possible that even some cytogenetically ‘good 
risk’ older patients might benefit from an upfront HSCT (Schoch, Kern et al. 2004).  
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Standard allogeneic HSCT offers disease control via both a highly intensive 
conditioning regimen and the immunological control offered by the graft-versus 
leukaemia effect (Gupta, Tallman et al. 2011).  Graft-versus leukaemia (GvL) is 
thought to result from the donor-derived T cells ability to recognise minor 
histocompatibility Ags expressed on host leukaemia cells (Weiden, Flournoy et al. 
1979; Baron, Maris et al. 2005). Even in patients with unfavourable cytogenetics 
who have an extremely poor prognosis, a GvL effect can lead to a long-term 
remission (Tallman, Dewald et al. 2007). HSCT is a high-risk procedure due to the 
toxicity of the induction regimen, the risks of immunosuppression and the potential 
to develop both acute and chronic graft-versus host disease. Due to this high level 
of toxicity, HSCT is reserved for patients who are unlikely to achieve a sustained 
remission with conventional chemotherapy. It is also traditionally only available for 
the young and the fit, which in a condition where over 60% of cases occur in 
patients over the age of 55 years, is a severe limitation (Statistics 2013).  
 
The three main limitations to transplantation are i) drug toxicity, ii) graft-versus host 
disease (GvHD) and iii) risk of relapse. These factors are inextricably linked, e.g. 
attempts to limit GvHD by T-cell depleting grafts leads to increased relapse rates- 
strengthening the case for a graft versus leukaemia (GvL) effect.  A highly ablative 
conditioning regimen might limit the risk of relapse but this will be at the risk of 
greater upfront toxicity.  
 
In recent years there has been a paradigm shift in the field of transplantation from 
heavy conditioning, aiming to eliminate residual disease whilst allowing 
engraftment, to a reduced intensity approach which relies on the therapeutic 
impact of the GvL effect. Non-myeloablative or reduced-intensity conditioning (RIC) 
regimens are now routine practise and have hugely extended the age at which an 
allogeneic HSCT is an option, with patients up to the age of 70 having been shown 
to benefit. In fact a large retrospective study concluded that age alone should no 
longer be seen as a contraindication to transplantation (McClune, Weisdorf et al. 
2010), an extremely important finding given the demographics of AML. Despite this 
huge increase in the average age of patients undergoing an allogeneic HSCT, the risk 
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of death has fallen steeply over recent years, with a greater than 50% reduction in 
non-relapse mortality reported over the same period (Gooley, Chien et al. 2010). As 
expected, the lower toxicity of this reduced conditioning is at the expense of an 
increased relapse risk however, most studies have concluded an overall benefit in 
selected patients (Russell, Kjeldsen et al. 2015).  
 
The incidence of relapse post RIC allograft is approximately 30%. Treatment of 
relapse includes removal of immunosuppression, chemotherapy and donor 
lymphocyte infusions resulting in approximately 30% of patients achieving a further 
complete remission, however 2yr survival post relapse is just 14% (Schmid, Labopin 
et al. 2012). RIC allografts are also not an option in patients with active disease, 
with studies showing 0% survival in this patient group (Shimoni, Hardan et al. 2006). 
Patients with residual disease only detectable by immunophenotyping also have a 
higher risk of relapse although cytogenetically detected MRD did not appear to have 
an impact (Ustun, Wiseman et al. 2013).     
 
Strategies to reduce relapse rates include post-transplant maintenance 
chemotherapy and the inclusion of targeted mutation inhibitors, immunotoxins or 
radioantibody therapy (Dohner, Weisdorf et al. 2015). Observations, such as the 
ability of CMV reactivation to induce anti-leukaemic activity (Elmaagacli, Steckel et 
al. 2011) and the ability of the donors’ killer-cell immunoglobulin-like receptor (KIR) 
phenotype to limit disease relapse (Cooley, Weisdorf et al. 2014) are being 
investigated to try and identify other mechanisms of improving outcome. The use of 
immunotherapy such as monoclonal antibodies, T-cell therapies or vaccination post-
transplant, in an attempt to augment the graft-versus leukaemia effect could also 
have a potential role. 
  
Several studies have revealed evidence of NK dysfunction in patients with AML 
compared to other disease groups post HSCT. Early NK cell function drops 
significantly by day 60 having been comparable to other disease groups at day 30 
(Pittari, Fregni et al. 2010). During early NK regeneration donor vs. recipient NK cells 
appear to protect against disease relapse whilst failing to cause GvHD (Ruggeri, 
30 
 
Capanni et al. 2002). Collectively, these data indicate that NK cells can play an 
important role in eliminating AML and suggests that therapeutic enhancement of 
NK function in the early period post transplantation could lead to improved relapse 
risk without an increased risk of GvHD.  
 
1.2.3 Immune System in AML  
 
AML is a disseminated malignancy at diagnosis with no specific tumour-draining 
lymph nodes and is therefore likely to utilise different immune evasion strategies 
compared to solid tumours. Whilst allogeneic SCT provides evidence that donor 
immune cells can control AML, there is also evidence that the patients’ own 
immune system can also mount an active response (Figure 1.1). Spontaneous 
remissions, whilst being a well-documented phenomenon in cancers such as renal 
cell carcinoma or malignant melanoma, are also very occasionally observed in AML 
(Mitterbauer, Fritzer-Szekeres et al. 1996; Muller, Trepel et al. 2004; Daccache, 
Kizhakekuttu et al. 2007; Trof, Beishuizen et al. 2007; Burger, Velev et al. 2010). The 
term ‘spontaneous’ is perhaps misleading, as remission is generally preceded by an 
episode of severe sepsis or blood transfusion. Remissions are thought to be due to 
an overwhelming response to sepsis resulting in raised levels of TNF-α, INF-γ and IL-
2 and activation of NK cells, CTLs and macrophages (Trof, Beishuizen et al. 2007). 
Understanding the mechanisms underlying the ability of patients’ own immune 
systems to eliminate AML is key to the development of successful immunotherapy 
for AML.  
 
In contrast to solid tumours, such as melanoma or lung carcinoma, in which 
complex genomic alterations give rise to a range of immunogenic neoantigens, 
exome and genome sequencing in AML has not only demonstrated a low 
mutational burden but most leukaemia-specific chromosomal translocations fail to 
give rise to immunogenic neoantigens (Anguille, Van Tendeloo et al. 2012). This not 
only makes it difficult for the immune system to recognize and eliminate AML blasts 
but also results in fewer leukaemia specific Ags (LSA) being available for discovery  
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Figure 1.1: Interactions of AML with Immune Cells. A range of genetic mutations 
and epigenetic mutations result in myeloid precursor cells being transformed into 
myeloid blast. These can be recognised and killed by the effector arm of the 
immune system via the presentation of tumour Ags to T cells. However AML has 
developed a range of mechanisms to avoid immune elimination.  
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and targeting (Mardis, Ding et al. 2009; 2013). Myeloid cells, such as monocytes, 
macrophages and myeloid derived suppressor cells (MDSCs), are important to the 
development of malignancy and can both promote and inhibit tumour growth (Sica 
and Bronte 2007; Allavena, Sica et al. 2008). In the setting of AML where malignant 
cells have arisen in the myeloid compartment, functions of myeloid cells could be 
distinct from other malignant conditions. For example, myeloid blasts themselves 
have immunosuppressive properties being able to directly suppress T-cell 
proliferation (Curti, Aluigi et al. 2007; Mussai, De Santo et al. 2013). 
1.2.3.1 Natural Killer cells in AML 
 
In vitro killing assays have shown that whilst in other diseases, such as ALL, only a 
minority of cells are killed by alloreactive NK clones, 100% of acute and chronic 
myeloid leukaemias are susceptible to lysis by NK cells (Ruggeri, Capanni et al. 
1999). In vivo, NK success is best demonstrated by the success of allogeneic HSCT in 
AML where donor-versus-recipient NK cell alloreactivity not only reduces the risk of 
relapse but also leads to better engraftment and protection from GvHD (Ruggeri, 
Capanni et al. 2002; Ruggeri, Mancusi et al. 2007). However, AML appears to use a 
variety of mechanisms to avoid NK clearance in vivo.  
 
NK cells from AML patients have an altered NCR profile with down-regulated 
surface expression of NKp30, NKp44 and NKp46 leading to impaired NK cell-
mediated cytotoxicity (Costello, Sivori et al. 2002; Fauriat, Just-Landi et al. 2007; 
Szczepanski, Szajnik et al. 2010). NK cells from patients with AML are more likely to 
have an unfavourable KIR phenotype (Verheyden, Bernier et al. 2004), high CD139 
expression (Baessler, Charton et al. 2010) and reduced IFN-γ secretion capacity 
(Tajima, Kawatani et al. 1996) all of which promote escape from NK cell immunity.  
 
A range of features of myeloid blasts lead to impaired NK cell mediated cytotoxicity 
and IFN-γ secretion. These include low or absent AML cell surface ligands for 
activating receptors (Verheyden and Demanet 2008), shedding of NKG2D-L (Salih, 
Antropius et al. 2003; Diermayr, Himmelreich et al. 2008), expression of surface and 
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soluble GITRL (Baessler, Krusch et al. 2009), increased CD137L expression (Baessler, 
Charton et al. 2010), high CD200 expression (Coles, Wang et al. 2011) and secretion 
of soluble immunosuppressive factors such as TGF-β and IL-2R (Lim, Worman et al. 
1991; Bergmann, Schui et al. 1995). AML cells also have defects in both their 
intrinsic (mitochondrial) and extrinsic (death receptor) apoptotic mechanisms  
which could result in a failure to trigger NK mediated killing (Schimmer, Pedersen et 
al. 2003; Del Poeta, Bruno et al. 2008; Ragusa, Avola et al. 2010). AML is also 
resistant to TRAIL and Fas-mediated killing due to both low receptor expression 
(Iijima, Miyamura et al. 1997; Min, Lee et al. 2004; Tourneur, Delluc et al. 2004) and 
high decoy receptor expression (Riccioni, Pasquini et al. 2005; Chamuleau, 
Ossenkoppele et al. 2011).  
 
1.2.3.2 Adaptive Immune Responses to AML 
 
Despite an increased absolute number of peripheral blood T cells in AML patients 
compared to healthy controls, AML uses several host-derived mechanisms in order 
to evade immune-mediated clearance. The disseminated nature of AML is perhaps 
key to its failure to trigger a host type I IFN response (Curran, Chen et al. 2016). This 
is in contrast to the essential role played by type I IFN in generating adaptive 
immune responses against solid tumours (Dunn, Bruce et al. 2005; Gajewski 2007; 
Diamond, Kinder et al. 2011; Fuertes, Kacha et al. 2011). The absence of a type I IFN 
response in AML results in a T-cell tolerant state with failed DC maturation and 
deletion of AML Ag-specific T cells (Curran, Chen et al. 2016). Induction of type I IFN 
and other inflammatory cytokines through activation of the stimulator of IFN genes 
(STING) pathway resulted in a potent leukaemia-specific immune response and 
prolonged survival (Curran, Chen et al. 2016).  
 
Gene expression profiling in AML reveals aberrant T-cell activation patterns which 
result in a failure to form effective immune synapses with AML blasts (Le Dieu, 
Taussig et al. 2009).  Myeloid blasts have been shown to express negative co-
stimulatory ligands such as programmed death-ligand 1 (PD-L1) and galectin 9 (Gal-
9) (Zhang, Gajewski et al. 2009; Zhou, Munger et al. 2011). PD-L1 functions by 
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binding to PD-1 expressed on T cells, B cells and NK cells, leading to their 
deactivation.  
 
Despite AMLs low mutation burden, several leukaemia-associated Ags (LAA), such 
as proteinase 3 (PR3) and Wilm’s tumor-1 (WT-1), have been identified 
(Scheibenbogen, Letsch et al. 2002; Greiner, Bullinger et al. 2008). Although these 
LAAs can be recognised by the immune system they are not specific to AML and are 
also expressed on a range of normal tissues, including the thymus. This means that 
any high affinity thymocytes that develop against the LAAs are likely to be deleted 
via central tolerance mechanisms, resulting in an ineffective immune response 
against leukaemia (Curran, Corrales et al. 2015).  
 
Host DCs also play a critical role in regulating deletional T cell tolerance in AML 
(Curran, Corrales et al. 2015). DCs engulf AML cells and cross-present AML cell-
derived Ags to T cells however, this only results in small numbers of partially 
dysfunctional Ag-specific T cells (Zhang, Chen et al. 2013; Curran, Corrales et al. 
2015). The role of DCs might be particularly important in AML, as due to its 
disseminated nature, the required levels of danger associated molecular patterns 
(DAMPs) required to activate DCs in solid tumours, may not be achieved. Targeted 
activation of innate immunity might thus overcome T cell tolerance in AML (Curran, 
Corrales et al. 2015).  
 
1.2.3.3 Immunosuppressive Mechanisms in AML (Figure 1.2) 
 
AML induces the expansion of immunoregulatory cells such as Tregs and MDSCs 
(Wang, Zheng et al. 2005; Zhou, Bucher et al. 2009). This is due to both increased 
proliferation and the ability of AML cells to trigger the conversion of CD4+25- T cells 
into Tregs via modulation of tryptophan catabolism (Wang, Zheng et al. 2005; Curti, 
Aluigi et al. 2007). Tregs accumulate in leukaemia-bearing mice with depletion 
resulting in enhanced anti-leukaemia T cell responses (Zhou, Bucher et al. 2009). 
Tregs are both more frequent and have a more suppressive phenotype in patients 
with AML compared to healthy controls (Szczepanski, Szajnik et al. 2009).         
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Figure 1.2: Immunosuppressive Mechanisms in AML. AML induces the expansion 
and activation of immunoregulatory cells such as Tregs and MDSCs. Myeloid blasts 
themselves also have direct immunosuppressive capabilities directly suppress T cell 
proliferation via the release of inhibitory enzymes such as arginase or indolamine 
2,3-dioxygenase (IDO), which is also released by MDSCs and tumour associated DCs.  
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Myeloid blasts themselves have direct immunosuppressive capabilities perhaps not 
surprising, given that they are a malignant expansion of immature myeloid cells, 
from which MDSCs are also derived. Myeloid blasts directly suppress T cell 
proliferation via the release of inhibitory enzymes such as arginase or indolamine 
2,3-dioxygenase (IDO) which are expressed on blasts taken from AML patients 
(Curti, Aluigi et al. 2007; Mussai, De Santo et al. 2013). IDO also inhibits T-cell 
activation and survival and stimulates the conversion of CD25_ cells into CD25+ 
Tregs (Curti, Trabanelli et al. 2009). High IDO mRNA expression in myeloid blasts 
correlates with significantly reduced overall and progression free survival 
(Chamuleau, van de Loosdrecht et al. 2008).  
 
STAT3 is a recognised mediator of cell growth, differentiation and apoptosis and is 
activated in the majority of AML patients (Benekli, Baumann et al. 2009) being 
associated with a worse outcome (Benekli, Xia et al. 2002). STAT3 also promotes 
tumour progression by both modulating CD4+ T cell responses via downregulating 
production of Th1 cytokines and upregulating production of Th17 cytokines, and by 
promoting the expansion and immunosuppressive effects of Tregs, MDSCs and 
tumour-associated macrophages (Zhou, Munger et al. 2011). Studies of the 
therapeutic effects of STAT3 inhibition in leukaemia reveal that it is these immune-
modulatory effects that are key to disease progression (Hossain, Dos Santos et al. 
2014). 
 
1.2.4 Non-transplant Immunotherapy in AML 
 
AML is known to alter normal immunological function and evidence from HSCT 
proves that it is possible to regain immunological control of the disease. The 
development of immune therapies in AML has lagged behind other solid tumours. 
This is probably due to the relative success of chemotherapy and HSCT in AML as 
compared to the very limited therapeutic options previously available in diseases 
such as malignant melanoma. However, the success of HSCT makes the potential 
role of alternative immune modulated therapies in AML particularly exciting.  A 
wide range of AML directed immunotherapies are being explored which aim to 
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deliver the disease control offered by HSCT without the related toxicities. 
Treatments such as cytokine therapy, monoclonal antibodies, vaccination and cell 
therapies have met with varying levels of success.  
 
1.2.4.1 Cytokine therapy in AML 
 
As discussed above, myeloid blasts directly impair T-cell and NK cell function 
resulting in a failure to control leukaemia. Various exogenous cytokines have been 
investigated in a bid to restore T cell and NK cell function.  
 
Interferon-α (IFN-α) acts via a wide range of mechanisms, involving dendritic cells, 
monocytes T-cells and NK cells, in order to stimulate the immune system. 
Monocytes, activated by IFN-α, are able to inhibit malignant growth and induce 
apoptosis of tumour cells (Bekisz, Sato et al. 2013). IFN-α also has direct inhibitory 
effects on leukaemia cells (Anguille, Lion et al. 2011). The use of IFN-α has been 
explored for induction, post-remission and relapse therapy for AML but has failed to 
demonstrate any clinical benefit. 
 
IL-2 is produced by T cells and activates both T and NK cells as well as stimulating 
cytokine production and triggering cell cycle proliferation. Whilst IL-2 can stimulate 
tumour-infiltrating lympohocytes (TILs) (Ettinghausen, Lipford et al. 1985), its effect 
is dose dependent with low doses both enhancing and suppressing the immune 
system (Alatrash, Jakher et al. 2013). Most trials of IL-2 occurred in a post-remission 
setting and meta-analysis has failed to demonstrate any leukaemia-free or OS 
benefit (Buyse, Squifflet et al. 2011). This failure is thought to be due to either the 
induction of negative feedback mechanisms (Acuto, Di Bartolo et al. 2008) or the 
induction of regulatory T-cells (Ustun, Miller et al. 2011). The presence of multiple 
compensatory mechanisms and feedback loops perhaps makes the failure of 
cytokine monotherapy unsurprising; combined approaches might prove more 
effective.  
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In a similar way to MDSCs, malignant myeloid cells produce ROS which create an 
arginase-dependent immunosuppressive environment (Mussai, De Santo et al. 
2013). Histamine dihydrochloride inhibits the formation of ROS thus restoring the 
ability of IL-2 to activate T and NK cells (Romero, Thoren et al. 2009). A phase 3 trial 
of post-remission therapy with IL-2 and histamine dihydrochloride led to an 
improved 3 year leukaemia-free survival of 40% compared with 26% in controls 
(Brune and Hellstrand 1996; Brune, Castaigne et al. 2006), however this did not 
translate to any differences in OS (Yang and Perry 2011). Recent data suggests that 
both the dynamics of NK cell subsets and NCR expression, and the use of T cell 
biomarkers that detect the re-distribution of CTL subsets towards a tumour- killing 
phenotype, could be used to predict clinical outcomes and hence identify patients 
who would benefit from maintenance therapy with IL-2 and histamine 
dihydrochloride (Martner, Rydstrom et al. 2016; Sander, Rydstrom et al. 2016).   
 
1.2.4.2 Antibody therapy in AML 
 
Antibody (Ab) therapy in AML is an extremely active area of research with several 
Ags having been identified for targeting (reviewed in (Gasiorowski, Clark et al. 
2014)). CD33 is a transmembrane receptor which although widely expressed on 
cells of myeloid lineage is also occasionally expressed on activated T and NK cells 
(Hernandez-Caselles, Martinez-Esparza et al. 2006). CD33 is expressed by 85-90%  of 
myeloid blasts along with leukaemic stem cells and as such offers an attractive 
target for monoclonal antibodies (mAb) (Tettamanti, Magnani et al. 2013). 
Gemtuzumab ozagamicin (GO), is a recombinant humanized CD33 mAb conjugated 
to the cytotoxic antibiotic calicheamicin. After initially disappointing trial results and 
toxicity issues, the use of lower or fractionated-dose GO has been better tolerated 
and has prolonged survival in patients with favourable-risk cytogenetics (Burnett, 
Hills et al. 2011).  
 
New Ab-drug conjugates such as SGN-CD33A, an anti-CD33 mAb bound to SGN-
1882, a potent DNA cross-linker, are also under investigation (Kung Sutherland, 
Walter et al. 2013). Upon binding of the mAb to CD33, SGN-1882 is internalised 
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resulting in cell-cycle arrest and induction of apoptosis. Promising phase 1 trial 
results showed blast clearance in 47% of poor risk patients at higher dosing levels 
with minimal toxicity (Stein EM 2014).  
 
Radiolabelled antibodies are also being used in a bid to deliver radiation directly to 
malignant cells. Due to toxicity, lack of efficacy and practical issues with delivering 
the therapy, despite more than 20 years of clinical research, none have moved 
beyond the research setting. It is likely that their most useful role will be in 
targeting radiation preferentially to haematopoietic tissues in the HSCT setting 
(Grosso, Hess et al. 2015). 
 
Bi-specific antibodies are composed of 2 different mAbs which bind to 2 distinct 
targets such as soluble ligands and cell surface receptors in order to mediate an 
effect.  They can function by re-targeting effector cells to disease-associated sites 
for example bringing a CTL and a tumour cell together in order to enable immune 
mediated clearance. They work on the basis that specific surface molecules such as 
CD3 on T lymphocytes or Fc receptors on monocytes, macrophages and NK cells, 
can trigger leukocytes to either phagocytose or kill tumour cells. Antibodies against 
CD123, part of the IL-3 receptor which is preferentially expressed on leukaemic 
stem cells (LSCs) have been combined with a CD3 Ab in order to form a bispecific T-
cell engager which aims to clear these leukaemic precursor cells. Both CD123-CD3 
and CD3- CD33 dual-affinity antibodies are  currently undergoing clinical trials 
(Dohner, Weisdorf et al. 2015).  
 
1.2.4.3 Vaccination in AML  
 
Active immunisation of high-risk AML patients following HSCT or conventional 
therapy is an attractive area of investigation. Vaccines aim to stimulate an anti-
leukaemic response in order to control residual disease and thus prevent relapse. 
Peptide vaccines, granulocyte-macrophage-colony-stimulating factor (GM-CSF) 
vaccines and dendritic cell (DC) vaccines have all been used to target AML.  
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Wilms tumor 1 (WT1) is the most widely investigated LAA used to stimulate CD8+ 
CTLs in AML. A phase 1 trial of a HLA-A*0201-restricted WT1 peptide vaccine in 
twelve AML patients in complete remission post therapy showed a response in five 
patients with three continuing on the vaccination and remaining in remission 8 
years later (Oka, Tsuboi et al. 2004). GM-CSF in conjunction with peptide 
vaccination has been used to stimulate an immune response. Of seventeen poor 
risk patients receiving GM-CSF in combination with HLA-A*0201-restricted WT1 
peptide vaccine, ten patients developed increased WT1-tetramer-positive T cells 
and stable disease, but none achieved a complete remission (Keilholz, Letsch et al. 
2009). 
 
PR1, a peptide derived from proteinase 3, is commonly expressed in AML. PR1 
peptide vaccination has led to some positive results in phase 1 trials with 4 AML 
patients vaccinated during their first complete remission who all remained in 
remission for 4 years post vaccination (Qazilbash MH 2004).  
 
DCs are key to priming Ag-specific CTLs; a role which has been exploited in order to 
develop leukaemic cell-derived DC vaccines. These originate from leukaemia cells 
induced to differentiate into mature DCs which are able to present LAAs and thus 
activate naive T cells (Yuan, Song et al. 2012). These have however proved 
disappointing with the minimal effects observed in a subset of patients failing to 
achieve any sustained responses (Roddie, Klammer et al. 2006). Monocyte-derived 
DC vaccines used in combination with WT1 have had slightly more encouraging 
results, including immune responses and a few molecular responses (Van Tendeloo, 
Van de Velde et al. 2010). It is therefore possible that better results will be achieved 
by using HLA matched allogeneic monocyte derived DCs to stimulate CTLs (Grosso, 
Hess et al. 2015).      
 
1.2.4.4 Immune Checkpoint Inhibitors in AML 
 
TCR/Ag binding has been demonstrated to be insufficient to result in full T cell 
activation but requires a second co-stimulatory signal from APCs (Jenkins, Pardoll et 
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al. 1987). The 1st T cell co-stimulatory molecule to be identified was CD28 (Martin, 
Ledbetter et al. 1986), the CTL antigen 4 (CTLA-4) was subsequently 
discovered(Brunet, Denizot et al. 1987; Linsley, Brady et al. 1991) but was 
unexpectedly found to have a suppressive effect on T cell responses (Walunas, 
Lenschow et al. 1994; Krummel and Allison 1995). Multiple interactions between T 
cells and APCs known as immune checkpoints, which fine-tune both duration and 
strength of T cell responses have since been identified and have led to the 
development of a range of therapeutic checkpoint inhibitors (Topalian, Drake et al. 
2015).  
 
CTLA-4 is a cell surface receptor that is upregulated during T cell activation and 
plays a role in downmodulating normal immune responses thus preventing 
uncontrolled immune responses. CTLA-4 is a key part of the natural immune 
response and key to peripheral T cell tolerance (Fife and Bluestone 2008). It is 
upregulated in chronically stimulated cells and can thus be co-opted by malignancy 
in order to hinder anti-tumour immune responses.  
 
The CTLA-4 mAb, Ipilimumab, binds to and blocks CTLA-4 thus taking the brakes off 
CTL activation. It is licensed for use in advanced melanoma and is currently under 
investigation in clinical trials for a range of malignancies. CTLA-4 polymorphisms 
influence the incidence of relapse in AML, suggesting a possible role in control of 
MRD (Perez-Garcia, Brunet et al. 2009). CTLA-4 blockade enhances immune 
responses against AML (Zhong, Loken et al. 2006). The safety and efficacy of 
Ipilimumab is currently being assessed in AML patients at relapse and following 
HSCT (Andersen 2014).  
 
The inhibitory receptor, programmed death 1 (PD-1), is also upregulated on 
activated T cells. Interactions between PD-1 and PD-L1, expressed on APCs, results 
in a contraction of normal immune responses by inhibiting T cell proliferation and 
cytokine production (Dong, Zhu et al. 1999). PD-L1 is also expressed by a range of 
malignant cells with its expression level correlating with the aggressiveness of 
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tumours, poor prognosis and increased risk of death (Thompson, Gillett et al. 2004; 
Hamanishi, Mandai et al. 2007; Nomi, Sho et al. 2007).  
 
CTLs at the sites of AML progression have elevated PD-1 expression and the PD1-
PDL1 interaction appears to facilitate Treg induced suppression of CTLs (Zhou, 
Munger et al. 2010). PD-1 knockout mice are resistant to AML and administering 
anti-PD-L1 mAb to WT animals increased CTL infiltration at disease sites, reduced 
AML burden and led to some long-term survivors. An even greater protective effect 
was observed when anti-PD-L1 mAb was used in combination with Treg depletion 
(Zhou, Munger et al. 2010).       
 
Responses to both anti-PD-L1 and PD-1 mAbs observed in patients with solid 
tumours (Brahmer, Tykodi et al. 2012; Topalian, Hodi et al. 2012) have translated 
into the clinical use of the anti-PD-1 mAb Nivolumab in both advanced melanoma 
and squamous cell non-small cell lung carcinoma. PD-1 blockade alone or in 
combination with DC vaccination or lymphodepletion is currently under 
investigation in AML patients at high risk of relapse. It remains to be seen whether 
provisional responses observed in a range of haematological malignancies translate 
into clinical practice (Berger, Rotem-Yehudar et al. 2008).  
 
TIM-3 and LAG-3 are other co-inhibitory receptors which are emerging as potential 
therapeutic targets (Pardoll 2012). The combined targeting of multiple negative 
regulatory receptors also offers an exciting opportunity to further improve efficacy 
with combined PD-1 and CTLA-4 blockade in melanoma proving more effective than 
either agent alone (Larkin, Chiarion-Sileni et al. 2015).         
 
1.3 The Complement System  
 
Complement was originally described over 120 years ago, as a heat-sensitive factor 
found in fresh serum which ‘complemented’ the role of specific Ab in causing lysis 
of bacteria and red blood cells. Complement has since been shown to be both a 
crucial effector of innate immunity and an important ‘complement’ to the innate  
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Figure 1.3: The Complement System. An overview of the classical, alternative and 
lectin complement activation pathways all of which converge on a shared terminal 
pathway which results in the insertion of a lytic pore into target cell membranes. 
The classical pathway is triggered by C1q binding antibodies and the lectin pathway 
by lectin binding mannose residues. In contrast the alternative pathway has no 
specific activation step, but is based on a ‘tickover’ mechanism centred around 
spontaneous low level hydrolysis or protease cleavage at sites of inflammation. 
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and adaptive immune responses. Complement also assists in the resolution of 
inflammation via clearance of apoptotic cells and immune complexes (Flierman and 
Daha 2007; Trouw, Blom et al. 2008). Complement is also involved in a diverse 
range of other processes such as angiogenesis, mobilization of haematopoietic stem 
cells (HPSC), coagulation, tissue regeneration and lipid metabolism (Ricklin, 
Hajishengallis et al. 2010).   
 
Complement is a complex system comprising of more than 50 circulating or cell-
surface bound proteins (Pio, Corrales et al. 2014). Three separate activation 
pathways exist which converge on a shared terminal pathway (Figure 1.3). 
Complement proteins either contribute to one or more complement activation 
pathways or have a regulatory role in order to control autologous complement 
attack (reviewed in (Walport 2001; Walport 2001)). Complement interacts via a 
cascade mechanism via which a trigger is amplified in order to culminate in the 
formation of the membrane attack complex (MAC) constructed from complement 
proteins C5b, C6, C7, C8 and multiple C9 (C5b-9).  MAC is inserted into the plasma 
membrane of target cells leading to a loss of cell homeostasis and, at an adequate 
dose, can result in rapid cell death (Morgan and Meri 1994). In addition to its role in 
direct cell lysis, complement also has a wide range of effects such as enhancing 
immune responses via the release of anaphylatoxins and opsonisation (Walport 
2001). Complement also has a range of non-lethal effects on angiogenesis, 
coagulation and cell tethering (Langer, Chung et al. 2010; Lupu, Keshari et al. 2014; 
Hamad, Mitroulis et al. 2015).  
 
Although complement components are primarily synthesized in the liver (Alper, 
Johnson et al. 1969), numerous other cell types also synthesize complement. Local 
production of complement proteins appears to have significant effects on tissue 
homeostasis and immune defence (Morgan and Gasque 1997). Complement 
production by alternative cells can be significant, for example, bone-marrow 
derived cells contribute 40% of total C3 in the serum (Morgan and Gasque 1997). C3 
is a 185kDa protein comprising two polypeptide chains linked by a disulphide bond 
(Tack and Prahl 1976). It is present in high concentrations in serum (1-2mg/ml) and, 
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being common to all three complement activation pathways, is central to the entire 
complement system. C3 deficiency leads to impaired CDC which results in recurrent 
bacterial infections (Walport and Lachmann 1984). 
 
Multiple pathways of activation and the catalytic nature of many steps mean that 
regulation of complement is complex (Morgan and Meri 1994). The complement 
system is able to attack altered or infected cells whilst limiting damage to host cells 
by a range of methods. These include tightly controlled activation mechanisms and 
protection of autologous cells from inappropriate complement attack via the 
expression of serum and membrane bound complement regulatory proteins 
(CRegs). Activation is controlled by the use of inactive precursor forms of the 
complement proteins, or ‘zymogens’, which require specific activation, allowing 
complement deposition to be limited to target cells. Upon activation of any of the 
three complement pathways, inactive precursors are enzymatically cleaved leading 
to localised deposition of active protein fragments on the target cell. The enzymatic 
nature of the pathways allows a small trigger to be rapidly amplified to result in a 
brisk, highly effective complement attack.  
 
A constant low level of activation mediated via the alternative pathway results in 
the complement system being maintained in a constant state of readiness. This 
means that when the complement system senses danger in the form of pathogens 
or altered/damaged self it is able to coordinate a rapid, appropriate cellular innate 
or adaptive immune response (Kohl 2006). It accomplishes this via the use of danger 
sensors, such as C1q, which recognise pathogens or altered cells and either 
activates cell-bound receptors or complement directly by initiating cleavage of C3 
and C5 (Kohl 2006). Both the danger signals themselves and the complement 
cleavage products they produce, function to direct the immune system to an innate 
or adaptive phenotype via their interactions with cell-bound receptors/regulators 
(Kohl 2006). Complement is able to discriminate between physiological danger 
where cells are flagged for enhanced phagocytosis without an inflammatory stimuli 
and a pathological danger where anaphylatoxins are also increased resulting in an 
inflammatory response (Kohl 2006).  
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1.3.1 The Classical Pathway  
 
The classical pathway (Figure 1.4) is triggered by the binding of the complement 
component C1q to Ab/Ag complexes, formed by the adaptive immune system, 
which have been deposited on target cells.  When an Ag is recognised by specific 
Abs, an immune complex is formed which allows the Fc portions of IgM and IgG Abs 
to interact with C1q, the globular domains of the initiator complex C1, triggering 
focused surface activation of the classical complement pathway (Sim and Reid 
1991). C1q can also recognise endogenous ligands such as dying cells, extracellular 
matrix proteins, and DNA leading to activation of the classical pathway in the 
absence of Abs (Pio, Corrales et al. 2014).  
 
Binding of C1q leads to activation of the serine protease pro-enzymes C1s and C1r 
(Kojouharova, Reid et al. 2010). C1s enzyme is able to cleave numerous molecules 
of the next protein in the cascade, C4, resulting in rapid amplification of the 
pathway. C4 cleavage results in release of a weak anaphylatoxin, C4a (Hugli, 
Kawahara et al. 1983) and formation of a larger, highly unstable, C4b component 
which, if unable to bind rapidly to the target, is rapidly hydrolysed. Surface bound 
C4b provides a Mg2+ dependent binding site for the next component, inactive C2, 
whose cleavage, which is mediated by activated C1s, releases the C2b component 
(Nagasawa and Stroud 1977). The resulting C4b2a complex, also known as ‘C3 
convertase’, is also very unstable and, unless it immediately binds to C3, will rapidly 
lose function stopping the cascade. C3 convertases’ short half-life provides the 
pathway with a high level of self-regulation preventing uncontrolled activation and 
autologous attack. Non-bound proteins are rapidly hydrolysed, limiting their 
deposition to the activation site and thus resulting in a highly localised complement 
attack.  
 
If the classical pathways C3 convertase (C4b2a) manages to bind to C3, this is 
cleaved resulting in a small anaphylactic component (C3a) and deposition of the C3b 
with the C4b2a forming a C4b2a3b complex (Kozono, Kinoshita et al. 1990), which  
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Figure 1.4: Classical Pathway Activation. The classical pathway is triggered by the 
binding of the complement component C1q to Ab/Ag complexes, formed by the 
adaptive immune system, which have been deposited on target cells.  C1q binding 
leads to activation of C1s and C1r, C1s in turn cleaves numerous molecules C4, 
resulting in rapid amplification of the pathway. C4 cleavage results in release of a 
weak anaphylatoxin, C4a and formation of C4b component which binds to C2a to 
form ‘C3 convertase’. Cleavage of C3 results in an anaphylactic component (C3a) 
and C3b which forms part of the C5 convertase. C3b deposits on the cell surface 
also act as a focus for further complement attack.  
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acts as the C5 convertase of the classical pathway initiating the terminal pathway. 
C3b deposited on the cell surface also acts as a focus for further complement 
attack. Approximately 240 C3b molecules are deposited for every original activated 
C1 complex (Ollert, Kadlec et al. 1994), meaning that, if the tight regulation is 
overcome, classical pathway activation can result in a huge amplification of the 
original trigger.       
 
1.3.2 The Lectin Pathway  
 
The lectin pathway (Figure 1.5) closely resembles the classical pathway but is 
initiated by carbohydrate binding proteins, such as mannose-binding lectin (MBL) 
and H, L or M- ficolins, recognising arrays of carbohydrates, such as mannose and N-
acetyl-glucosamine, found on the surface of pathogenic organisms (Thiel 2007). 
After binding, MBL interacts with 2 associated serine proteinases, MASP-1 and 
MASP-2, activation of which results in cleavage of C4 and then C2 resulting in 
formation of C2bC4a/ C3 convertase, as seen in the classical pathway.    
 
1.3.3 The Alternative Pathway  
 
The alternative pathway (Figure 1.6) differs from the other pathways in that it does 
not require a specific activation step, such as Ab binding, but is based on a ‘tickover’ 
mechanism (Nicol and Lachmann 1973). Spontaneous activation may result from 
aqueous hydrolysis of C3, this might lead to cleavage resulting in C3b deposition. 
Either circulating spontaneously hydrolysed C3 (C3(H20)) or C3b deposition on a cell 
membrane can lead to alternative pathway activation. In addition, any mechanism 
which results in C3 cleavage and activation, for example enzymes not specific to the 
complement cascade such as thrombin are able to cleave C3 and trigger the 
alternative pathway resulting in complement deposition. Activated C3(H20) can bind 
to factor B (fB) resulting in formation of a C3(H20)B complex which is then cleaved 
by factor D (fD) (Volanakis and Narayana 1996) resulting in the formation of 
C3(H20)Bb which is an unstable but active C3 convertase. Although C3(H20)Bb is 
able to cleave C3 releasing C3a and forming active C3b, as it is in the fluid phase,  
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Figure 1.5: Lectin Pathway Activation. The lectin pathway closely resembles the 
classical pathway but is initiated by carbohydrate binding proteins, such as 
mannose-binding lectin (MBL) recognising arrays of carbohydrates, such as 
mannose, on the surface of pathogenic organisms. After binding, MBL activates 
MASP-1 and MASP-2 which cleave C4 and C2 resulting in the formation of C3 
convertase.    
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Microbe
C2a C4b
C3
C3b
C3a
C5
C5a
C5b
C9
C8
C7
C6
C9 C9 C9
C9
C3b
Factor B
Ba
BbC3b
Bb
C3(H2O)
C3(H2O) Bb
Factor BFactor D
 
 
Figure 1.6: Alternative Pathway Activation. In contrast to the classical and lectin 
pathways, the alternative pathway has no specific activation step. It is based on a 
‘tickover’ mechanism caused by low level C3 hydrolysis or protease cleavage at sites 
of inflammation leading to spontaneous alternative pathway activation. Activated 
C3(H20) and C3b bind to fB forming C3(H20)B which is then cleaved by fD (Volanakis 
and Narayana 1996) resulting an unstable but active alternative C3 convertase.  
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unless the C3b produced is deposited on a cell surface of a target cell, it is rapidly 
hydrolysed. The pathway is further amplified by the ability of C3b, via a similar 
interaction with fB then fD, to form alternative C3 convertase. Properties of the 
surface of a potential target cell determine if the alternative pathway is able to 
continue or if C3b is cleaved to form surface bound inactive iC3b (Fearon 1979). For 
example, cell surfaces with low levels of sialic acid less readily bind the alternative 
pathway regulator factor H (fH) allowing the alternative pathway to be activated on 
their surface (Fearon 1979). In the presence of surface properdin, a positive 
regulator of the alternative pathway, the C3bBb is stabilised on the cell’s surface, 
preventing rapid dissociation (Pillemer, Blum et al. 1954) and can cleave numerous 
C3 molecules resulting in an amplification step. Furthermore, this capacity for 
amplification is not limited to activation by the alternative pathway but can also be 
triggered by deposition of surface C3b by the classical and MBL pathways. This is an 
important feature of the alternative pathway which has been exploited for 
therapeutic end in several diseases which although triggered by activation of the 
classical and lectin pathway can be treated by inhibiting the alternative pathway 
and hence preventing this amplification process (Hu, Holers et al. 2013; Abdel-
Magid 2014; Do, Pieramici et al. 2014; Grossman, Hettrick et al. 2016).   
 
1.3.4 Terminal Pathway and MAC Formation 
 
All three pathways converge on a common terminal pathway triggered by C5 
convertase which initiates cleavage of C5 resulting in the release of the anaphylactic 
molecule C5a and exposure of a binding site on C5b (Cooper and Muller-Eberhard 
1970). C6 spontaneously binds to C5b followed by C7 which results in a 
conformation change of the C5b67 complex leading it to be released from the C5 
convertase. This release exposes a hydrophobic region in C7 which is able to bind to 
the target cell membrane (Preissner, Podack et al. 1985). Following binding to 
C5b67, C8 is inserted into the lipid bi-layer allowing numerous hydrophobic C9 
molecules to polymerise into the complex (Tschopp, Podack et al. 1982). The ring 
structure formed creates a lytic pore through the cell membrane which is 
abbreviated as C5b-9 and is commonly known as MAC (Figure 1.7).  
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Figure 1.7: The Membrane Attack Complex. C5b, C6, C7, C8 and multiple C9 
molecules (C5b-9) form a ring structure which creates a lytic pore through the cell 
membrane which is commonly known as MAC. The channel formed by the insertion 
of MAC disturbs the homeostatic capabilities of the cell and in adequate doses can 
result in cell lysis. 
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An average of 3-4 C9 molecules typically interact to form MAC, although up to 14 
can be involved (Stewart, Monahan et al. 1984). The channel formed by the 
insertion of MAC disturbs the homeostatic capabilities of the cell and in adequate 
doses can result in cell lysis (Podack and Tschopp 1982).  
 
Although nucleated cells require the insertion of multiple MAC in order to be lysed, 
bacteria and eukaryotic cells, such as erythrocytes, are highly susceptible to 
complement attack and can be lysed by a single MAC complex. Certain pathogens 
such as gram-positive bacteria, are protected from terminal complement complex 
(TCC)-mediated lysis via their cell wall architecture by which a thick cell wall 
prevents MAC from reaching the inner cell membrane (Morgan 1990). MAC is 
however a major mechanism of lysis for gram-negative bacteria such that 
individuals who are deficient in components of MAC such as C6 or C7 are highly 
susceptible to infection with gram negative bacteria such as Neisseria which leads 
to an increased incidence of meningitis (Morgan and Walport 1991). Pathogens also 
employ alternative strategies to interfere with TCC assembly.    
 
In addition to its cytolytic role, the presence of MAC results in a range of other 
important biologically effects including proliferation, resistance to apoptosis, 
activation of immune cells and protection of the cell from further lytic attack (Cole 
and Morgan 2003).   
 
1.3.5 Complement Regulators 
 
The regulation of complement activation is a critical homeostatic mechanism which 
is controlled by a range of soluble and membrane-bound complement regulatory 
proteins (CRegs) (Table 1.1 and 1.2).  
 
These act via 3 main mechanisms:  
i) Blocking the activation cascade by inhibiting protease activity 
ii) Facilitating rapid decay and destruction of complement convertases 
iii) Preventing MAC formation 
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mCreg Expression Action 
Complement 
receptor type 1  
(CR1, CD35) 
Erythrocytes, neutrophils, 
eosinophils, monocytes, 
follicular dendritic cells, 
glomerular podocytes, B and 
some T lymphocytes(Fischer, 
Appay et al. 1986) 
- Cofactor for fI mediated 
C3b/C4b cleavage (Fearon 
1979) 
- Accelerates decay of 
classical and alternative 
convertases (Fearon 1979) 
Membrane 
cofactor protein 
(MCP, CD46) 
Most cells, except 
erythrocytes (Liszewski, Post 
et al. 1991) 
- Cofactor for fI mediated 
C3b/C4b cleavage 
(Liszewski, Post et al. 1991) 
Decay-
accelerating factor 
(DAF, CD55) 
All blood cells plus most 
other cells (Medof, Walter et 
al. 1987) 
- Accelerates decay of 
classical and alternative C3 
and C5 convertases (Lublin 
and Atkinson 1989) 
Protectin (CD59) Most cells (Morgan 1999) Binds C8 during formation 
of MAC and prevents 
insertion of C9 into lipid 
bilayer (Meri, Morgan et al. 
1990) 
 
Table 1.1: Summary of the Expression and Action of Membrane Bound 
Complement Regulatory Proteins (mCRegs).  
 
In addition to mediating binding of C3 activation products to a range of immune 
cells, complement receptor 1 (CR1, CD35) also acts as a membrane bound CReg 
impinging on both the classical and alternative pathways by accelerating the decay 
of both C3 and C5 convertases. It also acts as a co-factor for factor I (fI) mediated 
cleavage and thus inactivation of C3b and C4b (Fearon 1980).  
 
Membrane co-factor protein (MCP, CD46) is a co-factor for fI mediated cleavage 
and inactivation of deposited C3b and C4b (Liszewski, Post et al. 1991). Decay 
accelerating factor (DAF, CD55), accelerates the decay of both classical and 
55 
 
alternative C3 and C5 convertases (Lublin and Atkinson 1989). The final mCReg 
which should be mentioned is protectin (CD59) which differs from the others in that 
it is a specific regulator of the terminal pathway which binds C8 during formation of 
MAC thus preventing the insertion of C9 into the lipid bilayer (Meri, Morgan et al. 
1990). 
 
There are also a range of soluble CRegs (Table 1.2). These include the C1 inhibitor 
(C1inh) which binds and inactivates C1r, C1s and MASP-2 (Davis, Mejia et al. 2008). 
FI is a soluble CReg which can only function in conjunction with a range of other 
CRegs including CR1, MCP, C4bp and fH. Although unable to function alone, fI has a 
critical role in the regulation of the amplification capacity of the alternative 
pathway via cleavage and inactivation of C4b and C3b (Sim, Day et al. 1993). It also 
interacts with CR1 in order to generate C3dg from iC3b. C4 binding protein (C4bp) 
regulates both the classical and lectin pathways via binding with C4b. It prevents 
both assembly of C3 convertase and accelerates decay of both this and the C5 
convertases (Blom, Villoutreix et al. 2004).        
 
FH and its alternative splice variant fH-like protein 1 (FHL-1) are both alternative 
pathway regulators. They do this via binding C3b and preventing its association with 
fB thus reducing the formation of C3 and C5 convertases. They are also able to 
displace the Bb subunit from formed convertases and act as co-factors for fI 
mediated cleavage of C3b (Jozsi and Zipfel 2008).  
 
Vitronectin (s-protein) and Clusterin (complement lysis inhibitor, CLI) both inhibit 
the insertion of MAC into the cell membrane (Podack and Muller-Eberhard 1979; 
Jenne, Hille et al. 1989). Clusterin has a range of additional roles including 
modulating cell differentiation and regulating the release of pro-inflammatory 
cytokines such as TNF-α and IL-6 (Falgarone and Chiocchia 2009).  
 
In addition to the conventional CRegs, somewhat conversely, C8 can also function 
as an inhibitor of MAC. If soluble C8 binds to C5b67 before it has attached to the 
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membrane, it prevents the complex from being able to insert into the cell 
membrane and hence functions as probably the most potent inhibitor of MAC. 
 
 
sCreg Action 
C1 inhibitor Inactivates C1r, C1s and MASP-2 (Davis, Mejia et al. 2008) 
Factor I Cleaves and inactivates C4b and C3b (Sim, Day et al. 1993) 
Generates C3dg from iC3b 
C4BP Binds to C4b and: 
- Prevents assembly of C3 convertase  
- Accelerates decay of C3 and C5 convertases  
- Acts as co-factor to fI. (Blom, Villoutreix et al. 2004) 
FH and 
FHL-1 
Binds C3b and: 
- Competes with fB to reduce formation of C3 and C5 convertases 
- Displaces Bb subunit from convertases 
- Acts as cofactor to fI in cleavage of C3b (Jozsi and Zipfel 2008) 
Vitronectin Inhibits MAC insertion into cell membrane (Podack and Muller-
Eberhard 1979) 
Clusterin - Inhibits MAC insertion into cell membrane (Jenne and Tschopp 1989) 
- Modulates cell differentiation 
- Regulates production of proinflammatory cytokines i.e TNF-α 
and IL-6 (Falgarone and Chiocchia 2009) 
C8 - Binding of soluble C8 to C5b67 before it has bound to the 
membrane prevents the insertion of MAC into the cell 
membrane. 
 
Table 1.2: Summary of Action of the Main Soluble Complement Regulatory 
Proteins (CRegs). 
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1.3.6 Immune Modulation by Complement  
 
Since complement was first described in the 1800s, its wide-reaching role in the 
function of multipleareas of the immune system has become ever more apparent. 
Evidence for its critical position as a ‘bridge’ between the innate and both the 
humoral and cellular adaptive immune responses continues to grow (Dunkelberger 
and Song 2010). Thus complement is not only a chief component of the innate 
immune system in its own right, but also acts via the release of anaphylatoxins and 
opsonin deposition to enhance other branches of the immune response (Figure 
1.8). Complement has important roles in both inflammation and enhancing adaptive 
immune response. APC, B, T and NK cell responses are all regulated by an intricate 
interaction between complement activation products and cell surface receptors 
(Figure 1.6).  
  
1.3.6.1 Anaphylatoxins 
 
Cleavage of complement proteins results in both the creation of an active 
component, which goes on to trigger the next step in the cascade, and the release 
of smaller cleavage products which do not contribute directly to cell lysis. The 
complement cleavage products, C3a and C5a, act as powerful anaphylatoxins 
recruiting and activating numerous inflammatory cells to the site of complement 
activation (Gerard and Gerard 1994). The other complement-produced 
anaphylatoxins, C4a and Ba, appear to have very weak anaphylatoxic properties and 
are thus believed to have limited in vivo significance (Clark and Klebanoff 1978; 
Hamuro, Hadding et al. 1978).  
 
C3a and C5a mediate effector mechanisms of target cells and lead to a range of pro-
inflammatory immune responses including vasodilation, permeabilisation and 
smooth muscle contraction (Lambris 1988; Schumacher, Fantone et al. 1991; 
Ember, Sanderson et al. 1992). C5a and to a lesser extent C3a act as powerful 
chemoattractants which guide neutrophils, monocytes and macrophages towards 
sites of complement activation resulting in phagocytosis via binding of their  
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Figure 1.8: Complements Immune Modulatory Network. Complement has 
important roles in both inflammation and enhancing adaptive immune response 
acting via the release of anaphylatoxins and opsonin deposition to enhance other 
branches of the immune response. APC, B, T and NK cell responses are all regulated 
by an intricate interaction between complement activation products and cell 
surface receptors. Complement is thus at the centre of a dynamic hub-like network 
that is involved in both immune surveillance and cell homeostasis via tight 
connections to other systems.  
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complement receptors to opsonins, such as C3b, which coat target cells (Haas and 
van Strijp 2007; van Lookeren Campagne, Wiesmann et al. 2007). Both C3a and C5a 
are rapidly inactivated by carboxypeptidase-N to their desArg forms, thus avoiding 
excessive inflammatory activation and damage to host tissues.  
 
C3a 
 
As cleavage of C3 is the central step in the complement system, C3a is found in 
higher concentration than other complement cleavage products. C3a activates a 
respiratory burst in macrophages (Murakami, Imamichi et al. 1993) and neutrophils 
(Elsner, Oppermann et al. 1994) leading to the release of ROS, a major component 
of inflammatory response. C3a also recruits (Kretzschmar, Jeromin et al. 1993) and 
activates (el-Lati, Dahinden et al. 1994) mast cells and basophils resulting in the 
release of vasoactive amines such as histamine. C3a assists migration of cells which 
express the C3aR (Zwirner, Gotze et al. 1998) whilst other C3 products such as 
C3adesArg exert their effects in a receptor independent mechanism (Martin, Bock et 
al. 1997; Zwirner, Gotze et al. 1998).  
 
C3-deficient mice have impaired T cell responses which whilst detrimental in the 
setting of infection (Kopf, Abel et al. 2002; Nakayama, Kim et al. 2009) have proved 
advantageous in the setting of autoimmune disease and transplant rejection (Kaya, 
Afanasyeva et al. 2001; Marsh, Farmer et al. 2001). The ability of DCs to induce 
potent alloreactive CD4+ T cell responses is dependent on C3a signalling (Sacks 
2010).  
 
Complement is traditionally viewed as being a serum-operative system with 
activation and lysis occurring in the extracellular space however recent data have 
shown that C3 activation also occurs intracellularly (Liszewski, Kolev et al. 2013). 
Whilst mainly explored in T cells, intracellular C3a was found to be present in all cell 
types studied (myeloid, lymphoid, epithelial, endothelial and fibroblasts) suggesting 
that this could be a general, not a T cell-restricted, phenomenon and could thus 
have broad physiological significance (Liszewski, Kolev et al. 2013). C3 was 
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processed into active C3a and C3b by cathepsin L (CTSL), a protease expressed by T 
cells (Liszewski, Kolev et al. 2013). Resting T cells contain stores of C3 and CTSL as 
well as substantial amounts of C3a which was shown to be essential for 
homeostatic T cell survival (Liszewski, Kolev et al. 2013).  
 
C3a also has anti-inflammatory roles, with both C3a and C3adesArg suppressing 
polyclonal B cell responses (Fischer and Hugli 1997). In sepsis, contrary to the 
deleterious effects of C5aR signalling, C3aR signalling is protective (Hollmann, 
Mueller-Ortiz et al. 2008). During acute inflammatory response C3a has also been 
shown to inhibit mobilization of neutrophils into inflamed tissues (Wu, Brennan et 
al. 2013). C3a also appears to have anti-inflammatory roles independent of C3aR 
signalling, such as stimulating secretion of pituitary hormones (Francis, Lewis et al. 
2003) and suppression of the pro-inflammatory cytokines TNFα and IL-1 
(Takabayashi, Vannier et al. 1996). C3a should thus be considered an immune 
modulator rather than being considered purely pro-inflammatory (Coulthard and 
Woodruff 2015).  
 
C5a 
 
Whilst C3a is more plentiful, cleavage of C5 leads to production of the 11kDa C5a 
protein which, as it is both more resistant to carboxypeptidase-N cleavage and 
maintains biological activity in its alternative desArg form, is believed to be the 
most important complement derived anaphylatoxin in vivo (Burgi, Brunner et al. 
1994). C5a triggers mast cell degranulation leading to the release of histamine, 
matrix metalloproteinases and inflammatory cytokines (el-Lati, Dahinden et al. 
1994; Takafuji, Ishida et al. 2003) implicating it in the pathogenesis of a range of 
allergic and inflammatory conditions. C5a has chemoattractant effects on a range of 
cells which express C5aR including neutrophils (Ehrengruber, Geiser et al. 1994), 
macrophages (Aksamit, Falk et al. 1981), activated B (Ottonello, Corcione et al. 
1999) and T cells (Nataf, Davoust et al. 1999). Despite many positive roles, over-
production of C5a has been shown to be detrimental in sepsis, mainly due to 
paralysis of neutrophils (Riedemann, Guo et al. 2003) but also secondary to the 
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damaging effects of enhanced IFN-γ production by NK cells (Fusakio, Mohammed et 
al. 2011).  
 
C5a has other diverse roles which strengthen the immune response. Its role in 
regulating the mobilization of HPSCs from the BM acts to replenish the immune 
system (Jalili, Shirvaikar et al. 2010). Its ability to induce the expression of tissue 
factor and plasminogen-activator inhibitor 1 (PA-I1) (Ritis, Doumas et al. 2006; 
Markiewski, Nilsson et al. 2007), potentiates coagulation and inhibits fibrinolysis 
thus preventing the dissemination of infection via the bloodstream (Markiewski, 
Nilsson et al. 2007).  
 
Two receptors have been identified which bind with high affinity to C5a however, 
the vast majority of its effects seem to be mediated via binding to C5aR whilst the 
role of the alternative receptor, C5aR2 (previously known as C5L2) remains unclear 
(Okinaga, Slattery et al. 2003). C5aR2 is often referred to as a ‘decoy’ receptor 
which, by binding and removing active complement fragments from the 
extracellular environment, suppresses the inflammatory nature of C5aR stimulation 
(Scola, Johswich et al. 2009). Other studies have suggested that C5aR2 does have a 
functional role in sepsis beyond this with C5aR and C5aR2 being shown to have a 
synergistic role in detrimental outcome in sepsis (Rittirsch, Flierl et al. 2008). C5aR2 
was also demonstrated to have an independent role in release of the pro-
inflammatory mediator high mobility group box 1 protein (HMGB1) (Huber-Lang, 
Sarma et al. 2005).  
 
Both C3a and C5a are produced locally at the APC-T cell interface and determine the 
outcome of the T cell-APC interaction (Li, Anderson et al. 2008; Strainic, Liu et al. 
2008; Peng, Li et al. 2009). C5a promotes the migration of naive and memory B cells 
(Ottonello, Corcione et al. 1999). The effects of complement on T helper (Th) cells 
are influenced by both tissue-specific microenvironment and timing meaning that 
C5aR signalling can be both protective, in an allergen sensitization phase, but 
destructive once allergic inflammation is established (Kohl, Baelder et al. 2006). 
Interestingly, C3aR signalling appears to be able to counter the protective effects of 
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C5aR signalling in an allergen sensitization phase of asthma, contributing to Th2-
dependent airway hyper-reactivity (Drouin, Corry et al. 2002).    
 
The complement system uses both pattern recognition and missing-self recognition 
strategies in order to trigger its cascade. It is then able to communicate with other 
biological systems resulting in a coordinated innate immune response 
(Hajishengallis and Lambris 2010). For example, complement has been shown to 
cooperate with Toll-like receptors (TLRs) amplifying TLR-induced production of pro-
inflammatory cytokines in vitro and in vivo through C3aR and C5aR signalling 
(Zhang, Kimura et al. 2007). In this way, concomitant detection of infection by 
multiple distinct innate defence mechanisms acts to validate the danger and result 
in a more effective synergistic response.  
 
C5aR has been shown to lower the threshold for Fcγ receptor activation by both up-
regulating the expression of activating and down-regulating the expression of 
inhibitory Fcγ receptors (Shushakova, Skokowa et al. 2002; Kumar, Ali et al. 2006). 
FcγR activation also enhances the synthesis of C5 (Kumar, Ali et al. 2006) resulting in 
mutually reinforcing C5a-FcγR crosstalk which by combining phagocytosis with the 
specificity of IgG antibodies leads to the efficient clearance of pathogens.  
 
Infective, inflammatory or tumour related stimuli differentially regulate expression 
of a range of receptors for the complement C3 fragments C3a, C5a, C3b, iC3b and 
C3d which are expressed on NK cells (Min, Liu et al. 2014). Naive NKT and NK cells 
express high levels of C5aR mRNA, but no protein. During sepsis however, a subset 
of both NK and NKT cells begin to express C5aR on their surface, suggesting rapid 
translation of C5aR mRNA into protein on bacterial encounter (Fusakio, Mohammed 
et al. 2011). C5aR signalling up-regulates NKp46 expression on NK cells resulting in 
elevated IFN-γ and TNF-α levels which contribute to the detrimental effects of NKT 
and NK cells during early sepsis (Fusakio, Mohammed et al. 2011). NKT cells also 
exacerbate sepsis via IL10-mediated inhibition of CD55 expression on neutrophils 
resulting in enhanced C5a generation (Kim, Oh et al. 2014). Contrary to these 
findings C5aR signalling has also been shown to impinge on the expression of TRAIL, 
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a type 1 IFN target gene and pro-apoptotic factor, reducing the production of the 
type 1 IFNs, IFN-α and IFN-β and protecting against sepsis (Calame, Mueller-Ortiz et 
al. 2014).   
 
1.3.6.2 Opsonisation 
 
Complement activation results in the deposition of the ‘opsonic’ complement 
fragments C3b, C4b and associated inactivation products iC3b, C3d and C3dg. C3b 
cell surface deposition is essential to all 3 complement activation pathways. Various 
immune cells also express specific opsonin receptors which recognise deposition of 
C3b or its breakdown products. Opsonisation with C3b, and to a lesser extent C4b 
(Clark and Klebanoff 1978), results in enhanced immune responses via adherence of 
immune cells to complement ‘labelled’ cells (Fearon 1983; Lambris and Muller-
Eberhard 1986) and enhanced phagocytosis. Hence cells which activate 
complement are not only cleared via MAC deposition but via recruitment of other 
immune effector cells.       
 
Various immune cell types express cell surface proteins which bind to complement 
activation fragments these complexes are termed complement receptors 1-4 (CR1-
4) (Table 1.3). Complement receptors have a range of functions for example CR1 
interacts with both C3b and C4b to promote neutrophil-mediated phagocytosis and 
in doing so inactivates them, thus blocking further complement activation (Krych-
Goldberg and Atkinson 2001). CR1 also cleaves iC3b to C3dg both of which are 
ligands for CR2 which result in B cell activation and differentiation (Roozendaal and 
Carroll 2007; Carroll 2008). CR3 and CR4 also bind iC3b promoting phagoctosis 
whilst CR3 also regulates cytokine responses, leukocyte trafficking and synapse 
formation (Ricklin, Hajishengallis et al. 2010).  
 
Binding of C3 cleavage products to CR2 and/or CR1 on B cells is essential for Ag-
specific Ab responses to both T cell dependent and independent Ags (Thornton, 
Vetvicka et al. 1996; Da Costa, Brockman et al. 1999; Haas, Hasegawa et al. 2002).  
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 Expressed  Binds  Functions 
CR1 
(CD35) 
Erythrocytes 
B cells  
T cells 
Neutrophils 
(Wilson, Tedder et 
al. 1983; Fischer, 
Appay et al. 1986) 
C3b C4b 
(strong) 
iC3b 
(weak) 
Co-factor to fI→ increased C3b 
cleavage (Fearon 1979) 
Removal of immune complexes by 
erythrocytes for degradation in spleen 
(Cornacoff, Hebert et al. 1984) 
Opsoninsed cells targeted for 
endocytosis (Fearon, Kaneko et al. 1981) 
CR2  
(CD21) 
B- cells, 
DCs (Reynes, 
Aubert et al. 1985) 
C3dg, C3d  
iC3b (Kalli 
and Fearon 
1994) 
B cell activation and differentiation 
(Roozendaal and Carroll 2007; Carroll 2008) 
CR3 
(CD18/
11b) 
Macrophages iC3b 
C4b 
Integrin family of adhesion molecules 
Mediates phagocytosis of opsonised 
particles  (Hogg 1992) 
Regulates cytokine responses, 
leukocyte trafficking and synapse 
formation (Ricklin, Hajishengallis et al. 
2010) 
CR4 
(CD18/
11c) 
Neutrophils 
Platelets 
Macrophages 
Monocytes 
Erythrocytes 
(Myones, Dalzell et 
al. 1988) 
iC3b, 
C3dg, C3d 
(Vik and 
Fearon 
1985) 
Adhesion molecule 
Enhances localisation of coated 
immune complexes and particles 
 
Table 1.3:  The Expression, Binding and Activity of Complement Receptors.  
Various cell types express cell surface proteins which bind to complement activation 
fragments these complexes are termed complement receptors (CR) and are 
numbered CR1-4.  
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A CR2 targeted Ab was able to suppress 99% of primary B-cell Ab response in vivo 
via blocking binding sites for the opsonins iC3b and C3dg (Heyman, Wiersma et al. 
1990).  In addition, C3dg binding to CR2 enhances T-cell dependent B cell 
proliferation (Frade, Crevon et al. 1985; Dempsey, Allison et al. 1996) and promotes 
B cell survival by mediating Ag-independent signals (Fischer, Goerg et al. 1998). 
Complement also contributes to the maintenance of B cell memory with C3 
breakdown products being shown to bind to CR2 (and to a lesser extent CR1) on 
follicular DCs within lymphoid follicles (Papamichail, Gutierrez et al. 1975) 
enhancing the uptake and long-term retention of Ag (Roozendaal and Carroll 2007). 
 
1.3.7 Sub-lytic MAC 
 
MAC deposition results in disruption of the target cell’s membrane leading to a loss 
of homeostasis and at an adequate dose, rapid cell lysis. Anucleated eukaryotic 
cells, such as erythrocytes, can be lysed by a single MAC complex. More complex 
nucleated cells require the insertion of multiple MAC and use a variety of 
mechanisms in order to avoid complement mediated lysis and are thus far more 
resistant to CDC (Ohanian and Schlager 1981; Koski, Ramm et al. 1983). Low levels 
of MAC can result in a ‘sub-lytic’ attack which, although tolerated by the target cell, 
can lead to a wide range of effects. Factors that may lead to a sub-lytic level of 
complement attack include low levels of complement activation, the presence of 
inhibitory molecules and intrinsic membrane repair mechanisms, which can lead to 
shedding or internalisation of MAC (Koski, Ramm et al. 1983; Campbell and Morgan 
1985; Morgan, Dankert et al. 1987).  
 
MAC deposition, even in the absence of cell lysis, results in Ca2+ influx and inhibition 
of cyclic AMP formation (Campbell, Daw et al. 1981; Hallett, Luzio et al. 1981). This 
immediate influx of Ca2+ triggers a wide range of effects and has been shown to 
have a critical role in protecting nucleated cells from CDC (Morgan and Campbell 
1985). Sub-lytic MAC has been shown to drive inflammation and apoptosis via 
inflammasome activation (Triantafilou, Hughes et al. 2013) independently of C3a 
and C5a production (Laudisi, Spreafico et al. 2013).   
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Sub-lytic complement attack triggers protein synthesis and phosphorylation (Reiter, 
Ciobotariu et al. 1995) and stimulates cell proliferation (Niculescu, Badea et al. 
1999). Lipid metabolism has been shown to be affected by the insertion of MAC and 
plays a key role in cell survival following MAC deposition (Ohanian and Schlager 
1981; Papadimitriou, Carney et al. 1991). The finding that protein kinase C (PKC) 
inhibitors abrogate the protective role of sub-lytic MAC (Kraus and Fishelson 2000) 
led to the discovery that phosphorylation of ERK mitogen-activating protein kinases 
(Kraus, Seger et al. 2001), resulted in numerous downstream events including 
apoptosis, cell proliferation and regulation of gene expression (Pearson, Robinson 
et al. 2001).  Other pathways that have been shown to be activated by sub-lytic 
MAC include the Ras GTPase family (Niculescu, Badea et al. 1999) which has a role 
in cell proliferation and the c-Jun family (Rus, Niculescu et al. 1997) which is 
involved in cell cycle phase transition. Sub-lytic complement attack also leads to de 
novo protein synthesis in both normal (Benzaquen, Nicholson-Weller et al. 1994) 
and malignant cells (Quattrin, Albini et al. 1992).  
 
Aside from the effects of the actual deposition of terminal MAC, sub-lytic attack 
also results in the release of complement activation products which have a range of 
additional effects discussed above.  
 
All of these effects of sub-lytic MAC could be significant when considering the role 
of complement in tumour development and control. Crucially to the principal 
hypothesis of this thesis, sub-lytic MAC has also been shown to confer protection 
against subsequent complement attack (Quattrin, Albini et al. 1992).  
 
1.4 Evidence for a Role for Complement in Cancer  
 
Intimate interactions between emerging tumours and the host stroma mean that 
tumours develop under a strong selective pressure. Stromal elements such as 
fibroblasts, macrophages and endothelium facilitate tumour growth by promoting 
proliferation and neovascularisation and suppressing immune responses (Loveland 
and Cebon 2008). The diverse roles of complement in regulating mitogenic 
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signalling pathways, cell proliferation, angiogenesis, resistance to apoptosis, 
invasion and migration (Rutkowski, Sughrue et al. 2010) could also be critical to the 
malignant process.      
 
The complement system is activated within the malignant environment with 
complement deposition and elevated serum levels of complement components 
observed in a wide range of malignancies (Table 1.4). Interestingly, whilst NK cells 
and CD8+ T cells play a key role in limiting progression of carcinogen-induced 
tumours in mice, the complement system promotes progression of these same 
tumours (Turner 2010).  Whether complement deposition reflects an attempt by 
the immune system to clear tumours or an attempt by the tumour to evade 
immune clearance remains unclear.  
 
In lung carcinoma C3b deposition is seen in primary tumours (Niehans, Cherwitz et 
al. 1996) along with high plasma C3c, C4 and levels (Gminski, Mykala-Ciesla et al. 
1992) (Corrales, Ajona et al. 2012). Indeed, complement levels have been shown to 
correlate with tumour size (Nishioka, Kawamura et al. 1976; Guidi, Baroni et al. 
1988). Lung cancer cell lines are able to deposit C5b and generate C5a more 
efficiently than bronchial epithelial cells (Corrales, Ajona et al. 2012). C4d deposits 
are seen in low grade lymphomas such as follicular and MALT lymphomas but are 
absent in high grade disease (Bu, Zheng et al. 2007).  
 
MAC deposition is seen in a range of malignancies including breast cancer, where 
deposits increase following chemo- or radiotherapy and complement activity is also 
related to disease progression (Niculescu, Rus et al. 1992). Haemolytic complement 
activity also rises with tumour progression in brain tumours (Matsutani, Suzuki et al. 
1984). There is however only limited, and conflicting evidence for the effect of 
complement activation on prognosis. 
 
High serum MBL- associated serum protease 2 (MASP-2) levels, which is critical to 
activation of the lectin pathway, is an independent prognostic marker for poor 
outcome in colorectal cancer (Ytting, Christensen et al. 2005). 
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Tumour site  Complement abnormalities  Ref 
Lung   Increased plasma C3c, C4 and C5a 
levels. C3b and C5b (MAC) 
deposits. 
(Gminski, Mykala-Ciesla et al. 
1992; Niehans, Cherwitz et al. 
1996; Corrales, Ajona et al. 2012) 
Multiple 
myeloma 
Defective C3 activation and 
deposition 
(Zurlo, Schechter et al. 1989) 
Low grade 
lymphoma 
Deposition of C4d (not seen in high 
grade lymphomas) 
(Bu, Zheng et al. 2007) 
CLL  Low complement levels  (Schlesinger, Broman et al. 1996) 
(Fust, Miszlay et al. 1987) 
AML Classical and alternative pathway 
activation  
(Minh, Czink et al. 1983) 
Neuroblastoma  High C3 levels, classical pathway 
activation and haemolytic activity  
(Carli, Bucolo et al. 1979) 
(Gasque, Thomas et al. 1996) 
Breast  C5b-9, C3 and C4 deposits (Niculescu, Rus et al. 1992) 
Ovarian Elevated C3a and C5b-9 in ascitic 
fluid 
(Bjorge, Hakulinen et al. 2005) 
Thyroid C3d, C4d and C5b-9 complex 
deposition 
(Yamakawa, Yamada et al. 1994) 
(Lucas, Karlsson-Parra et al. 1996) 
Colorectal Activation of lectin pathway, 
elevated C3d 
(Ytting, Jensenius et al. 2004) 
(Baatrup, Qvist et al. 1994) 
Digestive tract + 
others  
Elevated ‘total haemolytic 
complement activity’ 
(Maness and Orengo 1977) 
‘Solid tumours’  Elevated C3c and C4.  (Guidi, Baroni et al. 1988) 
 
Table 1.4:  Complement Activation in Malignancy. Complement deposition and 
elevated serum levels of complement components are observed in a wide range of 
malignancy. Whether the presence of complement activation in the setting of 
cancer reflects an attempt by the immune system to clear malignant cells or 
evidence that tumours are using complement in order to evade immune clearance, 
remains unclear.  
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In contrast, low classical pathway activity at diagnosis has been shown to be highly 
predictive of short survival in chronic lymphocytic leukaemia (CLL) (Varga, Czink et 
al. 1995). Low levels of one or more of the complement proteins appear to be a 
feature of CLL and is related to disease progression with approximately 70% of CLL 
patients having low levels at diagnosis rising to 100% of advanced stage patients 
(Fust, Miszlay et al. 1987; Schlesinger, Broman et al. 1996). Interestingly, low 
complement levels are also observed in healthy first degree relatives of patients 
with CLL, suggesting that complement deficiency reflects a genetic predisposition to 
the development of CLL (Schlesinger, Broman et al. 1996).  
 
Despite a longstanding assumption that complement facilitates the elimination of 
cancer cells (Rutkowski, Sughrue et al. 2010) there is very limited data to support a 
role for complement in effective clearance of tumours. Complement activation does 
appear to play a key role in the mechanism of action of anti-cancer mAb 
immunotherapy, by both triggering direct cell lysis and enhancing Ab-dependent 
cell mediated cytotoxicity (Clynes, Towers et al. 2000; Dechant, Weisner et al. 
2008). In vivo studies have however given mixed results with several showing no 
role for complement in efficacy of mAb therapy (Uchida, Hamaguchi et al. 2004; 
Minard-Colin, Xiu et al. 2008; Hu, Turner et al. 2009) but others demonstrating a 
clear beneficial role (Di Gaetano, Cittera et al. 2003; Kennedy, Solga et al. 2003; 
Imai, Landen et al. 2005; Beurskens, Lindorfer et al. 2012). In human studies, 
enhancing complement activity appears to improve the efficacy of mAbs. The use of 
fresh frozen plasma as a source of complement in combination with rituximab in 
refractory CLL has been remarkably effective (Klepfish, Gilles et al. 2009; Xu, Miao 
et al. 2011). β-glycan, which has also proved a successful adjuvant to tumour mAb 
therapy, appears to function by priming the iC3b receptor CR3 on granulocytes and 
macrophages thus increasing chemotaxis of tumour cells opsonised with iC3b by 
anti-tumour mAb therapy, (Hong, Hansen et al. 2003). (Allendorf, Yan et al. 2005).  
 
Whilst both in vitro and in vivo evidence that anti-cancer mAbs activate 
complement, its role is complex and its contribution to their clinical efficacy is still 
70 
 
rather contentious.  As mAbs act via multiple effector mechanisms it is likely that 
complements role is both agent and clinical context dependent.  
 
In contrast complement appears to have a detrimental effect on the ability of NK 
activation to improve the efficacy of mAb therapy. C3b inhibits both NK cell 
activation and Ab-dependent cellular cytotoxicity induced by mAb coated 
lymphoma cells (Wang, Racila et al. 2008). C3 depletion enhances the ability of mAb 
coated cells to activate human NK cells and improves the efficacy of mAb therapy in 
an in vivo model (Wang, Veeramani et al. 2009). NK cells also appear to have a 
critical role in anti-tumour T cell responses triggered by decomplementation in a 
mouse model of melanoma (Janelle, Langlois et al. 2014).  Transient 
decomplementation with CVF during T cell priming resulted in a more robust and 
effective CD8+ T cell response which was dependent on increased NK infiltration 
(Janelle, Langlois et al. 2014).  
 
1.4.1 Complement Regulators in Cancer 
 
mCReg Cancer type Findings 
↑ CD59 
 
Melanoma (Brasoveanu, Altomonte et al. 1996) 
(Coral, Fonsatti et al. 2000) prostate (Jarvis, Li et al. 
1997) neuroblastoma (Chen, Caragine et al. 2000)  
Resistance to CDC  
Prostate (Loberg, Wojno et al. 2005) Increased metastasis  
Prostate (Xu, Jung et al. 2005), colorectal 
(Watson, Durrant et al. 2006) 
Poor prognosis 
↑CD55  Colorectal (Durrant, Chapman et al. 2003) Poor prognosis 
↓CD55 Breast (Madjd, Durrant et al. 2004)  Poor prognosis 
↑CD46  Breast (Rushmere, Knowlden et al. 2004) (Madjd, 
Durrant et al. 2005) 
Correlates with tumour 
grade and recurrence 
 
Table 1.5: Membrane Bound Complement Regulatory Protein (mCReg) Expression in 
Cancer 
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The expression of mCRegs is the best characterised complement-mediated cancer-
associated resistance mechanisms with most cancers over-expressing at least two 
separate mCRegs. The published associations of up-regulation of mCRegs 
expression in cancer are summarised in the Table 1.3.  A role for mCregs, in 
protecting against complement-mediated injury is supported by studies using mAbs 
against complement inhibitors which led to enhanced anti-tumour CDC (Gelderman, 
Kuppen et al. 2002; Sier, Gelderman et al. 2004; Allendorf, Yan et al. 2005). 
 
The sCRegs also appear to have a role in malignancy. Increased sCRegs expression is 
seen in a range of malignancies with fI and C4bp being overexpressed in lung cancer 
cell lines (Okroj, Hsu et al. 2008) and elevated C4bp levels being seen in the plasma 
of patients with a range of  solid tumours (Battistelli, Vittoria et al. 2005). C4bp is 
also able to bind to a range of ovarian carcinoma cell lines (Holmberg, Blom et al. 
2001). C1 inhibitor (Jurianz, Ziegler et al. 2001; Bjorge, Hakulinen et al. 2005) and 
clusterin (Trougakos and Gonos 2002) may also have a role in protecting cancer 
cells from complement mediated lysis.  
 
Several studies point to a role for the alternative pathway regulator factor H (fH) 
and its alternative splice variant fH-like protein 1 (FHL-1) in cancer. A clinically 
approved immunoassay based on the quantification of FH in the urine exists for the 
detection of bladder cancer (Kinders, Jones et al. 1998; Cheng, Corey et al. 2005). 
There is also evidence for a role of FH and/ or FHL-1 in glioblastoma (Junnikkala, 
Jokiranta et al. 2000), melanoma (Ollert, David et al. 1995), ovarian carcinoma 
(Junnikkala, Hakulinen et al. 2002) and lung cancer (Ajona, Castano et al. 2004; 
Ajona, Hsu et al. 2007), where high levels are associated with a poor prognosis (Cui, 
Chen et al. 2011).  
 
Complement has recently been demonstrated to be an essential component of 
tumour-promoting inflammation, an effect mediated via fH suppression (Bonavita, 
Gentile et al. 2015). The long pentraxin PTX53, an essential component of the 
humoral arm of innate immune system (Bottazzi, Doni et al. 2010), regulates 
complement by interacting with C1q and FH (Deban, Jarva et al. 2008). PTX53 
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deficiency results in tumour-promoting inflammation mediated via uncontrolled 
complement activation (Bonavita, Gentile et al. 2015). This could be relevant to 
human cancer as PTX53 is epigenetically repressed in a range of human tumours 
(Bonavita, Gentile et al. 2015). This implies that complement modulation might 
have a role in preventing malignancies associated with inflammation.        
 
Whilst increased CReg expression appears to be a feature of malignancy, the impact 
of this is controversial with conflicting studies demonstrating both low and high 
levels of CReg expression to be associated with disease progression (Koretz, 
Bruderlein et al. 1993; Hofman, Hsi et al. 1994; Madjd, Durrant et al. 2004) and high 
levels being linked to decreased survival (Durrant, Chapman et al. 2003; Xu, Jung et 
al. 2005; Watson, Durrant et al. 2006). Despite these seemingly conflicting findings, 
it is clear that complement activation and regulation is an active process in the 
malignant setting and appears to influence the phenotype of tumour cells and 
hence their capacity to proliferate and survive.  
 
1.4.2 C5a 
 
In 2008 a key paper was published by Markiewski and colleagues which for the first 
time showed that complement could promote tumour progression by modulating 
the anti-cancer immune response resulting in a favourable environment for tumour 
growth (Markiewski, DeAngelis et al. 2008). Using the TC-1 syngeneic model of 
cervival cancer, they demonstrated that C5a in the tumour microenvironment 
played a key role by suppressing the anti-tumour CD8+ T cell-mediated response via 
the recruitment and augmentation of MDSCs (Markiewski, DeAngelis et al. 2008). 
Regulation of the release of RONS by C5a amplified the suppressive capabilities of 
MDSCs (Markiewski, DeAngelis et al. 2008).   
 
A C5a mediated tumour promoting effect was also demonstrated in a transgenic 
model of ovarian cancer, however this effect was not found to be mediated via the 
immune system but via C5a stimulation of endothelial cells promoting angiogenic 
activity (Nunez-Cruz, Gimotty et al. 2012). C5a also creates a favourable 
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microenvironment for progression in lung cancer an effect mediated via both 
promoting angiogenesis and increasing MDSCs (Corrales, Ajona et al. 2012).  
 
C5a receptor (C5aR) signalling facilitates metastasis in breast cancer by suppressing 
both CD8+ and CD4+ T cell responses in the lungs via recruitment of MDSCs and 
regulation of their TGFβ and IL10 production however, no effect on the primary 
tumour was observed using this model (Vadrevu, Chintala et al. 2014). Other studies 
in breast cancer have supported a negative role for C5a with C5aR expression being 
associated with increased size, higher proliferation rates, presence of lymph node 
metastasis, advanced clinical stages and a worse OS (Imamura, Yamamoto-Ibusuki 
et al. 2015). Interestingly, examination of primary tumours from patients with C5aR 
positive metastasis, revealed over half to be C5aR negative supporting a possible 
role for C5a in tumour progression (Imamura, Yamamoto-Ibusuki et al. 2015).  
 
Contrary to the studies described above, a study pre-dating the Markiewski paper 
demonstrated that C5a expression by breast cancer clones led to a reduction in 
tumour growth due to cell cycle interference (Kim, Martin et al. 2005). This finding 
could be explained by a subsequent study demonstrating the effects of C5a to be 
dependent on the level of expression (Gunn, Ding et al. 2012).  As compared to a 
complete absence of C5a, high expression levels resulted in more aggressive tumour 
growth, via recruitment of MDSCs, whilst low levels resulted in a reduction in 
tumour growth, via enhancing NK, neutrophil and macrophage function (Gunn, Ding 
et al. 2012).  
 
The majority of evidence thus supports a role for C5a in promoting tumour 
progression in most cases mediated via inhibiting immune responses but also via 
promoting angiogenesis, however level of expression might be key. 
 
1.4.3 General Complement Depletion 
 
Using mouse models, it has been shown that whilst NK cells and CD8+ T cells play a 
key role in limiting progression of carcinogen-induced tumours, complement 
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actually promotes progression of these same tumours (Turner 2010). Ovarian 
cancer cell lines grew less well in C3KO and C3 HET mice and whilst tumours from C3KO 
mice were too scarce and small to be fully analysed (Nunez-Cruz, Gimotty et al. 
2012), tumours recovered from C3HET mice contained higher frequencies of effector 
T cells and fewer Tregs compared to WT mice (Nunez-Cruz, Gimotty et al. 2012).  
 
There are several methods of inhibiting complement in vivo although they all have 
limitations. The most widely used, cobra venom factor (CVF), is a structural and 
functional analogue of C3 which on contact with serum results in the formation of a 
long-lived C3/C5 convertase which activates C3 and C5 leading to soluble C5b-C9 
formation and resulting in the depletion of serum complement activity (Vogel, 
Smith et al. 1984). CVF is short acting and highly antigenic making data 
interpretation challenging however it is currently the standard method to which the 
inhibitory efficacy of experimental anti-complement agents are compared (Morgan 
and Harris 2003). The transient generalised complement inhibition achieved by this 
method results in impaired tumour growth in a range of models (Janelle, Langlois et 
al. 2014; Downs-Canner, Magge et al. 2015). 
 
CVF, humanised CVF and recombinant Staphylococcus aureus superantigen-like 
protein 7, which directly inhibits complement protein C5, were used to assess 
complement inhibition in a model of colon cancer (Downs-Canner, Magge et al. 
2015).  All resulted in a temporary decrease in tumour growth with CVF resulting in 
increased CD8+ T cells, reduced MDSCs and increased expression of the 
chemoattractive cytokines CCL5, CXCL10 and CXCL11 (Downs-Canner, Magge et al. 
2015).   
 
1.4.4 Complement-Induced Protection  
 
Sub-lytic levels of MAC have been shown to protect cells against further attack by 
fully lytic doses of complement (Reiter, Ciobotariu et al. 1992). This ‘induced 
protection’, which lasted 3-8 hours, was shown to be associated with Ca2+ influx and 
increased protein synthesis and was independent of levels of MAC deposition. Sub-
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lytic MAC was shown to almost completely protect cells from a 16-fold increased 
dose of complement required to lyse >70% of unprotected cells (Marchbank, van 
den Berg et al. 1997). Differential binding of complement binding Ab and CReg 
expression did not account for the protected phenotype. Leukaemic cell lines with 
sub-lytic MAC on their surface rapidly produce a large complement induced protein 
(L-CIP) (Reiter and Fishelson 1992) which is related to the heat shock protein family 
and is thought to have a role in tumour escape from CDC (Fishelson, Hochman et al. 
2001).  
 
The physiological relevance of this in vitro-defined process, termed “induced 
protection”, is unclear although it has been speculated that it prevents lysis of 
innocent bystander cells at sites of immune activity thereby limiting the extent of 
collateral damage caused by a given immune response (Reiter, Ciobotariu et al. 
1995). Sub-lytic MAC has also been shown to confer resistance to other pore- 
formers including perforin (Reiter, Ciobotariu et al. 1995), the cytolytic protein used 
by both NK and CD8+ T cells. In the tumour setting, the consequences of failed CDC 
and perforin mediated lysis could be highly significant. Malignant cells activate 
complement and complement proteins are often seen deposited on tumour cells. In 
contrast to this reflecting elimination of malignant cells, sub-lytic complement 
attack might protect tumours from clearance by both CDC and NK /CD8+ T cells.  
Whilst there is no direct evidence to support this hypothesis, it is compatible with 
many studies demonstrating that complement promotes progression of cancer is 
mediated by inhibiting CD8+ T cell and NK responses (Turner 2010; Nunez-Cruz, 
Gimotty et al. 2012; Janelle, Langlois et al. 2014; Downs-Canner, Magge et al. 2015).  
 
Tumour infiltrating lymphocytes (TILs) are often hypo-functional with tumour 
specific CTLs appearing to co-exist with the tumour without eliminating it (reviewed 
in (Rosenberg 2004)). Adoptive immunotherapy using in vitro expanded tumour 
specific CTLs has proved disappointing with effector function being progressively 
lost in vivo (Kaech, Hemby et al. 2002; Riddell, Murata et al. 2002; Morris, Hart et al. 
2006; Mantovani, Romero et al. 2008; Le Dieu, Taussig et al. 2009). T-cells induced 
by vaccination have also failed to impact on disease progression  
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- Complement Regulatory Proteins
- Shedding of MAC
-Secretion of complement 
proteins by tumour
- Partial recognition by 
complement
- Inflammation
Malignant cell MACCD8+ T cell
Natural Killer CellLysed cell
No MAC
Lysis
Lysis
Lytic MACSub-lytic MAC
Malignant cell protected 
from lysis by NK and CD8+ T 
cells by sub-lytic MAC
 
Figure 1.9: Potential mechanisms resulting in induced-protection of malignant 
cells. Malignant cells could use a range of mechanisms including secretion of 
complement proteins, expression of complement regulatory proteins and shedding 
of MAC in order to maintain complement in a constant state of low level activation. 
In addition low level complement activation may result from malignant cells being 
partially recognised by the host’s immune system. Concomitant low grade infection 
or inflammation may also result in the correct conditions required for induced-
protection to occur.    
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(Monsurro, Wang et al. 2004) . With these data in mind it is reasonable to expect 
that compromising the killing capacity of NK cells and CTLs, through a mechanism 
such as complement-induced protection (CIP), would favour tumour progression 
(discussed in theoretical paper, (Kempshall, Thebault et al. 2012 see appendix 1) 
(Figure 1.9).  
 
It is clear that the complement system plays a key but complex role in malignancy 
which has yet to be fully explored. It is possible that the role of complement could 
be analogous to the dichotomous role played by the immune system in malignancy 
with its tumour promoting or protective roles being dependent on both the context 
and level of activation.  
 
1.5 Complement in AML 
 
There has been very little research into the role of complement in AML. Increased 
haemolytic activity of both the classical and alternative pathways is observed in 
patients with AML (Minh, Czink et al. 1983). C4, C3 and fB titres are elevated in 
patients with AML with serial measurements revealing the highest titres in patients 
in blastic phase compared to those in remission (Minh, Czink et al. 1983). Myeloid 
blasts also produce factors which increase complement protein synthesis by 
monocytes and hepatocytes in vitro; an effect mediated by IL-1 and IL-6 (Gyapay, 
Schmidt et al. 1991; Schmidt, Valay et al. 1995).    
 
More recently a proteomics study identified complement C3f-desArg and its 
derivative as having a potential role in the diagnosis and MRD assessment of acute 
leukaemia (Liang, Wang et al. 2010). This study used bead fractionation/MALDI-
TOF-MS analysis of sera from patients with AML or ALL (Liang, Wang et al. 2010). 
Two C3f fragments were identified whose relative intensities gradually decreased as 
the degree of leukaemic remission deepened (Liang, Wang et al. 2010). Acute 
promyelocytic leukaemia (APL) is a distinct subtype of AML characterised by the 
presence of a t(15;17) translocation that results in an abnormal fusion protein 
termed PML/RARα which is a well characterized and widely used MRD marker 
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(Grimwade, Jovanovic et al. 2009). Detection of the two C3f fragments was found to 
be as sensitive a marker for MRD as the PML-RARα fusion protein in identifying 
MRD positive APL (Liang, Wang et al. 2010). However, in contrast to PML-RARα, 
MRD detection of these C3 derivatives is applicable across all sub-groups of AML 
and ALL, thus offering a powerful, widely applicable, diagnostic tool.     
 
These derivatives of C3f have also been identified in other forms of cancer including 
bladder, prostate, thyroid and breast (Villanueva, Martorella et al. 2006; Profumo, 
Mangerini et al. 2013). Elevated levels of C3f found in the sera of women affected 
with the benign condition gross cystic disease of the breast, correlating with the 
development of breast cancer even 20 years later (Profumo, Mangerini et al. 2013). 
C3f is cleaved from the α-chain of C3b when it is converted into its inactive form 
iC3b by fI and H and is rapidly degraded into C3f-desArg (Liang, Wang et al. 2010). 
FH has been identified as being important in several malignancies including colon, 
lung, ovarian and bladder cancers (Kinders, Jones et al. 1998; Junnikkala, Hakulinen 
et al. 2002; Ajona, Castano et al. 2004; Ajona, Hsu et al. 2007; Wilczek, Rzepko et al. 
2008). A clinically approved immunoassay used to detect bladder cancer is based on 
the quantification of both FH and FH-related molecule in the urine (Kinders, Jones 
et al. 1998; Cheng, Corey et al. 2005).  
 
1.6 Summary 
 
The dual role of the immune system in both fostering and preventing the 
development of cancer is now widely accepted. The proven ability of the immune 
system to eliminate leukaemia is demonstrated by the efficacy of allogeneic SCT. 
Naturally occurring immune responses against leukaemia are inhibited by a range of 
suppressive mechanisms which both hamper attempts to develop successful 
immunotherapy and offer novel therapeutic targets aimed at unleashing natural 
immune responses. Any mechanism which impinges on the ability of the immune 
system to eliminate leukaemia warrants investigation with the aim of empowering 
patients’ own immune system to control and eliminate leukaemia. The maximal 
therapeutic benefit is likely to have already been achieved using conventional 
79 
 
combination chemotherapy. Whilst targeting genetic or epigenetic aberrations is an 
active area of research in AML, this is limited by the genetic heterogeneity that 
exists both within individual patients and between cases. Research aimed at 
circumventing this heterogeneity by targeting AML-niche interactions is extremely 
interesting and has implications on immune interactions. Immune mediated 
therapies are highly likely to play an important role in future improvements to 
outcomes in AML.  
 
The complement system has a role as both a crucial effector of innate immunity in 
its own right and as a mediator of both innate and adaptive immune responses. 
Complement has been demonstrated to have both inflammatory and anti-
inflammatory roles and both protect against and promote the progression of 
malignancy in both a context and dose dependent manner. The complement 
system’s role in the progression of AML is largely unexplored but limited data 
implies that it could be critical to both the initiation of leukaemia and its escape 
from immune control.      
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1.7 Research Questions 
 
1) Does exposure to sub-lytic complement protect AML cells from lysis by NK 
cells in vitro? Published work suggests that sub-lytic complement not only 
protects cells from lytic attack by complement but also from a range of other 
pore-formers including perforin. This study used a flow cytometric method to 
test the hypothesis that sub-lytic complement attack protects AML cells from 
lysis by NK cells. 
  
2) Is there a genetic signature for complement-induced protection? This study 
compared the genetic signature of untreated AML cells to cells subjected to sub-
lytic complement attack.  
 
3) Does complement affect the progression of AML in vivo?  Studies in other 
malignancies suggest a role for complement in promoting the progression of 
cancer. This study tested the hypothesis that complement impacts on 
progression of AML in vivo.   
  
4) Which components of the complement cascade impinge on progression of 
AML? Several components of the complement cascade including C3a, C5a, C3b 
and MAC have the potential to impact on the progression of AML. A 
combination of mice genetically deficient in various components of the 
complement system and inhibitors administered to WT mice were used in order 
to systematically investigate the role of complement in progression of AML.  
 
5) What are the mechanisms underlying the role of complement in the 
progression of AML? Complement has been shown to suppress the CD8+ T cell 
response against cancer. Experiments were conducted to test the hypothesis 
that complement promotes progression of AML through effects on the anti-AML 
T cell response.  
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Chapter 2- Materials and Methods  
 
2.1 Reagents 
 
Complement Fixation Diluent (CFD): 2.8mM Barbituric acid, 145.5mM NaCl, 0.8mM 
MgCl2, 0.8mM CaCl2, 0.9mM Sodium Barbital, pH 7.2. 
Flow Cytometry Buffer: PBS, 1% BSA (Sigma), 1% NaN3, pH 7.4 
Freezing solution: 10% DMSO (sigma), 90% FCS (Invitrogen) 
Glycine elution buffer: Ultrapure RNAse/DNAse free H2O (Invitrogen) 0.1M Glycine 
(Fisher) acidified to pH 2.5 with molecular grade HCl (Sigma) 
Low IgG R10 tissue culture media: RPMI-1640 (Gibco) containing 15% heat-
inactivated low-bovine IgG FCS (Gibco), 50U penicillin/streptomycin, 2mM L-
glutamine, 1mM sodium pyruvate and 1% non-essential amino acids 
MACS buffer: PBS, 05.% BSA, 5mM EDTA 
Phosphate Buffered Saline (PBS) (for use in in vitro studies): 8.1mM Na2HPO4, 1.5M 
KH2PO4, 137nM NaCl, pH 7.4  
PBS-BSA: PBS, 1% Bovine Serum Albumin 
PBS-Tween: PBS, 0.1% Tween 20 (Acos Organics) 
R10 tissue culture media: RPMI-1640 (Gibco), 10% heat inactivated foetal calf 
serum (FCS), 50U penicillin/streptomycin, 2mM L-glutamine, 1mM sodium pyruvate 
and 1% non-essential amino acids (Invitrogen) 
R+ tissue culture media: RPMI-1640 supplemented with 50U 
penicillin/streptomycin, 2mM L-glutamine and 1mM sodium pyruvate 
SDS-PAGE Loading Buffer (reduced): 0.1M Tris (pH6.8), 10% Glycerol, 2% SDS, 
0.01% Bromophenol Blue, 2% β-mercaptoethanol. 
SDS-PAGE Running Buffer: 25mM Tris, 191mM glycine, 1% SDS 
Transfer Buffer: 25mM tris, 191mM glycine, 20% methanol  
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2.2   Antibodies 
 
Antibody Specificity Isotype Application Dilution Source 
Anti IgM  Goat anti-mouse 
anti-IgM biotin 
conj pAb 
igG FACs 10μg/ml Invitrogen 
SA PE Strepavidin, R-
phycoerythrin 
conj Ab 
 FACs 2μg/ml Invitrogen 
Anti-C3 
HRP 
HRP conjugated 
goat-anti-mouse 
C3 mAb 
IgG WB 1μg/ml Abcam 
11H9 Rat anti-mouse 
C3, C3b, iC3b, 
C3dg mAb 
IgG2a IHC 5μg/ml Hycult 
Isotype 
control 
Rat IgG2a  IgG2a IHC 5μg/ml Caltag 
BB5.1 Mouse anti-
mouse C5 mAb 
IgG1 Depletion 10mg/ml In house 
D1.3 Mouse anti-hen 
egg lysozyme 
IgG1 Control for 
BB5.1 
10mg/ml In house 
Anti-rab 
eryth 
Mouse anti-rabbit 
erythrocyte pAb 
 Killing assay 2.8mg/ml In house 
AN-18 Rat anti-mouse 
anti-IFN-γ  
Rat 
IgG1 
Capture mAb 
ELISpot 
15μg/ml Mabtech 
R4-6A2 Biotinylated rat 
anti-mouse IFN-γ  
Rat 
IgG1 
Detection 
mAb 
ELISpot 
1μg/ml Mabtech 
Anti CD8a PB conjugated 
anti-mouse CD8a 
Mouse 
IgG2aκ 
FACs 5μg/ml BD 
Biosciences 
Anti Fitc conjugated Mouse FACs 5μg/ml Biolegend 
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NK1.1 anti-mouse NK1.1 IgG2aκ 
Isotype 
control 
Mouse IgG2a IgG2aκ FACs 5μg/ml Biolegend 
PK-136 Mouse anti-
mouse anti-NK-1 
mAb 
Mouse 
IgG2aκ 
Depletion 5mg/ml  In house 
YTS-156 Rat anti-mouse 
anti-CD8 mAb 
Rat 
IgG2b 
Depletion 1mg/ml In house 
YTS-169 Rat anti-mouse 
anti-CD8 mAb 
Rat 
IgG2b 
Depletion 1mg/ml In house 
YTS-191 Rat anti-mouse 
anti- CD4 mAb 
Rat 
IgG2b 
Depletion 1mg/ml In house 
YTA-3 Rat anti-mouse 
anti CD4 mAb 
Rat 
IgG2b 
Depletion 1mg/ml In house 
GL113  Isotype control Rat 
IgG2b 
Isotype for 
depletion Ab 
1mg/ml In house 
 
Table 2.1 Antibodies. Summary of the characteristics of antibodies used.  
 
 
2.3  Cell lines 
 
2.3.1  K562  
 
K562 cells are undifferentiated blasts originally derived from a patient with chronic 
myeloid leukaemia during blast crisis. K562 has a doubling time of 12 hours, lacks 
HLA, ALL and thymocyte antigens and is described as being myeloid in origin 
(Koeffler and Golde 1980). K562 was used in the original studies describing 
complement-induced protection (Reiter, Ciobotariu et al. 1992; Reiter, Ciobotariu et 
al. 1995). The K562 cell line is a highly sensitive target for NK cells due to low 
expression of MHC class I molecules (Drexler 2001). 
2.3.2  C1498 
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C1498 is a mouse acute myeloid leukaemia (AML) cell line which developed 
spontaneously in C57BL/6 (B6) mice and is classified histologically as myelo-
monocytic (Dunham and Stewart 1953). It expresses both a granulocyte marker 
(gran-1) and 2 macrophage markers (Mac 1, Mac 3) and is uniformly positive for the 
pan-haematopoietic (CD45) marker Ly 5 (Boyer, Orchard et al. 1995). It is MHC class 
I positive but class II negative and lacks expression of T cell, pre-B cell and NK cell 
markers as well as FcR II  (Boyer, Orchard et al. 1995). It also expresses both ICAM-1 
and ICAM-2 and high levels of LFA-1 (Boyer, Orchard et al. 1995).  
 
C1498FFDsR is a stable transfectant of C1498 that was prepared using a non-viral 
vector delivery system to achieve expression of both fluorescent Discoma coral-
derived protein DsRed and firefly luciferase (Sauer, Ericson et al. 2004). C1498FFDsR 
was initially used in order to accurately detect disease within tissue samples but 
was subsequently found to allow in vivo analysis of disease development using 
fluorescence imaging equipment.  
 
2.4  Cell Culture 
 
Both the human K562 and murine C1498 cell lines were maintained in R10 tissue 
culture media. Cells were maintained at a confluence level of between 1 x 105 and 1 
x 106 cells per ml in  ssue culture  asks (Nunc) incubated at 3   C, 5% C02.  
 
2.5  Cell freeze, thaw and storage 
 
For in vivo experiments the original vial of C1498FFDSRed cell (henceforth referred 
to as C1498) supplied by Professor Blazar were bulked up and frozen into multiple 
aliquots on receipt such that an identical aliquot could be used for each experiment. 
Cells were re-suspended in freezing solution and aliquoted into 1ml cryovials which 
were placed into Cryo 1  C Freezing containers (Nalgene) and stored at -80  C. Cells 
were thawed in a 3   C water bath, re-suspended in 10mls of R10, centrifuged at 
450G for 5 minutes before being re-suspended in 10ml of fresh R10.  
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2.6  Antibody preparation 
 
TG1 is an anti-myeloid cell IgM monoclonal antibody (Ab) originally raised against 
the glycoprotein fraction of thymocyte membranes(Beverley, Linch et al. 1980). An 
original batch of TG1 supernatant along with the TG1 secreting cell line was kindly 
supplied by Dr Alison May (Dept of Haematology, Cardiff University). Following 
success with early studies using the TG1 supernatant, further supernatant was 
produced in order to complete the in vitro experiments described in Chapter 3. 
Supernatant from anti-C5 antibody BB5.1 (BB5.1) and its isotype control D1.3 
hybridomas were also prepared in this way and then purified using an endotoxin-
free method for use in the in vivo studies described in Chapter 4.  
 
Hybridomas were cloned by limiting dilution in order to obtain a stable clone 
secreting high amounts of antibody. This clone was then inoculated at an initial 
density of 2 x 107 cells, suspended in 15mls low IgG R10 media into the lower 
compartment of a CELLine 1000 Integra flask (Integra Biosciences). This comprises a 
lower (small) and upper (large) compartment separated by a 10kDa semi-permeable 
membrane. 1L R+ media was then added to the upper compartment and the  ask 
was incubated at 3   C, 5% C02.  
 
Supernatant was harvested 1-2 times per week. This was done by first draining the 
upper compartment then during the initial period the cell suspension was removed 
from the lower compartment under sterile conditions and centrifuging at 450G for 
5mins, supernatant was removed and the cell pellet re-suspended in 15mls of fresh 
low IgG media and replaced in the lower compartment of the Integra. Once a large 
pellet of cell had been achieved, 15mls of cell suspension was removed from the 
lower compartment and replaced with fresh low IgG media in order to maintain the 
cells at an optimal confluence and reduce the risk of contamination. The upper 
compartment was then refilled with 1L fresh R+ media and the Integra replaced at 
3   C, 5% C02. Supernatant was centrifuged at 900G for 10mins x 2 in order to 
remove cell debris before being frozen at -20  C. 
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2.7  ‘Endotoxin-low’ antibody purification 
 
Hybridoma supernatant was thawed and pooled before high speed centrifugation at 
1350G for 15 minutes at 4  C. Supernatant was then filtered through 0.22μM 
Stericup filter unit (Millipore) in order to remove any residual cell debris. All buffers 
were made in a class II cabinet in advance of purification. The AktaPrime protein 
purifier (GE Life Sciences) was pre-washed 3 times with 0.5M NaOH wash buffer to 
remove all traces of endotoxin. All lines were then rinsed x 3 with ultraclean water 
and checked with pH fix 0-14 litmus strips (Fisher) to ensure that all NaOH had been 
removed.  
 
A 5ml Hi-Trap Protein G column (GE healthcare) was then attached to the Akta 
prime and Ab containing supernatant passed over the column. 0.1M Glycine elution 
buffer was used to elute protein from the column. Fractions were collected in 
sterile FACs tubes (BD biosciences) and neutralised using 100μl 1M Tris/HCl pH 9. 
Ab-containing fractions were identified using the absorbance trace via Primeview 
software. The column was cleaned between each cycle with ultraclean H20 acidified 
to pH 1.5 with HCL.   
 
Neutralised Ab fractions were pooled and loaded into Lyser dialysis cassettes 
(Fisher), dialysed three times into sterile PBS (Invitrogen) and then harvested into 
sterile tubes using a needle and syringe. Concentration was assessed using an A280 
reading on the Nanodrop spectrophotometer (Labtech) before the antibody was 
frozen in aliquots in sterile freezing vials.    
 
2.8  Preparing normal human serum  
 
Normal human serum (NHS) was prepared from blood taken from healthy 
volunteers. This was collected into glass tubes and left at room temperature for 
20mins with the edges of the forming clot being released intermittently. Following 
this, samples were then transferred to ice for a further 20mins. Samples were then 
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transferred to large falcon tubes and spun at 900 G for 10 minutes. The resulting 
supernatant and any loose cells were then transferred to a fresh falcon and spun for 
a further 10minutes at 900 G. Serum was then pooled, aliquoted and frozen at -
80  C.  
 
2.9  Complement Lysis Assay  
 
K562 cells were incubated with titrated dilutions of supernatant from TG1 cells in 
Complement Fixation Diluent containing 0.1% gelatin w/v (CFD-g). Once coated in 
the TG1, K562 cells were exposed to dilutions of NHS (in CFD-g), as a source of 
complement. Ab and NHS doses were titrated in order to achieve 5-10% 
complement mediated cell lysis. The nucleic acid dye 7-amino-actinomycin D (7-
AAD, BD pharminogen) was used to identify non-viable cells. ‘Sub-lytically’ attacked 
cells and controls were then coated with a titrated dose of TG1 such that surface 
levels were equivalent before being exposed to a lytic dose of NHS. Surface IgM was 
quantified using mouse anti-IgM biotin conjugated antibody followed by 
strepavidin, R-phycoerythrin conjugated antibody (both Invitrogen).  
Each condition was performed in triplicate with assay volume tightly controlled and 
a fixed time and speed being used during sample acquisition. The level of cell lysis 
was calculated by counting the number of live cells at the end of the assay and 
expressing this as a percentage of the live cells present in the control (equivalent 1st 
step with no subsequent lytic step). 
 
number of live cells in test condition          x  100         (method A) 
number of live cells in internal control  
 
2.10  CFSE labelling  
 
K562 cells were washed in PBS then resuspended in 3ml warm PBS/0.1%BSA at a 
concentration of 2 x 106/ml. A 1uM carboxyfluorescein succinindyl ester (CFSE) 
(CellTrace, CFSE cell proliferation kit, (Invitrogen) solution was made using warm 
PBS/0.1%BSA. K562 were then added to CFSE (final concentration 0.5uM CFSE and 
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106 cell/ml). Following a 10 minute incubation at 3   C, cells were ‘quenched’ by 
adding 5 x volume of ice cold R10 then incubating on ice for 5mins. Following this, 
cells were centrifuged at 450 G for 5 mins, washed x 2 in CFD-g then resuspended at 
1 x 106/ml and stored in the dark until use.   
 
2.11  Ficoll Separation of PBMCs 
 
Heparinised whole blood (200μl heparin/ 20 ml blood) was layered over an equal 
volume of Lymphoprep (Axis-Shield, Oslo, Norway) then centrifuged at 900 G for 20 
mins at room temperature with no brake. A Pasteur pipette was then used to 
extract the PBMC layer from the Lymphoprep interface which was then washed 
twice in R10. 20μl of cell suspension was then mixed 1:1 with Trypan blue and 
counted using a haemocytometer under a light microscope.  
2.12  NK Killing Assay 
 
PBMCs were preconditioned overnight with or without 50IU/ml or 1000IU/ml IFNα 
(Roferon, Roche) in R10. The following day, K562 were labelled with CFSE, in order 
to discriminate them from PBMCs in co-culture.  Labelled K562 were then exposed 
to sub-lytic complement. TG1 was re-titrated before cells entered a 4 hr NK killing 
assay using pre-conditioned PBMCs as a source of activated NK cells at a 5:2 
effector: target ratio.  
 
NK target lysis is conventionally expressed as:      
 
      dead targets         x 100                             (Method B) 
        total (live + dead) targets     
 
Due to target lysis and hence loss from the assay, Method A was reintroduced as a 
more accurate method of calculation.  
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number of live cells in test condition          x  100             (Method A) 
number of live cells in internal control  
 
A modified experiment in which the sub-lytic step and NK kill occurred 
simultaneously was also developed in which the 10% FBS present in R10 was 
replaced with 10% normal human serum as a source of complement.   
 
2.13  MACs removal of dead cells 
 
A magnetic-activated cell sorting (MACS) based dead cell removal kit (Miltenyi 
Biotec) was used in accordance with the manufacturers’ guidance following the 
initial sub-lytic attack in order to remove apoptotic and dead cells. Cells were re-
suspended in 100μl of MACS bead, mixed and left at room temperature for 15 
minutes. During this time binding buffer (BB) was prepared by diluting BB stock 
1/10 in sterile, double distilled H20. 500μl of BB was then used to prime each MACS 
column. Following incubation with MACS beads, 500μl of BB was added and the 
solution was then applied to the column. Columns were then rinsed 4 x with 500μl 
BB. Live cells present in the resulting effluent were washed twice in R10. 
 
2.14  RNA extraction 
 
A Qiagen RNeasy Mini Kit was used to extract RNA from the samples. All samples, 
which had been stored at 4  C in RNAlater, were centrifuged at 450 G for 5 minutes 
to pellet the cells. Supernatant was then completely removed before cells were 
lysed and homogenised in the presence of a highly denaturing guanidine 
isothiocyanate-containing buffer which immediately inactivates RNases to ensure 
isolation of intact RNA. Ethanol was then added to allow all RNA >200 nucleotides, 
to bind effectively to the membrane of the RNeasy mini column whilst washing 
away contaminants. The isolation of only RNA >200 nucleotides in length enriches 
for mRNA. RNA can then be eluted from the membrane using water.  
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The amount of RNA present in the eluted sample was then measured using a 
Nanodrop ND1000 (Labtech) spectrophotometer (Nanodrop). The Nanodrop was 
first used to set a baseline ‘zero’ absorbance reading at 260nm (A260nm) using carrier 
only (water) and then sequential RNA samples were measured with the arm being 
cleaned and blanked with H20 between each sample. An A280nm/A260 ratio was 
calculated in order to assess purity and a desired ratio of ≈ 2 was achieved in all 
RNA samples.  
 
2.15  Microarray   
 
DNA microarrays simultaneously measure the expression levels of many genes by 
using probes specific to a DNA sequence within a given gene. The level of RNA 
hybridized to the probes is detected and quantified using fluorescent labelled target 
sequences allowing the gene expression level to be determined. Relative 
quantification is used to compare the intensity of a given probe in a sample exposed 
to a different condition. An Illumina Human HT-12v4 BeadChip, which uses probes 
immobilized to microscopic beads and analyses twelve samples simultaneously, was 
used.   
 
2.16  Microarray statistical analysis   
 
Microarray Analysis was completed in collaboration with the Bioinformatician, Dr 
Robert Andrews. The code an007.R was used to run the analysis and the lumi and 
limma packages in BioConductor were used to analyse the data. Raw data was 
inputed from GenomeStudio with replicate probes being averaged to a single value 
per probe. Data were normalised using Variance Stabilizing Transformation (VST) 
(the standard method for Illumina gene expression arrays) where data are 
background subtracted, VST transformed and quantile normalised.  
 
Box plots of both raw and quantile-normalised data were used to assess the quality 
of the data. Hierarchical cluster analysis and principal component analysis were 
used to assess the natural clustering of the experimental groups. Hypothesis-driven 
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statistical analysis was then carried out in order to identify statistically significant 
changes in gene expression unique to the IP condition. Results were then validated 
by changing the normalisation method, building a batch effect into the model and 
removing potential outliers form the analysis. Methods and findings were reviewed 
by a second Bioinformatician.  
 
2.17  Mice 
 
Mice were bred and maintained in standard cages in the Joint Biological Services 
Unit (JBIOS), Cardiff University, Heath Park. Imaging studies were initially carried 
out in JBIOS before all imaging equipment was moved to a dedicated imaging suite, 
also on the Heath Park campus.  
 
C3-/- mice were previously back-crossed onto C57BL/6 (B6) background at least 10 
times (Morgan, Chamberlain-Banoub et al. 2006). C3aR-/- mice were originally 
obtained from Professor Craig Gerard and permission was granted to use these 
mice for these studies. C6-/- mice were available in our laboratory but had only 
been back crossed 7 times, these were therefore back-crossed onto B6 mice a 
further 3 times prior to commencing these studies. In experiments using knock-out 
mice, age-matched WT B6 mice aged between 6- 10 weeks were also used. All 
experiments were performed in compliance with Home Office regulations. Personal 
license number i49f49f29 (previously 30/9922). Project license 30/2891, protocol 2.  
 
2.18  Splenocyte preparation 
 
Individual spleens were gently crushed in 5ml PBS using the flat end of a 5ml syringe 
plunger through a 70m cell strainer into a 50ml tube. A further 10ml of PBS was 
then added to the tube through the strainer. Cells were then centrifuged at 500 G 
for 5 min. Supernatant was removed and the cell pellet re-suspended in 5ml red cell 
lysis buffer diluted 1/10 with sterile water. After 90 seconds, 15mls of PBS was 
added and cells were centrifuged for 5 mins at 500 G. Cells were then re-suspended 
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in 5mls R10, removing any visible cell debris. Cells were counted and resuspended 
in facs buffer or R10 at the desired concentration.  
 
2.19  Murine serum collection 
 
Mouse serum was either harvested from live mice following tail tipping and milking 
of 100μl into a collection vial or following schedule 1 sacrifice when blood was 
collected by intrathoracic cardiac aspiration. Blood was clotted on ice for 15 
minutes before being spun at 450 G for 10 minutes at 4  C before the upper serum 
frac on was used immediately or stored at -80  C.   
 
2.20  C1498 cell inoculation 
 
Cells were thawed 4- 7 days prior to each experiment. Cell viability and density was 
assessed and cells passaged on day 1 post thaw and the day prior to inoculation. 
Viability was assessed using cells pre-mixed with 1/1 Trypan blue solution (Fluka) 
and was required to be >95% in order for tumour cell inoculation to proceed. Cells 
were counted using a haemocytometer and resuspended at 1 or 5 x 107 cells/ ml in 
sterile PBS such that 100μl would provide 1 or 5 x 106 cells as per experimental 
protocol.         
   
For intravenous (IV) studies inoculums of 106 and 5 x 106 were explore in my initial 
experiment with animals in all subsequent experiments receiving 5 x 106  C1498 
cells  IV. These were administered via tail vein injection into study animals which 
had been warmed for >15mins prior to injection to achieve maximal vasodilation. 
For subcutaneous (SC) studies inoculums of 106 were injected into the left lateral 
abdominal wall.     
 
2.21  In vivo imaging 
 
Experimental mice were first anaesthetised with inhaled isofluorane which was 
maintained throughout the imaging process. The abdomens of mice were shaved to 
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allow optimal imaging. Kodak FX Pro fluorescence imaging equipment (FX-Pro) was 
used to image DSRed positive leukaemic infiltrations using an excitation filter of 
550nm and emission filter of 600nm in conjunction with an exposure time of 20 
seconds. Fluorescent images were superimposed on white images to allow accurate 
disease localisation of the cellular DSRed fluorophore in malignant tissue. A 
combined imaging and health (IH) score was devised which scored both imaging 
findings and health factors to allow consistent decisions to be made on 
experimental endpoints (Table 2.2).  
 
Mouse Health Points 
Minor behavioural- easier to catch, not trying to escape 1 
Piloerect, dishevelled 2 
Palpable lump 3 
Abnormal posture or locomotion 4 
Definite symptoms of ill health- piloerect, hunched, isolated  4 
Imaging finding  
Lesion visible when settings adjusted but not at experimental settings 1 
Single positive lesions 2 
Multiple positive lesions 3 
Full body bioluminescence 4 
 
Table 2.2: Imaging and Health (IH) Score. This incorporates both imaging findings 
and health factors in a combined score allowing consistent decisions to be made on 
experimental endpoints. Initial experiments used an IH score of 4 points as the 
experimental endpoint. This was later revised to 3 and then 2, in order to minimise 
any ill effects experienced by the mice.  
 
Following euthanasia, livers, spleens and ovarian tumours were harvested and 
preserved in op mal cu ng temperature compound ( CT) at -80  C or in 4% 
paraformaldehyde solution (PFA) at RT prior to being embedded in paraffin. 
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2.22  T and NK cell depletion  
 
The anti-NK antibody PK136 was used at a dose of 0.5mg IP (2 mice). Two anti-CD8 
antibodies (YTS-169 and YTS-156) were used in combination, each at a dose of 
100μg IP (2 mice). Dosing was repeated 3 days later.  n day five these mice along 
with a control mouse were harvested and their spleens analysed for the presence of 
NK and CD8+ T cells.  Splenocytes from mice treated with NK or CD8 depleting 
antibodies along with an untreated control were first stained with live/dead aqua 
then with pacific blue conjugated anti-CD8a, Fitc conjugated anti-NK1.1 or isotype 
controls antibodies as listed in Table 2.1.    
 
For in vivo depletion studies groups of eight 7-13 week old C3-/- or age matched WT 
mice were injected on day -3, day -1 and then fortnightly with a total of 200μg of 
either CD8 depleting (100μg of each YTS-169+ YTS-156), CD4 depleting (100 μg of 
each YTS-191 and YTA-3) or control (GL113) antibodies.   
 
2.23  SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
 
In order to determine whether the C1498 cell line was producing C3, both cell lysate 
and 20 x concentrated cell supernatant were analysed by SDS-PAGE. Based on 
preliminary studies a 1/25 dilution of mouse serum and a 1/50 dilution of purified 
mouse C3 were used as positive controls with undiluted C3-/- mouse serum being 
used as a negative control. C1498 supernatant was 20 x concentrated using an 
Amicon pressure ultrafiltration system. A C1498 cell lysate was produced by first 
washing cells x 3 in PBS before snap freezing the cell pellet in liquid nitrogen. 20μl of 
each protein containing sample was then boiled for 2-5 minutes with 10μl of 
loading buffer under reducing conditions. A ready-made NuPAGE SDS PAGE 4-12% 
Bis-Tris gel was submerged in 1 x NUPAGE MES SDS-PAGE running buffer (both Life 
Technologies). Duplicates of 15μl of protein solution were loaded into wells along 
with pre-stained broad range markers in order to allow size estimation (New 
England Biolabs). The gel was subjected to 200V for 60 minutes.   
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2.24  Western blot 
 
Resolved gels were submerged in TRIS glycine transfer buffer and blotted onto 
nitrocellulose membrane sandwiched between filter paper and sponges pre-soaked 
in transfer buffer and placed in a cassette at 30V for 60 minutes. Following transfer 
the nitrocellulose membrane was removed and blocked with 5% PBS-milk for 30 
minutes at room temperature. After washing in PBS T the membrane was incubated 
with HRP conjugated goat anti-mouse anti-C3 mAb at a 1/10,000 dilution in 0.5% 
PBS-milk for 60 minutes. The membrane was then washed with PBS-T before bound 
antibody was visualised using an enhanced chemiluminescence kit (GE Healthcare), 
subjected to light sensitive hyperfilm (GE Healthcare) and developed using a 
Compact X-2 X- Ograph developer machine.      
 
2.25  Immunohistochemistry 
 
Fresh tumour samples were immediately embedded in  CT compound and frozen 
on dry ice before being stored at -80  C in freezers until use. 5μm thick sections were 
cut and placed on slides. Sections were fixed in ice cold acetone for 15mins then 
washed x 3 in PBS. Sections were encircled using a PAP pen then blocked with 
Donkey serum in PBS/2% BSA 200μl per section for 40 mins at RT. After washing 
with PBS, samples were incubated with either an anti-mouse C3 antibody (11H9) or 
a rat IgG2a isotype control, at a final concentration of 2μg/ml overnight in a 
humidity box at 4  C. The following day samples were washed x 3 in PBS then 
incubated for 30 mins at RT in 488 anti rat secondary antibody at 1:500. Following 3 
x PBS washes, samples were fixed for 10 minutes in 1% PFA then washed a further 3 
x in PBS. DAPI stain (vector shield) was then applied to a cover slip onto which the 
slides were placed. The slides were then sealed with nail polish prior to analysis.    
 
2.26  Vaccination  
 
5 x 107 irradiated (10,000 rad) C1498 cells were injected SC into WT and C3-/- mice. 
This was repeated after 4-6 weeks. 7 days after the second vaccination, vaccinated 
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mice along with unvaccinated WT and C3-/- controls were euthanized and their 
splenocytes used in ELISpot assays.    
 
2.27  IFN-γ ELISpot Assays 
 
Polymer-backed 96-well filtration plates (MAIP-S-4510) (Millipore, Moslheim, 
France) were used for ELISpot assays along with an IFN-γ ELISpot ALP Kit (Mabtech 
3321-2A). The plate was first pre-wetted for 2 mins with 70% ethanol, 50μl/ well 
then washed 5 x with sterile PBS. Wells were then coated with 50μl of 15μg/ml rat 
an -mouse an -IFN-gamma capture an body (1-DIK). Plates were tapped gently to 
ensuring the whole well was covered before being incubated overnight at 4  C. The 
following day, wells were washed x 5 with PBS to remove excess an body then 
blocked with 50μl R10 for   1 hour at 3   C.  
 
Effectors, splenocytes and targets, irradiated C1498, were each seeded in a volume 
of 50μl in R10 at a range of target: effector ratios.  50μl of phytohaemogglutinin 
(PHA) at a final concentration of 10μg/ml was used as a positive control with 50μl 
R10 being used in negative controls such that the final volume of each well was 
150μl. All conditions were performed in triplicates. Plates were then incubated at 
3 ’ C for 18-24hrs. The next day cells were removed and plates washed x 6 with PBS. 
50μl of 1μg/ml biotinylated rat anti-mouse interferon-gamma (7-B6-1) was added 
to each well and incubated for 2 hours at room temperature. Plates were then 
washed x 6 in PBS before adding 50μl Streptavidin-Alkaline Phosphatase Polymer 
(Mabtech, Sweden) diluted to 1μg/ml in PBS and incubated at room temperature 
for 1 hour. Following 6 further washes, the ELISpot wells were developed using 
50μl/well of colour development buffer (Biorad AP Conjugate sub kit 170-6432, 
Hercules, California) and incubated at room temperature until spots were clearly 
visible (approx 10-15mins). The reaction was then stopped by washing plates in tap 
water and left to dry overnight. IFN-γ- producing T cells were enumerated at the 
single-cell level by counting the number of spots per well using an automated 
ELISpot plate reader (Autoimmun Diagnostika GMBH, AID, Strasberg, Germany) and 
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analysed using the ELISpot 5.0 software package to ensure consistent analysis of 
spots between wells before manually verifying spot counts.  
 
2.28  Validating Efficacy of the anti-C5 antibody BB5.1 
 
BB5.1 and its isotype control D1.3 were produced and purified using methods 
described above. Following purification, the efficacy of BB5.1 vs D1.3 was assessed 
using an in vitro haemolysis assay using sensitized rabbit erythrocytes. The in vivo 
efficacy of BB5.1 following a single dose of 1mg IP vs isotype control was assessed 
using complement haemolysis assays on blood taken prior to and at 3 time-points 
following administration.  
 
2.28.1  Haemolysis assays  
 
Rabbit erythrocytes were first coated with antibody in order to sensitize them for 
complement attack. This was done using rabbit blood that had been mixed with an 
equal volume of Alsever’s following harvest, in order to preserve cells and prevent 
clotting. Cells were centrifuged at 450 G for 5 minutes at 4  C then diluted in 4% CFD. 
Polyclonal mouse an -rabbit erythrocyte an body was diluted to 0.5% v/v in CFD 
then incubated 1:1 with the rabbit erythrocyte suspension for 30 minutes at 3   C. 
Cells were then washed (450 G, 5 mins, 3   C) in order to remove any unbound 
antibody before being re-suspended in 2% CFD.  
 
Duplicate wells of 50μl mouse serum were plated with 50μl of CFD into a 96-well 
round bottomed plate and then ½ serially diluted down. Duplicate positive controls 
containing 50μl dH20 and a nega ve control containing 50μl CFD were also included. 
50μl of an body coated rabbit erythrocytes were added to both test and control 
wells and incubated for 30 minutes at 3   C. Intact erythrocytes were pelleted by 
centrifugation (450 G, 5 mins). 50μl of erythrocyte supernatant from each test and 
control well was then added to a flat-bottomed plate containing 100μl dH20 per 
well. Absorbance of each well was read at 415nm using a Dynex MRX II plate reader. 
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Percentage lysis was calculated using the positive control to provide 100% lysis and 
the negative 0% lysis using the following equation: 
 
% lysis  =  (A415
sample – A415
0%)        x       100 
        (A415
100% - A415
0%) 
 
A 1/25 dilution of serum resulted in 60% lysis and was taken forward to assess the 
ability of the anti-C5 mAb vs control Ab to deplete C5 in vitro. Abs were diluted to 
200μg/ml in CFD. 50μl was plated in duplicate and ½ serially diluted in CFD. 1/25 
mouse serum and Ab coated erythrocytes were then added resulting in a final top 
concentration of 50μg/ml. The level of haemolysis was then measured as described 
above.    
 
2.29  In vivo complement depletion 
 
A dose of 1mg BB5.1 was administered via an IP injection twice weekly beginning on 
day -1 (day 0 being the day of tumour cell injection). An isotype control antibody 
(D1.3) was used at an equivalent dose in age- and sex-matched control mice.  
 
The Cyclic hexapeptide antagonist AcF-[OPdChaWR], also known as PMX-53 
specifically blocks the main C5a receptor (Markiewski, DeAngelis et al. 2008; 
Corrales, Ajona et al. 2012; Vadrevu, Chintala et al. 2014) and was kindly provided 
by Professor Trent Woodruff. C5a receptor antagonist (C5aRA) was used at the dose 
described in other studies (1mg per kg) in both a 3 times per week and a daily 
dosing regimen. Treatment commenced the day prior to administration of C1498 
cells and continued for the duration of the experiment. Mice were imaged twice 
weekly from day 7.  
  
An antisense oligonucleotide which targets C6 mRNA preventing the synthesis of C6 
in the liver and hence the production of MAC was used to reduce C6 synthesis in WT 
mice. The C6 antisense along with a control oligonucleotide was kindly provided by 
Professor Kees Fluiter (Fluiter, Opperhuizen et al. 2014). A dose of 5mg/kg dose 
99 
 
subcutaneously (SC) three times a week was used, in line with his recommendation. 
This was commenced the day prior to administration of 5 x 106 C1498 cells IV. 
 
2.30  Statistical and Graphical Analysis 
 
Analysis of flow cytometry data was performed using FlowJo version 7.6.5.  
Statistical analysis of my in vivo studies was carried out using Graphpad Prism 
version 5. Kaplan Meier survival curves were used to plot results with log-rank 
(Mantel-Cox) tests being used to assess statistical significance between 
experimental groups.  
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Chapter 3: An exploration of whether complement-induced protection 
is protective against natural killer cell attack in vitro and whether 
‘protected’ cells have a genetic signature  
 
3.1 Introduction 
 
As described in Chapter 1, sub-lytic doses of complement protect cells from a 
subsequent lytic dose of complement, a phenomenon termed complement-induced 
protection (CIP) (Reiter, Ciobotariu et al. 1992). Cross-protection is also observed 
between other pore forming proteins, such as perforin, melittin and streptolysin, 
that are incorporated into cell membranes via a similar mechanism (Reiter, 
Ciobotariu et al. 1995). This is important to these studies as NK cells utilise perforin 
in order to form the pores through which inducers of cell death, such as granzymes, 
are introduced to the target cell. It is therefore possible that sub-lytic complement 
protects tumour cells from lysis by cytotoxic cells, including NK cells and T cells. 
 
The myeloid leukaemia cell line K562 was the original cell line in which CIP was 
described (Reiter, Ciobotariu et al. 1992). These studies utilised polyclonal anti-K562 
antibodies and pooled normal human serum (NHS) in order to create both sub-lytic 
and lytic complement attacks with chromium-release assays being used to 
determine levels of cell death (Reiter, Ciobotariu et al. 1992). The aims of 
experiments described in this Chapter were to develop a flow cytometric method to 
demonstrate CIP in vitro, to use this assay to determine if exposure to sub-lytic 
complement also protects cells from lysis by natural killer (NK) cells in vitro and 
finally, to determine a genetic signature for CIP. 
 
In order to develop a flow cytometric method capable of demonstrating CIP in vitro 
the K562 cell line was also used. TG1, an IgM anti-myeloid antibody (Ab) was used 
to coat the K562 cells in order to target them for complement-mediated lysis with 
NHS (see Chapter 2 for details).  
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In order to convincingly demonstrate the phenomenon, it was important to ensure 
that an appropriate level of sub-lytic attack had occurred in each experiment.  It 
was also essential that an equivalent level of target Ab was present in all test 
conditions prior to the 2nd lytic complement attack.      
 
Once developed the flow cytometric assay was altered in order to substitute the 
second lytic complement attack for a natural killer (NK) cell killing assay. Donor 
PBMCs were conditioned overnight with interferon α (IFNα) and then used as a 
source of NKs in the killing assays (see Chapter 2 for details). The effect of Ab, NHS, 
donor, effector:target (E:T) ratio, time-scale  and alternative experimental methods 
were assessed in order to explore whether exposure to sub-lytic complement 
protects cells from lysis by NK cells in vitro.    
 
The third part of this chapter investigates whether CIP is the result of altered gene 
transcription. CIP has been shown to be dependent on both protein and RNA 
synthesis. The use of protein synthesis inhibitors results in complete loss of the 
protective phenotype whilst RNA synthesis inhibitors led to a partial loss of 
phenotype (Reiter, Ciobotariu et al. 1992). It was therefore reasonable to assume 
that a sub-lytic complement attack which resulted in a protected phenotype would 
lead to a specific genetic signature.  
 
This was investigated by performing a microarray transcriptome analysis on RNA 
extracted from cells that had been exposed to sub-lytic complement and confirmed 
to have a protected phenotype. This section aimed to define the genetic signature 
of CIP.  
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3.2 Results 
 
3.2.1 Develop a flow cytometric method of demonstrating complement-induced 
protection in vitro  
 
3.2.1.1  Establishing a sub-lytic level of complement attack 
 
Conditions required for a sub-lytic level of complement attack were established by 
examining cell lysis following incubation with titrated doses of TG1 Ab and NHS. The 
aim was to identify a level of cell death which was 5-10% above control cells, which 
had not been exposed to Ab. This level of cell death was a surrogate marker that 
cells which survived the complement attack had  been subjected to a sub-lytic dose 
of MAC. This was achieved by keeping NHS dose constant at 1/8 dilution and 
diluting TG1 Ab (Figure 3.1). 
 
3.2.1.2  Re-titrating TG1 prior to lytic complement attack 
 
Following sub-lytic attack, cells were re-exposed to TG1 prior to the second 
complement attack. It was shown that cells previously exposed to TG1 could not be 
saturated with Ab following a second exposure, probably due to antigen capping 
(Figure 3.2). This was an important finding as different levels of TG1 binding would 
affect the extent of lysis observed during the second kill step and could therefore be 
misleading. It was therefore essential that controls were coated with titrated levels 
of Ab prior to the lytic complement step such that surface Ab levels (as measured by 
an anti IgM Ab) were comparable to ‘protected’ cells prior to exposure to lytic doses 
of NHS (Figure 3.3). In each case, a control with a slightly lower level of surface TG1 
was chosen as a comparator such that any bias was in the favour of the control. 
 
3.2.1.3  Effect of Sub-Lytic MAC on Lytic Complement Attack  
 
Following the sub-lytic step and re-exposure to titrated TG1, cells were exposed to a 
range of lytic doses of complement. Cell death was assessed using 7AAD staining.  
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Figure 3.1: TG1/ NHS killing curve. K562 cells were first incubated with titrated 
dilutions of supernatant from anti-myeloid cell IgM mAb producing TG1 cells in CFD 
containing 0.1% gelatine (CFD-g). These cells were then exposed to a range of 
dilutions of NHS, as a source of complement (also diluted in CFD-g). 7AAD staining 
was used to identify non-viable cells. TG1 and NHS doses were titrated in order to 
achieve 5-10% complement-mediated cell lysis.  
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Figure 3.2: TG1 saturation post second incubation. K562 cells were first exposed to 
a variable dilution of TG1 then to a ½ dilution of TG1. TG1 saturation following the 
second exposure is plotted. This demonstrates an inability to saturate cells that had 
had a prior exposure to TG1, in a dose dependent manner.   
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Figure 3.3: TG1 saturation prior to second lytic complement attack. A 
representative plot showing levels of surface IgM (TG1) following a 2nd incubation 
with the TG1 Ab containing supernatant, prior to the 2nd ‘lytic’ step. Levels of 
surface IgM were assessed using a biotynylated anti-IgM Ab conjugated to 
strepavidin PE. In each case, a control with a slightly lower level of surface TG1 was 
chosen as a comparator such that any bias was in the favour of the control.  
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Percent survival was measured using a calculation based on live cell numbers 
present at the end of the experiment. 
 
number of live cells in test condition          x  100             (Method A) 
number of live cells in internal control)  
 
Tightly controlled assay volume, time and speed of sample accrual and triple 
repeats were all used to ensure accuracy. A schematic demonstrating the 
experimental protocol is shown in Figure 3.4.  
 
This flow-cytometric assay confirmed that sub-lytic complement attack offered 
protection against a subsequent lytic complement attack (Figures 3.5 and 3.6). 
 
3.2.2 Determine if exposure to sub-lytic complement protects cells from lysis by 
NKs cell in vitro 
 
3.2.2.1  Experimental protocol 
 
The experimental protocol described above was modified in order to determine 
whether a sub-lytic dose of complement was also protective against NK cell attack. 
Both NK and CD8+ cytotoxic T lymphocytes utilise perforin in order to insert pores 
and lyse cells via a similar mechanism to MAC. A NK killing assay, using normal 
donor peripheral blood mononuclear cells (PBMCs) pre-conditioned overnight with 
variable doses of IFNα as a source of NK cells, was adapted from the above protocol 
(Figure 3.7).  
 
CFSE was used to label target K562 cells such that they could be discriminated from 
the effector PBMC cells. Dual staining with 7AAD allowed the level of cell death to 
be measured, allowing an accurate calculation of the level of target cell lysis. By 
applying the same gating strategy to a PBMC-only sample I confirmed that dual 
staining led to no overlap between targets and effector cells (Figure 3.8). 
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Figure 3.4: Schematic of fluorescent-based flow cytometric assay developed to 
demonstrate complement-induced protection.  TG1 was used to sensitise K562 to 
complement attack using NHS as a source of complement. Following a sublytic 
attack, defined as 5-10% cell death, the surviving cells were exposed to a lytic 
complement attack. 
 
 
Coat K562 cell line with low levels of TG1  
Expose to low dose pooled normal 
human serum 
Wash, re-incubate  test with neat TG1, 
controls with titrated TG1 
Expose to lytic serum 
Use 7AAD to analyse by flow 
cytometry- number of live K562 
compared to internal control 
Confirm correct level of TG1 pre-lytic step. 
Confirm correct level of cell lysis with sub-
lytic step 
Sub-lytic step 
Lytic step 
Analysis 
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Figure 3.5: Flow cytometric plots demonstrating complement induced protection. 
Following a sub-lytic complement attack and re-titration of antibody on their 
surface, K562 cells were exposed to variable dilutions of NHS as a source of 
complement. 7AAD was then used to assess cell viability. In this example, the 
absence of a  AAD +ve peak in the ‘protected’ (blue) vs control (red) cells reflects 
almost complete protection at all NHS concentrations. 
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Figure 3.6: Killing curves demonstrating complement-induced protection. Cells 
exposed to sub-lytic MAC (1/4 TG1+ 1/8 NHS) were protected from a range of lytic 
doses of complement when compared to control cells.  
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Figure 3.7: Schematic showing modifications used to assess complement-induced 
protection against NK cell cytotoxicity. An NK killing assay was incorporated into 
the original assay, using IFN-α conditioned PBMCs as a source of NKs. K562 target 
cells were labelled with CFSE to enable them to be distinguished from effectors and 
allow killing to be quantified. K562 cells which had been exposed to a sub-lytic dose 
of complement then entered a 4 hr NK killing assay. At the end of this time, 7AAD 
and CFSE staining were used to calculate cell death  
 
 
Coat K562 cell line with low levels of TG1  
Expose to low dose pooled 
normal human serum 
4 hr NK killing assay 
Use 7AAD vs CFSE to analyse by flow 
cytometry 
Confirm correct level of cell lysis 
with sub-lytic step 
Sub-lytic step 
Lytic step 
Analysis 
Source of NKs-normal donor PBMCs pre-
conditioned overnight with IFN-α 
Label K562 with CFSE 
111 
 
 
 
Figure 3.8: Gating strategy used in NK assays. Cells were first gated on forward vs 
side scatter A) K562/ targets only, B) full killing assay (K562 + PBMCs). Assays were 
then gated on CFSE vs 7AAD, the CFSE staining allowing the +ve target K562s to be 
distinguished from the –ve effector PBMC. 7AAD staining identified whether a cell 
was live (-ve ) or dead (+ve). C) this gating strategy allowed calculation of the level 
of target lysis. D) analysis of a sample containing  PBMCs only confirmed no overlap 
into live K562 gate from PBMCs. 
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3.2.2.2  Effect of Antibody and Serum on NK Killing  
 
The presence of TG1 Ab on the target cell surface was assessed in order to see 
whether this would have an impact on NK killing activity. Cells exposed to variable 
concentrations of TG1 Ab were compared with controls, demonstrating that 
increasing amounts of the Ab did appear to lead to a slightly higher rate of target 
cell lysis (Figure 3.9). It was therefore concluded that it was critical to titrate and 
control for the level of TG1 Ab prior to the NK killing assay, as with the complement 
assays described above.  
 
The presence of NHS as opposed to foetal bovine serum was next assessed in order 
to determine whether this had an impact on the level of NK mediated cell lysis. The 
source of serum was shown to have no impact on NK mediated cell lysis (Figure 
3.10).  
  
3.2.2.3   Method of Calculating NK Mediated Cell Lysis 
 
NK killing is conventionally calculated by expressing dead/ 7AAD positive cells as a 
percentage of total targets in the assay. 
 
               dead targets          x 100                             (Method B) 
        total (live + dead) targets     
 
         
Initial experiments, using this method appeared to demonstrate that sub-lytic 
complement attack did indeed lead to a degree of protection from subsequent NK 
cell lysis (Figure 3.11).   
 
However, it was noted that in the setting of a prior complement attack, the 
conventional method of NK analysis appeared to be inaccurate. This was due to 
cells being completely lysed and lost into the debris gate and therefore not being 
counted in the dead K562 gate. Figure 3.12 demonstrates the increased incidence of 
7AAD+ve debris in the samples that had been exposed to sub-lytic complement as 
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Figure 3.9: Effect of TG1 on NK mediated cell death. PBMCs pre-conditioned 
overnight with 0, 50 or 1000 IU/ml of α interferon (IFNα) were used as effectors in a 
NK killing assay against K562 cells which had or hadn’t been coated with TG1 Ab at a 
E:T ratio of 5:2. A reproducible slightly higher NK mediated cell death was observed 
when K562 cells were coated with TG1 anti-myeloid cell Ab compared to untreated 
controls.  
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Figure 3.10: Effect of normal human serum on NK mediated cell death. PBMCs pre-
conditioned overnight with 0, 50 or 1000IU IFNα were used as effectors in a NK 
killing assay against K562 cells in the presence of either 10% NHS or 10% fetal 
bovine serum (FBS). The presence of NHS vs FBS had no effect on the level of  NK 
mediated cell death. 
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Figure 3.11: Initial NK assays using conventional methods of calculating cell lysis. 
PBMCs pre-conditioned overnight with 0, 50 or 1000 IU/ml IFNα were used as 
effectors in a NK killing assay against K562 cells. Results were calculated using 7AAD 
positive cells as a percentage of total targets in the assay. This appeared to show 
that cells exposed to sub-lytic complement (1/16 TG1 + 1/8 NHS) were protected 
from subsequent NK attack.  
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Figure 3.12: Flow cytometric plots demonstrating increased incidence of 7AAD 
positive ‘debris’. Control samples (A) had less events recorded in the area where 
cell debris usually occurs. Cells which had previously been exposed to ‘sub-lytic’ 
complement attack (B) had far more cells in the ‘debris’ gate.  41% of events 
recorded in the debris gate of control samples were 7AAD positive (C). Debris from 
samples that had undergone a sub-lytic complement attack had almost twice the 
level of 7AAD positive debris (81.8%) (D). This suggests that these were lysed dead 
cells.  
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compared to controls. The higher numbers of cells lost from conditions that had 
previously undergone sub-lytic attack appeared to equate to the level of protection 
that had been observed using conventional methods of calculating levels of NK 
mediated cell lysis (Figure 3.13).   
 
The alternative ‘live cell’ method of calculation, that was used in the original CIP 
assay described above, was therefore introduced. This expresses live cell numbers 
in each condition as a percentage of live cells in the internal control. 
 
 
dead targets/ total targets) x 100  
dead targets  x  100
 total targets
         live cell numbers     x  100
live cells in the internal control
 
 
This method allowed the cells ‘lost’ from the assay via the debris gate to be 
accounted for. The same experiment analysed by the two different calculation 
methods, confirmed that the initial degree of ‘protection’ observed was equal to 
the percentage of cells lost from the assay. Despite several repeats, when the ‘live 
cell’ calculation method was used, no CIP from NK lysis was observed (Figure 3.14).      
 
The protocol was then modified to include the removal of apoptotic and dead cells 
via Magnetic Activated Cell Sorting (MACS) following the sub-lytic step. This meant 
that only live cells entered the second NK killing step (Figure 3.15). When these 
dead cells were removed, both the conventional and the ‘live cell’ method of 
calculating NK target cell lysis produced the same results; this confirmed that sub-
lytic complement did not protect cells against lysis by NK cells in these experiments. 
 
3.2.2.4 Timescale of NK Assay 
 
As a 4 hour NK killing assay failed to show any protective effect of sub-lytic MAC, it 
was possible that this could be due to the length of the assay. CIP has previously 
been shown to gradually wear off over a period of 8 hours in K562 cells (Reiter, 
Ciobotariu et al. 1992). This progressive loss of the phenotype means that the  
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Figure 3.13: Bar charts demonstrating number of live, dead and ‘lost’ cells. 
Number of cells ‘lost’ from the assay was calculated based on the number of cells 
that were observed in the internal control. Control cells (A), had proportionally 
more cells visible as dead targets (compared to a no PBMC control), but less cells 
were ‘lost’ from the assay. ‘Sub-lytically’ attacked targets exposed to the same NK 
assay (B) had more cells ‘lost’ from the assay. This accounts for differences seen 
according to calculation methods. 
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Figure 3.14: Results from same experiment analysed via alternative methods A) 
experimental results analysed by the conventional method of calculating cell lysis in 
NK killing assays- (dead targets/total targets) x100 B) the same experiment analysed 
by (live cell numbers/ live cells in internal control) x 100. This demonstrates that the 
observed ‘protection’ is due to a failure to account for complete cell lysis. 
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Figure 3.15: MACs removal of dead cells.  A dead cell removal kit (Miltenyi Biotec), 
which recognises an antigen on the surface of both apoptotic and dead cells, was 
used, in accordance with the manufacturers guidance. It successfully removed dead 
cells as determined by 7AAD. 
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protective effect may have been lost during the 4-hour assay. This was explored 
using time-course experiments to determine whether the duration of the assay 
could be masking a protective effect. Level of target cell lysis was explored after 1, 
2, 3, 4 and 5 hours. No evidence of CIP was observed at any of these time-points 
(Figure 3.16). 
 
By using a range of PBMC donors, it was shown that NK function was highly donor-
dependent with both the extent of NK lysis and the level of target cell lysis over 
time varying between donors. Some donors had a gradual increase in target cell 
lysis over time whilst others had similar levels of target cell lysis observed after one  
hour as seen over the subsequent four hours (Figure 3.17). No protected phenotype 
was observed using PBMCs from any of the donors.  
 
3.2.2.5 Effector: Target Ratio 
 
Next the effect of altering the E:T ratio was investigated. The original assays utilised 
an E:T ratio of 5:2, ratios of 2:1, 6:1 and 18:1 were therefore also explored. Despite 
these modifications, no complement- induced protection from lysis by NK cells was 
observed (Figure 3.18). 
 
3.2.2.6 Concomitant sub-lytic complement and NK cell attack 
 
The protocol was then modified in order to combine the sub-lytic complement and 
NK cell killing steps. In this assay, K562 were initially coated with a low dose of TG1 
Ab and then exposed to NK cells in media in which the 10% FBS was replaced with 
10% NHS (Figure 3.19). This resulted in a sub-lytic complement attack occurring 
concomitantly with the NK killing assay. The assay was explored at a range of E:T 
ratios. These assays again failed to demonstrate any evidence of CIP from NK killing 
(Figure 3.20).   
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Figure 3.16: Cell death after 1, 2, 3 and 4hrs. Samples were analysed at hourly 
timepoints to assess for level of cell lysis. PBMCs preconditioned overnight with 0, 
50 or 1000IU IFNα were used as effectors at an E:T ratio of 5:2.  No evidence of sub-
lytic complement offering a protective effect was observed at any time point in any 
of the conditions tested. 
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Figure 3.17: Target cell lysis over a 4/5 hr time-course in 2 normal donors. PBMCs 
preconditioned overnight with 0, 50 or 1000IU IFNα were used as effectors at a E:T 
ratio of 5:2.PBMCs  from donor A resulted in a gradual increase in target lysis over 
the 4 hr time-course peaking at ≈ 60% cell death. Donor B had a similar level of 
target lysis at one hour as observed over the subsequent 4 hours. These findings 
were confirmed on repeat analysis.  
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Figure 3.18: Cell death as a range of effector: target ratios. K562 exposed to sub-
lytic complement had similar level of target lysis as control targets when exposed to 
PBMCs conditioned overnight with 50IU IFNα at E:T ratios of 2:1, 6:1 and 18:1.  
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Figure 3.19: Schematic showing an assay combining sublytic complement attack 
with the NK killing assay. In this assay the 10% foetal bovine serum present in the 
media used during the NK assay was substituted with NHS which allowed TG1 
coated target cells to be attacked by a sublytic dose of complement and NK cells 
simultaneously. 
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Figure 3.20: Combined sub-lytic complement and NK killing assay. TG1 coated and 
control K562 were exposed to PBMCs conditioned overnight with 50IU IFNα at E:T 
ratios of 2:1, 6:1 and 18:1 in an assay which contained 10% NHS as a source of 
complement. Thus a sub-lytic complement and NK attack were occurring 
simultaneously. This assay revealed no evidence of CIP from NK killing at a range of 
E:T ratios. 
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3.2.3 Determine a Genetic Signature for Complement-Induced Protection 
 
As demonstrated earlier in this chapter, exposure to a sub-lytic dose of complement 
induces a high level of protection from subsequent lytic attack. Although it is known 
that the CIP is dependent on the assembly of the complete MAC, the presence of 
extracellular Ca2+ and on active cellular metabolism, the exact mechanism 
underpinning it remains unknown. In order to explore potential mechanisms, a 
transcriptomic analysis was performed to determine whether protection is 
accompanied by genetic changes within protected cells.  
 
3.2.3.1 Experimental Design 
 
Experimental design is critical in order for data analysis to arrive at a statistically 
and biologically valid conclusion. Experimental plans were therefore discussed with 
a bioinformatician and a biostatistician prior to embarking on the experiment. It 
was agreed that biological replicates would offer better data than technical 
replicates alone. Design is a balance of resources, accuracy and reliability. It was 
generally felt that large differences in gene expression could be detected with 3 
samples per condition whereas smaller differences might require 5 samples per 
condition. Due to the range of controls required, there were 5 experimental 
conditions included in this study, meaning that cluster analysis would be possible. In 
order to perform clustering analysis it is generally perceived that more than 20 
samples are required. It was therefore decided that two Illumina beadchips would 
offer the ability to analyse 24 RNA samples, derived from 4/5 experimental repeats, 
simultaneously. 
 
Figure 3.21 gives an overview of the experimental protocol and illustrates the 
checks that were in place to confirm the validity of each experiment repeat. A great 
deal of care was taken to standardise experimental conditions such as RNA 
stabilisation and extraction techniques. K562 were passaged the day prior to each 
experiment such that they were in fresh media and were not over-confluent. Fresh 
cells were thawed from the same batch of frozen K562 stock at regular intervals 
such that the passage number was the same. As complement attack required  
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Figure 3.21: Protocol for acquiring and assessing samples for RNA extraction. K562 
cells were exposed to titrated doses of TG1 and NHS, resulting in 5-10% 
complement mediated lysis. Dead cells were then removed using Magnetic 
Activated Cell Sorting. RNA was extracted from 2 x 106 protected cells (IP) and 
control cells which had been exposed to either Ab alone, NHS alone or neither. The 
remaining cells then underwent a 2nd kill step to confirm that cells had a strong 
‘protected’ phenotype. Protected cells were also allowed to recover overnight 
before extracting RNA from a further 2 x 106 cells as an additional control group.     
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exposure to both Ab and NHS, controls which had been exposed to an equivalent 
dose of either NHS (SC) or the TG1 Ab (TC) were included in the experiment along 
with cells which had been exposed to neither (C). An additional control was 
included which contained RNA from cells which had been exposed to sub-lytic MAC 
but had been allowed to recover overnight (ON) and were therefore no longer 
‘protected’. Several additional checks were put in place to confirm that each 
experiment was viable.  
 
Following the sub-lytic attack, a sample of cells taken from each condition was 
stained with 7AAD and fixed in order to confirm that the first complement attack 
had resulted in the correct level of cell kill (5- 10%) (Figure 3.22). In order to prevent 
interference from the presence of apoptotic cells, a MACS kit which recognises and 
removes both apoptotic and dead cells was also used prior to RNA extraction. 2 x 
106 cells from each test condition were then immediately submerged in RNAlater 
Stabiliza on Reagent and stored at 4  C. RNAlater rapidly permeates cells, stabilising 
the RNA and preserving the RNA expression profile. This prevents changes to the 
gene expression profile occurring due to RNA degradation and gene induction and 
down-regulation, which can be triggered by sample manipulation. This ensures that 
downstream analysis accurately reflects the expression profile of the cells.  
 
TG1 Ab was then re-titrated on both the remaining IP and SC cells. A sample of 
these cells were stained for surface TG1 binding and fixed so that levels could be 
confirmed to be equivalent/ slightly lower on the SC cells such that any bias was in 
favour of control cells (Figure 3.23). TG1 coated cells were then exposed to a range 
of NHS dilutions so that a survival curve for both the IP and SC cells could be plotted 
to confirm protection (Figure 3.24).  
 
Some protected cells were allowed to recover in the incubator overnight. The 
following day, 2 x 106 of these cells were also stored in RNAlater. TG1 was then 
titrated on the cell surface and a further exposure to lytic doses of complement 
confirmed that cells were no longer protected (Figure 3.25).  
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Figure 3.22: Cell death post sub-lytic complement. A) control cells demonstrated 
5.27% 7AAD +ve cells whereas cells exposed to a sub-lytic dose of complement (B) 
were 14.1% 7AAD +ve resulting in a cell death above baseline of 8.83% (target 5-
10%). 
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Figure 3.23: Levels of surface IgM (TG1). Following 2nd incubation with the anti-
myeloid TG1 Ab, levels of Ab were assessed by measuring levels of surface IgM 
using a biotynylated anti-IgM Ab conjugated to strepavidin PE. In each case, a 
control with a slightly lower level of surface TG1 was chosen as a comparator, such 
that any bias was in the favour of the control.  
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Figure 3.24: Killing curves confirming the presence of complement-induced 
protection. Cells exposed to a sub-lytic dose of complement were protected from a 
lytic dose of complement when compared to control cells that had a prior exposure 
to complement. 
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Figure 3.25: Killing curves confirming that complement-induced protection is a 
time-limited phenotype. Sub-lytically attacked cells were allowed to recover 
overnight before being re-incubated with TG1 Ab and exposed to a lytic dose NHS 
confirming that cells had lost their protected phenotype. 
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When each of the following three checks were met: i) correct level of sub-lytic 
attack ii) equivalent surface TG1 iii) protection from lytic complement, RNA was 
then extracted.  A Qiagen RNeasy Mini Kit was used to extract RNA from both the 
cells that had recovered overnight (ON) and the cells from the other conditions (IP, 
SC, TC, C) which had been stored in RNAlater overnight. An aliquot of the resulting 
eluted RNA was used to measure the amount of RNA present using a 
spectrophotometer (nanodrop).  
 
Samples from four complete experiments were included in the microarray. In order 
to maximise use of the chips 4 additional RNA samples were also included resulting 
in inclusion  of 24 RNA samples extracted from: 7 IP, 5 TC, 4 SC, 4 C and 4 incubated 
overnight (ON) cell samples (summarised in Table 3.1).    
 
 IP SC TC C ON 
Experiment 1 X 2 X 1 X 1 X 1 N.I 
Experiment 2 X 2 X 1 X 2 X 1 X 2 
Experiment 4 X 1 N.I N.I N.I N.I 
Experiment 5 X 1 X 1 X 1 X 1 X 1 
Experiment 6 X 1 X 1 X 1 X 1 X 1 
 
Table 3.1: RNA samples taken forward for microarray analysis. IP = induced 
protection, SC = NHS control, TC = TG1 control, C = untreated control and ON = 
incubated overnight. N.I = not included. 
     
 
All extracted RNA included in the analysis was shown to be of high quality with only 
minimal degradation (Agilent 2100 Bioanalyzer). An Illumina Human HT-12v4 
BeadChip was used to probe for mRNA expression. BeadChips use oligonucleotides 
immobilized to microscopic beads held in microwells on the surface of array 
substrate. Each array targets 47,231 probes, covering well-characterised genes, 
gene candidates and splice variants and is able to analyse twelve samples leading to 
reduced sample to sample variability.  
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3.2.3.2 Microarray Analysis 
 
As microarray data sets are extremely large they offer significant statistical 
challenges. It is essential to take into account effects of background noise and to 
use appropriate normalization of the data. Analysis was completed in collaboration 
with a Bioinformatician, Robert Andrews. The code an007.R was used to run the 
analysis. The lumi and limma packages in BioConductor were used to analyse the 
data. Raw data was inputed from GenomeStudio with replicate probes on the array 
being averaged to a single value per probe. Normalisation of data within an array 
controls for systematic biases introduced by factors such as variable dye coupling or 
hybridisation efficiencies allowing true biological differences to be found. For the 
purpose of comparing datasets, data were normalised using Variance Stabilizing 
Transformation (VST) (the standard method for Illumina gene expression arrays) 
where data are background subtracted, VST transformed and quantile normalised.  
 
3.2.3.3 Quality control 
 
Box plots of both raw data and quantile-normalised data were used to assess the 
quality of the data. These illustrate the distribution of spot intensities on the array 
with any sample having a disproportionately slim or wide box, in the context of all 
other samples, indicating an issue. My arrays resulted in uniform box sizes 
illustrating good consistency between spot intensities on the arrays, confirming the 
quality of my data to be good (Figure 3.26).  
 
3.2.3.4 Class Discovery Analysis 
 
Class discovery analysis or unsupervised classification aims to identify whether 
microarrays cluster together in groups and whether these have biological 
significance. This classification is not hypothesis-driven, but uses pattern 
recognition to find an optimal number of clusters in the data. In this study 
hierarchical cluster analysis and principal component analysis were used to assess 
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the natural clustering of the experimental groups. Biological replicates would be 
expected to cluster together within the plot.   
 
An initial Hierarchical Clustering analysis revealed that samples were not grouping 
by experimental group but appeared to be more closely aligned to the experimental 
batch they had arisen from (Figure 3.27). A principal component analysis also 
confirmed this observation (Figure 3.28). 
 
3.2.3.5 Hypothesis-Driven Statistical Analysis 
 
Hypothesis-driven statistical analysis was then carried out in order to identify 
statistically significant changes in gene expression unique to the IP condition.  
Analysis of data demonstrated no differentially expressed genes unique to IP. This 
was initially analysed using pair-wise comparisons which, although giving a short list 
of differentially expressed genes between IP and TC and C, failed to show any 
differences between the IP and SC. As both the IP and SC conditions had been 
exposed to NHS, this suggests that the expression changes seen between the other 
pairings (where in each case one had and one had not been exposed to NHS) was 
likely to be due to a serum effect. In line with this, on review of the hierarchical 
clustering dendrogram, it was noted that IP and SC conditions were generally paired 
together.   
 
Bioreplicates not clustering together could indicate several things:  
 
(i) accidental sample swaps/mislabelling  
(ii) differential gene expression is only slight relative to the differences 
observed between the biological replicates- i.e it is a noisy system  
(iii) the list of significant genes is small (1-50 genes) 
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Figure 3.26: Box plots showing microarray intensity of both A. raw data and B. 
quantile-normalised data: box plots are used to assess the quality of the data by 
demonstrating the distribution of spot intensities on the array. No sample was 
identified to have a disproportionately narrow or wide box. It was concluded that 
the quality of the RNA samples analysed was good.    
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Figure 3.27: Hierarchical Clustering of samples. The dendrogram shows the 
relatedness of data based on 24,848 genes with SD/mean >0.1. Green/IP = induced 
protection, blue/SC = NHS control, purple/TC = TG1 control, red/C = untreated 
control, grey/ ON = recovered overnight. Number specifies which experimental 
repeat the RNA sample originated from. 
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Figure 3.28: Principal component analysis. The relatedness of gene expression data 
is demonstrated using a principal component analysis based on 24,848 genes with 
SD/mean >0.1. Green/IP = induced protection, blue/SC = NHS control, purple /TC = 
TG1 control, red/C = untreated control. Only experiments 1, 2, 5 and 6, which had a 
complete set of controls, were included in this analysis. This alternative method of 
unsupervised classification again demonstrated data to group far more by 
experimental repeat (defined by shape) than by biological replicate (defined by 
colour). 
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The multiple checks in place, consistency of experimental grouping and different 
days on which experiments took place made accidental swapping/ mislabelling an 
unlikely explanation. The consistency of cell passage, experimental repeats and 
controls meant that the system was as consistent as possible. 
 
3.2.3.6  Result Validation 
 
The following methods were used to validate these findings:  
 
(i) changing the normalisation method  
(ii) building a batch effect into the model 
(iii) removing potential outliers from the analysis 
 
3.2.3.6.1  Changing the Normalisation Method 
 
Where an analysis involves comparisons between 3+ samples (in this case ≥4 
samples), normalisation of data typically follows a method of normalising all data 
together.  This method is preferred for the reason that an outlier array (one that 
behaves slightly differently) will be normalised in line with the bulk of "good" data.  
This method fails where an outlier array behaves very differently from all other 
data, and the array therefore ‘poisons’ the good data of other arrays.   
 
In this study both "all array" normalisation and pair-wise normalisation were 
performed and compared. Pair-wise normalisation in this case means that for the 
comparison of A vs B only data for arrays A and B were normalised with respect to 
each other. No differentially expressed genes were observed whether data were 
normalised by an “all array” or a “pair-wise” method.   
 
3.2.3.6.2 Building a Batch Effect into the Model 
 
The batch effect seen within the hierarchical cluster would likely be observed if (i) 
there was a significant batch effect; (ii) there was no biological effect to be 
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observed and the act of "zooming into" the data showed a batch effect.  The 
analysis was performed both with and without a batch correction, for both 
normalisation methods. Again, no differentially expressed genes were observed. 
This suggests there is no biological effect and that the observed ‘batch effect’ was 
the result of over amplifying small non-significant differences between experiments.  
 
3.2.3.6.3 Identify Potential Outliers and Remove from the Analysis 
 
Potential outliers were identified by examining the hierarchical clustering analysis. 
These were removed individually and in combination and the residual samples were 
analysed for differentially expressed genes. No differentially expressed genes were 
observed. 
 
3.3 Discussion  
 
Results described in this chapter show that CIP is a convincing, reproducible 
phenomenon. Whilst this has previously been demonstrated using chromium 
release assays, I have shown that CIP can also be demonstrated using a flow 
cytometric based assay.  
 
Previous studies using C7 and C8 deficient serum have proved that it is the presence 
of MAC itself, as opposed to any earlier components of the complement cascade, 
which leads to the protective phenotype (Reiter, Ciobotariu et al. 1992), however 
the exact mechanism remains unclear. The ‘protected’ phenotype is immediate and 
very reproducible. Although aiming for a target of 5-10 % cell death, I noted that 
even when this level was exceeded, surviving cells were always and often even 
more convincingly protected. This suggests that high surface levels of MAC, as long 
as they don’t result in immediate cell lysis, lead to a profound protective effect from 
subsequent complement attacks.  
 
The level of protection was also noted to be most convincing when tested for 
immediately, with delays resulting in a lower level of protection being observed. 
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The inclusion of additional steps, such as MACS removal of dead cells, whilst 
improving the data in some respects and allowing use of conventional methods of 
calculating cell death, led to a less profound protective phenotype, most likely due 
to the delays ensued. This is supported by the literature with ‘protected’ cells being 
shown to become gradually sensitive to lytic complement doses over time (Reiter, 
Ciobotariu et al. 1992).  K562 cells start removing MAC from their surface within 5-
10 minutes of complement attack by outward and inward vesiculation (Moskovich 
and Fishelson 2007). 
 
Despite investigating multiple variations to my experimental protocol including 
timescale analysis, altering E:T ratio, using alternative PBMC donors and developing 
an alternative combination assay, no convincing evidence of in vitro CIP from NK cell 
attack was observed during my studies.  
 
This could be because K562 cells are extremely susceptible to NK mediated lysis and 
sub-lytic complement attack is not sufficiently protective to offer any effect. Future 
experiments should revisit this system with as minimal intensity as possible via 
removing any IFNα pre-conditioning and using an even lower E:T ratio. However, my 
studies thus far have offered no evidence to suggest that this approach would prove 
successful. As K562 was used in the original studies describing CIP and is widely use 
in the study of NK biology, it was the obvious choice of cell line to be used in these 
studies. However, a cell line which is less susceptible to NK cell lysis might offer 
more insight into the role of CIP in this setting. Alternatively, K562 could be altered 
in order to make it less susceptible to NK lysis via methods such as increasing its 
expression of MHC class 1 (Kaufman, Schoon et al. 1995).  
 
As previous studies used perforin purified to homogeneity from the granules of NK 
cells (Reiter, Ciobotariu et al. 1995), it could also be the case that sub-lytic 
complement attack does not offer protection from whole cell NK attack, which 
utilises a range of mechanisms .  
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Whilst complement relies on MAC to disrupt cell homeostasis and lyse cells, NK cells 
mediate cytotoxicity via a range of distinct mechanism. The most studied 
mechanism is degranulation which utilises perforin in order to form the pores 
through which inducers of cell death such as granzymes are introduced into target 
cells. Degranulation occurs following the formation of an immunological synapse 
which is the result of complex interaction between activating cell surface receptors 
counteracted by signals from inhibitory receptors, most of which bind to MHC class 
1 molecules (Bryceson and Long 2008). A sub-lytic complement attack is likely to 
result in cellular stress. Cellular stress, from physical, pathogenic or oncogenic 
sources, leads cells to down-regulate MHC class 1 and up-regulate ligands for NK 
activating receptors, resulting in them becoming more susceptible to NK attack 
(reviewed in (Chan, Smyth et al. 2014)). This stress response could be compensating 
for any protection provided by CIP against the insertion of perforin into the cell 
membrane. Thus more activated NK cells forming immunological synapses could be 
compensating for their hampered ability to form cytolytic pores. This would only be 
relevant in a whole cell assay and might explain why CIP was not observed in this 
model as opposed to observations from earlier studies which utilised purified 
perforin.  
 
 NK cells also exert their cytotoxic effects on target cells through death receptor 
pathways such as the TNF-related-apopotosis-inducing-ligand (TRAIL)–TRAIL and 
Fas-FasL pathway. Death receptors induce apoptosis via caspase activation thus 
inducing cytotoxicity independently of NK cell degranulation. The impact of 
complement on TRAIL and FAS pathways has not been explored but might be an 
alternative mechanism through which cells exposed to complement are being killed.  
 
As CIP has been shown to be dependent on both protein and RNA synthesis (Reiter, 
Ciobotariu et al. 1992), it was reasonable to assume that it would result in a unique 
gene expression phenotype or ‘signature’. Perhaps somewhat surprisingly, 
comprehensive microarray analysis revealed no significant gene expression 
changes. Finding no differentially regulated genes is an unusual event during 
microarray analysis, where the more usual concern is having too long a list of 
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dysregulated genes. A range of confirmatory steps were therefore performed along 
with a review of the data by a second Bioinformatician, all of which supported our 
original conclusions.  
 
A strong ‘protected’ phenotype was confirmed to be present in all sub-lytically 
attacked cells from which RNA was extracted. This, along with the fact that we 
could clearly observe a ‘serum effect’ in RNA extracted from samples exposed to 
NHS, strengthens the case that if the protected phenotype was due to alterations in 
gene transcription, this would have been detected. This raises the possibility that 
CIP is due to an alternative underlying mechanism.  
 
As discussed above, during my studies I observed that the ‘protected’ phenotype 
was strongest immediately following a sub-lytic attack. This is supported by 
previous data demonstrating that cells gradually became susceptible to lytic 
complement over the 8 hours following a sub-lytic attack (Reiter, Ciobotariu et al. 
1992). Within minutes of complement attack polymorphonuclear cells repair their 
membranes, approximately 35% via endocytosis and 65% via membrane shedding 
(Morgan, Dankert et al. 1987). The insertion or shedding of membrane attack 
complexes could result in structural or compositional change to the cell membrane, 
or underlying scaffolding elements, which could prevent MAC or other pore-formers 
from being inserted into the cell membrane.  
 
The preferential loss of cholesterol-rich regions of the cell plasma membrane, 
termed lipid rafts, could impinge on subsequent attack. The lipid raft hypothesis 
suggests that the lipid bilayer is not structurally passive but instead organises itself 
into sub-compartments of cell membrane which have specific bioactivity (Lingwood 
and Simons 2010). Lipid rafts are dynamic, nanoscale assemblies enriched in 
sphingolipid, cholesterol and GPI anchored proteins which form functional 
platforms (Hancock 2006). Ab cross-linking at the cell surface leads to raft lipids and 
proteins co-localising and excluding non-raft proteins (Harder, Scheiffele et al. 
1998). The assembly of lipid rafts is always cholesterol dependent and some studies 
have demonstrated a requirement for the rearrangement of actin (Suzuki, Fujiwara 
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et al. 2007; Goswami, Gowrishankar et al. 2008). The enrichment of GPI anchored 
proteins, such as the complement regulators CD55 and CD59, in lipid rafts (Brown 
and London 2000) suggests that they could be a target for complement attack. The 
ability to induce lipid rafts also leads to the activation of complement dependent 
cytotoxicity (Cragg, Morgan et al. 2003). If MAC is preferentially inserted into these 
lipid rich areas, a sub-lytic complement attack would not only lead to shedding of 
membrane vesicles containing MAC, but could also result in the loss of lipid rafts. 
Loss of these cholesterol rich areas could impinge on the ability of MAC or other 
pore-formers to insert into the cell membrane until lipid rich areas are replenished.   
 
Alternatively, re-configuration of the actin skeleton, a mechanism utilised by 
pathogens such as cytomegalovirus (CMV), could be relevant. Certain strains of 
CMV have evolved immune evasion genes which protect the host cell from NK and T 
cell attack. This protection is provided via remodelling the actin skeleton resulting in 
a dramatic reduction in the efficiency of immune synapse formation (Stanton, 
Prod'homme et al. 2014). Whilst cytotoxic cells are known to reorganise their actin 
skeletons in order to promote adhesion, polarization of cytotoxic granules, 
organisation of the immunological synapse and degranulation, there is surprisingly 
little data regarding the role of the actin cytoskeleton in target cells. The ability of 
actin reorganisation in target cells to influence synapse formation could also affect 
the ability of pore-formers to insert into the cell membrane making this a potential 
mechanism through which sub-lytic complement attack might result in resistance 
from further pore-forming attack.  
 
Concluding remarks 
 
Whilst sub-lytic complement offers convincing protection against a subsequent lytic 
complement attack, I have failed to demonstrate any convincing protection against 
NK cell killing. This does not however, rule out the possibility that CIP is a 
mechanism at play during NK cell attack. This could be due to failings in 
methodology such as the use of a cell line that is highly susceptible to NK mediated 
cell lysis or alternative mechanisms, such as the cellular stress caused by a 
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complement attack, could be compensating for the protective effect. Further 
studies are required in order to investigate these mechanisms.  
 
Despite a strongly protective phenotype, I have also failed to demonstrate a genetic 
signature for CIP. Comprehensive analysis and confirmatory steps have shown no 
dysregulated genes unique to CIP despite the ability to identify a genetic signature 
for other experimental variables such as exposure to NHS. This strongly suggests 
that an alternative mechanism is involved. I have discussed two potential 
mechanisms that could be significant and believe that further studies involving actin 
imaging and lipidomic investigation of cell membranes following complement attack 
are warranted. As previous studies suggest that this phenomenon is not unique to 
the complement system, it would also be informative to explore a range of pore-
formers including MAC, perforin, melittin and streptolysin.    
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Chapter 4- Complement promotes progression of AML through 
multiple mechanisms 
 
4.1 Introduction 
 
The complement system is activated in a range of malignancies (discussed in 
Chapter 1, reviewed in Table 1.4) with the level of activation often being 
proportionate to disease progression (Nishioka, Kawamura et al. 1976; Matsutani, 
Suzuki et al. 1984; Guidi, Baroni et al. 1988; Niculescu, Rus et al. 1992). Production 
of the complement anaphylatoxin C5a can create a favourable microenvironment 
for disease progression by impinging on CD8+ T cell responses (Markiewski, 
DeAngelis et al. 2008). C5aR expression has also been shown to be a feature of 
metastatic spread (Vadrevu, Chintala et al. 2014).   
 
AML cells exert a range of effects on the immune system in a bid to evade immune 
elimination (reviewed in Chapter 1). However, the effect of the complement system 
on the progression of AML has not as yet been explored. The complement system is 
activated in AML, with levels of complement proteins falling once a remission is 
attained (Minh, Czink et al. 1983). More recent studies have revealed a potential 
role for the complement protein C3f-desArg in both diagnosis and detection of 
minimal residual disease (MRD) (Liang, Wang et al. 2010) in acute leukaemia, 
suggesting that the complement system could be activated during the earliest 
stages of disease development and relapse. This led me to postulate that AML cells 
activate the complement system in order to evade immune elimination.  
 
Immune therapies are already widely used in the treatment of AML, with novel 
agents constantly being investigated and developed for use. If complement has a 
role in the progression of AML, then complement-targeted therapeutics may not 
only have an independent role in improving spontaneous immune responses to 
leukaemia, but may also impact on all therapies aimed at controlling AML via 
immune mediated mechanisms.    
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The main aims of experiments described in this Chapter were to: 
 
- Investigate whether complement activity affects the progression of AML 
- Determine which components of the complement cascade are key 
- Explore the underlying mechanisms.  
 
Studies outlined in this chapter used the mouse AML cell line, C1498, which was 
originally cultured in vitro from AML which developed spontaneously in a B6 mouse. 
The C1498 cell line used expressed the fluorescent protein DSRed which enables 
detection of the tumour within the tissue in vivo (Sauer, Ericson et al. 2004). In my 
studies, progression of AML was monitored in vivo using Kodak FX Pro fluorescence 
imaging equipment (FX Pro).  
 
4.2 Results 
 
4.2.1. Disease developing post IV administration of C1498FFDsR is detectable 
using Kodak FX Pro fluorescence (FX Pro) imaging equipment 
 
Initial studies assessed the dose of C1498FFDsR which would result in consistent 
take and progression of AML. Based on available literature, a dose of 106 cells was 
initially compared with a higher dose of 5 x 106 cells. Cells were administered IV to 
three immunocompetent female WT mice. At day 28 mice were culled, shaved and 
imaged using the FX Pro. Livers, spleens and any other areas of tumour infiltration 
were harvested for analyses by flow cytometry.  
 
All 3 mice receiving 5 x 106 cells developed disease which was readily detectable by 
imaging (Figure 4.1). At harvest, each mouse had visible liver lesions and 2 mice also 
had large ovarian tumours. The findings at harvest corresponded well with the 
images achieved by the FX Pro which were able to identify both diffuse and 
localised disease (Figure 4.1). 1 of the 3 mice receiving the lower dose of 106 cells 
also developed disease that was detectable by imaging and was found to have an 
ovarian tumour at harvest. Flow cytometry confirmed the presence of DSRed +ve  
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Figure 4.1: In vivo imaging identifies both diffuse and localised disease. By 
superimposing fluorescent images on white light images disease is localised via 
identification of the cellular DSRed fluorophore in malignant tissue. Diffuse 
bioluminescent disease (left panel, left mouse) and localised live lesions (left panel, 
central mouse, demonstrated by arrow) are clearly visible. At the time of harvest, 
large granulocytic lesions were often seen arising from the ovaries (right panel, 
ovarian mass indicated by arrow).  
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Figure 4.2: DSRed +ve granulocytic infiltration. Representative flow cytometric 
plots demonstrating DSRed +ve AML cells infiltrating the liver of an experimental 
mouse B) as compared to a control animal A).   
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granulocytic infiltration in the organs of affected mice, but not in the 2 mice 
receiving the lower dose of cells which were negative on imaging (Figure 4.2). It was 
therefore concluded that the higher dose of 5 x 106 cells IV resulted in consistent 
disease with no adverse effects.  
 
4.2.2. AML fails to progress in mice lacking C3  
 
There are several components of the complement system which might have a role 
in the progression of AML.  In order to assess the over-reaching effect of a range of 
these components, the progression of AML in a fully complement deficient 
environment was first investigated. In order to do this genetically modified C3 
knockout (C3-/-) mice were used. The C3-/- mice used in these experiments were 10 
X back-crossed onto a B6 background.  C3-/- mice lack the ability to produce the 
membrane attack complex and are therefore unable to lyse cells via complement-
mediated lysis. They are also unable to produce the anaphylatoxins C3a and the 
opsonizing protein C3b and therefore lack the wide range of functions mediated by 
these proteins (Figure 4.3).  
 
In order to determine whether any complement components below the level of C3 
had an impact on progression of AML, 8 female age matched WT and C3-/- mice 
received 5 x 106 tumours cells IV on day 0. The development of disease was 
monitored using the FX Pro with fluorescent images being superimposed onto white 
light images in order to allow accurate disease localisation of the cellular DSRed 
fluorophore in malignant tissue. Mice were shaved and imaged under inhaled 
isofluorane anaesthetic weekly for 2 weeks, twice weekly for 3 weeks and then 
weekly until the end of the experiment. An imaging and health (IH) score which 
scored both imaging findings and health factors was used to allow consistent 
decisions to be made on experimental endpoints (Table 2.2). Mice were harvested 
when they reached a combined imaging and health (IH) score of 4.  
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Figure 4.3: Phenotype of C3 deficient (C3-/-) mouse. C3-/- mice lack the ability to 
produce the membrane attack complex and are therefore unable to lyse target cells 
via complement-mediated lysis. They are also unable to produce the anaphylatoxin 
C3a and the opsonizing protein C3b and therefore lack the wide range of functions 
mediated through these proteins.  
 
 
 
 
 
153 
 
The development of leukaemia was readily detectable in shaved, anaesthetised 
mice using serial imaging with the FX Pro. Disease was detectable from day 15 in 
WT controls with all 8 mice being harvested between days 23 to 37.  
 
No tumours were detected in the C3-/- mice, despite repeated imaging for a total of 
77 days and full examination of all mice post mortem (Figures 4.4 and 4.5).  
 
Over the course of 4 experiments a total of 32 C3-/- mice (24 female, 8 male) 
received IV C1498 at a dose of 5 x 106 cells that was lethal to age and sex matched 
WT mice (Figure 4.6). Most C3-/- mice (29/32) failed to develop detectable disease, 
P <0.0001***, median survival WT = 29.5 days, C3-/- = not reached. It was 
concluded that C3-/- mice, which lack the ability to form any component of the 
complement cascade, are resistant to progression of AML when injected IV with the 
murine AML cell line C1498.   
 
4.2.3. T Cells are required to control growth of AML in C3-/- mice  
 
Having demonstrated that AML fails to progress in a complement–deficient 
environment, how this protection was mediated was next explored. Complement 
has previously been shown to promote tumour progression via impingement on 
CD8+ T cell responses. Chapter 3 described a possible role for complement in 
impinging on both CD8+ T cell and NK mediated immune responses via 
complement-induced protection. Whether NK or CD8+ T cell depletion had any 
effect on progression of AML in a complement deficient vs sufficient environment 
was therefore next explored.   
 
The anti-mouse-NK monoclonal antibody PK136 and the combination of two anti-
mouse-CD8+ antibodies, YTS-169 and YTS-156, have been used widely by our group 
to deplete NK and CD8+ T cells in WT mice in vivo. Their efficacy has not as yet been 
explored in a complement deficient environment. As the function of some 
antibodies depends on the presence of complement, the ability to deplete NK or 
CD8+ T cells in the absence of complement was assessed.  
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Figure 4.4: Serial in vivo imaging of DSRed+ve AML. Serial imaging of wild type 
(WT) and C3-/- mice demonstrated detectable disease in WT mice resulting in the 
animals being killed by day 37. C3-/- mice were imaged for a further 40 days. Over 
the course of the 11 week experiment, no C3-/- mice developed AML as detected by 
either serial imaging or post mortem examination at the end of the experiment.   
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Figure 4.5: In vivo imaging showing disease progression. Images demonstrate 
disease progression in a representative WT mouse over a period of 30 days. In 
contrast, C3-/- mice failed to develop detectable disease. 
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Figure 4.6: Survival of C3-/- vs WT mice. 5 x 106 C1498 cells injected IV into a total 
of 48 WT and 32 C3-/- mice. Kaplan Meier survival curve; P = <0.0001*** (Log-rank 
(Mantel-cox) test). Median survival WT = 29.5 days, C3-/- = not reached.  
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In order to do this 6-9 week old female C3-/- mice were treated with either anti-NK 
or anti-CD8 antibodies.  The anti-NK antibody PK136 was used at a dose of 0.5mg IP 
(2 mice). Two anti-CD8 antibodies (YTS-169 and YTS-156) were used in combination,  
each at a dose of 100μg IP (2 mice). Dosing was repeated 3 days later.  n day five 
these mice along with a control mouse were harvested and their spleens analysed 
for the presence of NK and CD8+ T cells.   
 
Results demonstrated that the combined use of two CD8 depleting antibodies, YTS-
169 and YTS-156, depleted CD8+ T cells in a C3-/- mice (Figure 4.7). Although not 
complete, the 85-90% CD8+ depletion observed suggested that the antibodies were 
able to deplete the majority of CD8+ T cells even in the absence of complement. We 
therefore went on to use these antibodies to explore the effect of CD8+ T cell 
depletion on tumour progression in C3-/- mice.   
 
Contrary to this, the NK depleting antibody PK136, did not appear to deplete NK 
cells in C3 deficient mice (Figure 4.8), implying that depletion of NK cells by PK136 is 
complement-dependent, a finding supported by other studies(Janelle, Langlois et al. 
2014). I was therefore unable to further explore the impact of NK cells on 
progression of AML in C3-/- mice.     
 
In addition to CD8+ T cell depletion we also explored the effect of CD4+ T cell 
depletion on the progression of AML in complement sufficient vs deficient 
environment. The combination of 2 CD4 depleting antibodies YTS-191 and YTA-3, 
which work via a similar mechanism to the CD8 depleting antibodies YTS-169 and 
YTS 156, were used in these studies.  
 
Groups of eight 7-13 week old C3-/- or age matched WT mice were injected on day -
3, day -1 and then fortnightly with a total of 200μg of either CD8 depleting (100μg 
of each YTS-169+ YTS-156), CD4 depleting (100 μg of each YTS-191 and YTA-3) or 
control (GL113) antibodies. On day 0 all mice received 5 x 106 IV C1498FFDsR cells.  
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Figure 4.7: CD8-depletion in representative C3-/- mice. Two CD8-specific depleting 
antibodies, YTS-169 and YTS-156, were used in combination to deplete CD8+ T cells 
in two C3-/- mice. The antibodies were each administered at a dose of 100μg IP, this 
dose was repeated 3 days later. On day five mice were harvested along with an 
untreated control. Following red cell lysis, splenocytes were stained with CD8-
specific antibodies along with live/dead aqua and analysed by flow cytometry for 
the presence of live CD8+ cells.  
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Figure 4.8: Attempted NK depletion in a representative C3-/- mouse. The NK 
depleting antibody PK136 was administered 0.5mg IP (2 mice) with repeat dosing 3 
days later. Mice were harvested along with an untreated control on day 5. 
Following red cell lysis, splenocytes were stained with a FITC conjugated anti NK1.1 
antibody along with live/dead aqua and analysed by flow cytometry for the 
presence of live NK cells. There was no evidence of successful NK depletion in the 
C3-/- mice suggesting that the PK136 antibody depletes NK cells via a complement 
mediated mechanism.   
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Mice were imaged twice weekly from day 7 (Figure 4.9) and harvested when a 
combined IH score of 4 was reached. 
 
Untreated WT mice began developing disease from day 20 with 5 being harvested 
between days 20 to 31. Two further untreated WT mice were harvested on day 40 
and there was one long-term survivor. CD8-depleted WT mice had a more 
aggressive phenotype than controls with lesions developing from day 14 and all 
mice being harvested by day 17. P <0.0001***, median survival: WT = 31 days, CD8-
depleted = 18 days. CD4-depleted WT mice also showed the first signs of disease on 
day 14 with 6 mice being harvested between days 17 and 25. One CD4-depleted WT 
mouse developed diffuse disease by day 54 and there was one long-term survivor. 
There was no statistically significant difference in survival observed between CD4+ T 
cell depleted and WT mice. P = 0.3588 (ns), median survival: WT 31 days, CD4-
depleted 25 days (Figure 4.10).  
 
As previously shown, untreated C3-/- mice exhibited a highly significant reduction in 
disease progression compared to untreated WT mice. In contrast, the CD8 depleted 
C3-/- mice began developing detectable lesions on day 14, with 6 mice being 
harvested between days 17 and 28. The remaining 2 mice were long-term survivors. 
This resulted in a highly significant survival advantage being observed in untreated 
vs CD8-depleted C3-/- mice, P = 0.0036** (Log-rank (Mantel-cox) test). Median 
survival: untreated C3-/- = not reached, CD8-depleted C3-/- = 20 days. CD4-depleted 
C3-/- mice began developing lesions from day 20 with 6 mice being harvested 
between days 20 and 31. There were again, 2 long-term survivors. The difference 
between CD4-depleted and untreated C3-/- mice just reached statistical 
significance, P = 0.049* (Log-rank (Mantel-cox) test). Median survival: CD4-depleted 
C3-/- = 28 days, C3-/- control = not reached (Figure 4.11).   
 
Despite disease developing in the CD8-depleted C3-/- mice, this was significantly 
less aggressive than disease seen in CD8-depleted WT mice P = 0.0014**. Median 
survival: CD8-depleted WT = 18 days, CD8-depleted C3-/- = 20 days. Disease 
progression in CD4-depleted C3-/- mice was comparable to that seen in their CD4-  
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Figure 4.9: Protocol for in vivo T cell depletion studies. Groups of 8 age and sex-
matched B6 or C3-/- mice were treated with CD8-depleting (YTS-169 and YTS-156 
100μg of each), CD4-depleting (YTS-191 and YTA-3 100μg of each) or control 
(GL113) antibodies. In each group, a combined dose of 200μg was administered IP 
on day -3, day -1 and then fortnightly. Mice received 5 x 106 C1498 cells IV on day 0 
and were then imaged twice weekly from day 7.   
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Figure 4.10: Survival of WT mice depleted of CD8+ or CD4+ cells. 5 x 106 C1498 
cells injected IV into 8 CD8-depleted and 8 CD4-depleted WT mice along with 8 age 
and sex matched controls. Kaplan Meier survival curve; A) +/- CD8-depleted P 
<0.0001*** (Log-rank (Mantel-cox) test). Median survival WT = 31 days, CD8-
depleted = 18 days. B) +/- CD4-depleted P = 0.3588 (ns). Median survival WT = 31 
days CD4-depleted = 25 days.  
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Figure 4.11: Survival of C3-/- mice depleted of CD8+ or CD4+ cells. 5 x 106 C1498 
cells injected IV into 8 CD8 depleted and 8 CD4 depleted C3-/- mice along with 8 age 
and sex matched controls. Kaplan Meier survival curve; A) +/- CD8+ T cell depletion 
P = 0.0036** (Log-rank (Mantel-cox) test). Median survival C3-/- = not reached, CD8 
depleted = 20 days. B) +/- CD4+ T cell depletion P = 0.049*. Median survival CD4 
depleted C3-/- = 28 days.  
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depleted B6 counterparts leading to no significant difference being demonstrated 
between the two groups P = 0.2804 (ns). Median survival: CD4-depleted WT = 25 
days, CD4-depleted C3-/- = 28 days (Figure 4.12). Table 4.2 provides an overview of 
the statistically significant findings. 
 
Experimental Group Experimental Group P-value Significant? 
C3-/-  vs WT 0.0098 Yes ** 
C3-/- vs C3-/-  - CD8 0.0036 Yes ** 
C3-/- vs C3-/-  - CD4 0.049 Yes * 
C3-/-  - CD8 vs WT  -  CD8 0.0014 Yes ** 
C3-/-  - CD4 vs WT  -  CD4 0.2804 No 
WT vs WT  -  CD8 <0.0001 Yes *** 
WT vs WT  -  CD4 0.3588 No 
 
Table 4.2:  Summary of CD4/CD8-depletion studies. Log-rank (Mantel-Cox) tests 
were used to assess statistical significance between WT and C3-/- mice +/- CD8 or 
CD4 depleting antibodies.  
 
In conclusion, CD8- (and to a lesser extent CD4-) depletion resulted in C3-/- mice 
consistently developing AML. This suggests that complement deficiency protects 
against the progression of AML via a mechanism mediated by CD8+ (and/or CD4+) T 
cells.  
 
4.2.3. C1498 cells produce no detectable C3 protein  
 
Several malignant cell lines have been shown to produce C3 (Kitano and Kitamura 
1993; Legoedec, Gasque et al. 1995; Andoh, Fujiyama et al. 1998). It is therefore 
possible that the C1498 AML cell line produced C3 which would be immunogenic in 
C3-/- mice since the mice would not have encountered C3 during thymic selection. 
This could result in immune mediated clearance of the C1498 cells through T cell 
recognition of MHC / C3 peptide complexes. Evidence of C3 production by C1498 
cells was therefore investigated.   
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Figure 4.12:  Survival of C3-/- vs WT mice depleted of CD8+ or CD4+ T cells. 5 x 106 
C1498 cells injected IV into 8 CD8 depleted and 8 CD4 depleted WT and C3-/- mice. 
Kaplan Meier survival curve; A) CD8+ T cell depletion in C3-/- vs WT mice P = 
0.0014** (Log-rank (Mantel-cox) test). Median survival CD8 depleted WT = 18 days, 
CD8 depleted C3-/- = 20 days. B) CD4+ T cell depletion in C3-/- vs WT mice P = 
0.2804 (ns). Median survival CD4 depleted WT 25 days CD4 depleted C3-/- = 28 
days. 
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In order to determine whether C1498 cells were producing C3 in vitro a C1498 cell 
lysate along with a 20X concentrated C1498 supernatant were tested for the 
presence of C3 by Western Blot. Mouse serum and concentrated mouse C3 were 
used as positive controls and C3-/- mouse serum was used as a negative control. 
There was no evidence that C1498 cells produce C3 in vitro (Figure 4.13).  
 
The ability for C1498 cells to produce C3 in vivo was then assessed by 
immunohistochemistry. Discrete C1498 tumours, which had developed above the 
ovaries of C3-/- mice were stained for C3 deposition by malignant cells in vivo. As 
only 1 C3-/- mouse had developed solid tumours, ovarian tumours from CD8-
depleted C3-/- mice were also used allowing multiple tumours taken from WT and 
C3-/- to be assessed. No evidence of C3 production by C1498 tumours in vivo was 
observed (Figure 4.14).  
 
4.2.4: C3-/- mice do not mount a better CD8+ T cell response against C1498 
leukaemia cells 
 
AML fails to progress in CD8+ T cell replete C3-/- mice however when CD8+ T cells 
are depleted C3-/- mice develop AML. It was therefore postulated that the CD8+ T 
cell response against AML was more robust in a complement deficient vs sufficient 
environment.  In order to investigate this, both WT and C3-/- mice were vaccinated 
with irradiated AML cells. Irradiated cells were used as previous experiments 
suggest that the kinetics of AML progression following injection of live cells is 
unlikely to be comparable between WT and C3-/- mice. Irradiating cells removed 
any disparities introduced by variable growth kinetics thus delivering a more 
comparable dose/ stimuli in WT vs C3-/- mice. 
 
Splenocytes from vaccinated/ unvaccinated WT vs C3-/- mice were then assessed 
for IFNγ release in response to irradiated C1498 in an ELISpot assay.  Full details are 
provided in Chapter 2 but in brief, 4 WT and 5 C3-/- mice were vaccinated SC with 5 
x 107 irradiated C1498 cells. Vaccination was repeated after 4-6 weeks with  
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Figure 4.13: Immunoblot of C3. HRP conjugated goat anti-mouse C3 antibodies 
were used at 0.1μg/ml in order to detect C3. Two positive control samples (WT 
mouse serum and purified mouse C3) along with one negative control (C3-/- mouse 
serum) were included on the blot. Two bands characteristic of C3 staining were 
observed in both positive controls (arrows, β-chain = 65kDa, α-chain fragments 
approx 46kDa). A C1498 cell lysate along with 20 x concentrated supernatant from 
confluent C1498 cells were tested for expression of C3. No C3 was detected.  
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A. B.
 
 
Figure 4.14: C3 staining on a liver from a WT mouse and C1498 ovarian tumour 
from a C3-/- mouse. C3 deposition was assessed using a two step staining protocol 
as detailed in Chapter 2. A rat anti-C3 monoclonal antibody (11H9) was used with a 
488 anti-rat secondary detection antibody alongside an isotype control antibody 
(negative, not shown). Multiple tumours taken from WT and C3-/- mice were 
assessed. A. C3 deposition around a venule in a liver taken from a tumour bearing 
WT mouse (arrow). B. Cross section through a solid ovarian tumour harvested from 
a C3-/- mouse (CD8 depleted) revealed no evidence of C3 deposition.  
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vaccinated mice being harvested 7 days later along with 3 WT and 3 C3-/- 
unvaccinated controls. Splenocytes were then assessed for their IFNγ response to 
irradiated C1498 at a range of effector: target ratios. Results demonstrated that all 
vaccinated mice responded to the cell line in the ELISpot assay. The response 
observed in C3-/- mice was no better than seen in WT mice (Figure 4.15). 
 
4.2.5: The impact of components of the complement pathway on progression of 
AML  
 
Thus far it has been demonstrated that C3-/- mice are protected against 
progression of C1498 leukaemia. This appears to be mediated through CD8+ T cells 
although the exact mechanism remains unclear. As C3-/- mice lack several 
potentially relevant components of the complement cascade including C3a, C3b and 
MAC. Which components of the complement system were key to disease 
progression was therefore investigated (Figure 4.16).   
 
The three main mechanisms identified as having a potential role in the progression 
of AML were:  
 
i) Anaphylatoxins, C5a and C3a 
ii) Complement-induced protection 
iii) Cell adherence and migration 
(Figure 4.17) 
 
In order to systematically investigate the role of complement in the progression of 
AML, genetically complement-deficient mice, or mice administered with 
complement inhibitors, to block or inhibit complement activation respectively were 
used. 
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Figure 4.15: Graph demonstrating ELISpot responses to vaccination with irradiated 
C1498 cells in WT vs C3-/-mice. WT and C3-/- mice were vaccinated with 5 x 107 
irradiated C1498 cells. This was repeated 4 weeks later. 7 days later animals were 
harvested, along with unvaccinated control animals. Splenocytes were tested for 
their response to irradiated C1498 cells as targets at a range of E:T ratios. IFN-γ 
secreting cells were analysed and a mean responses from 4 WT, 5 C3-/- vaccinated 
animals and 3 non-vaccinated WT and C3-/- controls are shown. 
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Figure 4.16: Schematic of the complement cascade demonstrating areas to be 
explored in an in vivo model of AML. C3, C3a receptor and C6 knockout mice were 
utilised along with anti-C5 blocking antibodies, C5a receptor antagonist and C6 
antisense oligonucleotide.  
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Figure 4.17: Components of the complement cascade that might contribute to the 
protective phenotype. Three mechanisms were identified through which 
complement could be mediating the progression of AML i) anaphlylatoxins ii) 
complement-induced protection and iii) adherence and cell migration.  
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4.2.5.1. The role of the anaphylatoxins C5a and C3a  
 
C5a Anaphylatoxin 
 
Investigating the role of the complement anaphylatoxins, particularly C5a, was the 
most obvious starting point. C5a has been shown to create a favourable 
environment for tumour growth by modulating the anticancer immune response via 
suppression of the anti-tumour CD8+ T cell response by myeloid derived suppressor 
cells (MDSCs) (Markiewski, DeAngelis et al. 2008). Other studies have also 
implicated C5a in promoting tumour growth via both similar and distinct 
mechanisms such as promoting the activation of Tregs, or increasing tumour 
infiltration with macrophages or monocytes (Caso, Silvera et al. 2010; Corrales, 
Ajona et al. 2012; Gunn, Ding et al. 2012; Nunez-Cruz, Gimotty et al. 2012; Vadrevu, 
Chintala et al. 2014; Imamura, Yamamoto-Ibusuki et al. 2015). These studies suggest 
the immunomodulatory functions of C5a are highly context dependent. 
 
It was hypothesised that blocking complement activation at the level of C5, which 
would both prevent the production of MAC and the anaphylatoxin C5a, would 
impact on progression of C1498 AML. The anti-mouse C5 antibody (anti-C5 mAb), 
BB5.1, was used (Figure 4.18).  
 
The presence of endotoxin can have major effects on numerous immune functions 
(reviewed in (Heine, Rietschel et al. 2001)). Endotoxin-low anti-C5 mAb was 
therefore generated for use in these studies (see Chapter 2). The efficacy of the Ab 
was then assessed by first testing its ability to inhibit complement-mediated lysis in 
vitro (Figure 4.19). A dose of 3.125μg/ml anti-C5 mAb completely inhibited 
complement-mediated lysis of antibody-coated rabbit erythrocytes by 4% mouse 
serum in vitro.  
 
Based on a review of published literature, a dose of 1mg IP was then assessed in 
vivo. Anti-C5 mAb was administered via an IP injection twice weekly beginning on 
day -1 (day 0 being the day of tumour cell injection). An isotype matched control  
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Figure 4.18: Phenotype achieved by the anti-C5 mAb. Mice treated with the anti-C5 
mAb were unable to form MAC hence lacked any ability for complement mediated 
lysis. They are also unable to make the main complement anaphylatoxin C5a but 
retain the ability to produce both the anaphylatoxin C3a and the opsonising protein 
C3b.    
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Figure 4.19: In vitro inhibition of complement by anti- C5 mAb. Rabbit erythrocytes 
were sensitised by incubation with a mouse anti-rabbit erythrocyte antibody. They 
were then treated with 4% normal mouse serum pre-incubated with a range of 
titres of anti-C5 mAb or the control antibody D1.3.  Haemoglobin release was 
measured and expressed relative to 100% control (erythrocytes lysed with H2O).  
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antibody (D1.3) was used at an equivalent dose in age- and sex-matched control 
mice. Blood was taken prior to the 1st injection and again on days 1, 2 and 4, such 
that adequate complement depletion could be confirmed up until the next dose of 
antibody was due. Complete inhibition of complement haemolytic activity was 
achieved at all time points in all mice treated with anti-C5 mAb (Figure 4.20). The 
dose of 1mg IP twice weekly was therefore taken forward into subsequent studies. 
 
Groups of 8 age- and sex-matched WT mice were treated with either 1mg IP anti-C5 
mAb or control antibody from the day prior to administration of 5 x 106 C1498 cells 
IV;subsequent maintenance doses of 1mg were administered twice weekly. In vivo 
imaging was performed twice weekly from day 7. This revealed equivalent disease 
development in treated and control mice P = 0.8270, median survival WT = 29.5 
days, WT + anti-C5 mAb = 35.5 days (Figure 4.21). 
 
There are three explanations for this result i) C5a has no effect on the progression 
of AML in this model ii) the method of C5a neutralisation was flawed or iii) 
additional effects of C5-depletion were affecting the results. It is possible that 
despite confirming a complete suppression of the haemolytic capacity of the 
complement system in plasma, the effect of the C5 depleting antibody was 
incomplete at a tissue level. C5a is produced at a local level and has important roles 
in mediating both CD4+ and CD8+ T cell responses (Lalli, Strainic et al. 2008; Strainic, 
Liu et al. 2008). In addition to preventing the production of C5a, anti-C5 mAb also 
inhibits the production of MAC. It is therefore possible that the absence of MAC was 
impinging on any protective effect conferred by the depletion of C5a (experiments 
described later in this Chapter).  
 
Other studies investigating the role of C5a in malignancy have used the Cyclic 
hexapeptide antagonist AcF-[OPdChaWR] also known as PMX-53 in order to 
specifically block the main C5a receptor (Markiewski, DeAngelis et al. 2008; 
Corrales, Ajona et al. 2012; Vadrevu, Chintala et al. 2014). The independent role of 
the C5a-C5aR signalling axis was explored using this alternative reagent, which was 
kindly provided by Professor Trent Woodruff (Figure 4.22).  
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Figure 4.20: In vivo inhibition of complement. 8 mice had blood taken prior to 
administration of either 1mg IP of control antibody, D1.3 (A) or the anti-C5 mAb (B). 
Further blood samples were then taken on day 1 and 2 post dose and again on day 
4, before a 2nd dose of antibody was due. Serum haemolytic ability was assessed 
using rabbit erythrocytes sensitised using mouse anti-rabbit erythrocyte antibody. 
Lysis was measured relative to 100% control erythrocytes lysed with H2O. 
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Figure 4.21: Survival of WT mice treated with anti-C5 mAb. 5 x 106 C1498 cells 
injected IV into a total of 8 WT mice treated with anti-C5 mAb, along with 8 age and 
sex-matched WT mice treated with isotype control, D1.3. Kaplan Meier survival 
curve; P = 0.8270 (Log-rank (Mantel-cox) test). Median survival WT = 29.5 days, WT 
+ anti C5-mAb = 35.5 days.  
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Figure 4.22: Phenotype achieved by the C5a receptor antagonist PMX-53. 
Although mice treated with the C5a receptor antagonist PMX-53 could still produce 
C5a they lack the ability to respond to it via its main receptor C5aR. They are still 
able to form MAC and hence maintain their capacity for complement-mediated 
lysis. They also retain the ability to produce both the anaphylatoxin C3a and the 
opsonising protein C3b.    
 
 
 
 
 
 
 
 
 
180 
 
The C5a receptor antagonist (C5aRA) was used at the dose described in other 
studies (1mg per kg) in both a 3 times per week and a daily dosing regimen. 
Treatment commenced the day prior to administration of C1498 cells and continued 
for the duration of the experiment. Mice were imaged twice weekly from day 7. 
 
As no difference was observed between thrice weekly vs daily dosing, the results of 
the two experiments were combined. Results demonstrating no difference in 
survival C5aRA treated and control mice P = 0.3958, median survival WT = 25.5 
days, WT + C5aRA = 24 days (Figure 4.23). It was however noted that approximately 
20% C5aRA treated mice failed to develop detectable disease.  
 
C3a anaphylatoxin 
 
Though several studies have explored the role of ‘complement anaphylatoxins’ in 
tumour progression, this has either been investigated via complete complement 
inhibition (C3-/- mice) or by therapeutic  or genetic ablation of the C5aR (reviewed 
in(Sayegh, Bloch et al. 2014)), with little attention being paid to the specific role of 
C3a.  
 
It was therefore hypothesised that whilst C5a has a role in cancer progression in 
other tumour models, C3a might be more important in the case of AML. The effect 
of C3a-C3aR signalling on the progression of AML was therefore explored using 
genetically modified mice that did not express the C3a receptor (C3aR-/-).  These 
mice are able to produce but not respond to C3a due to the lack of C3aR expression 
(Figure 4.24).  
 
These studies revealed that AML in a C3aR-/- mouse had a more aggressive 
phenotype than observed in control mice, P<0.0064**, median survival WT = 25.5 
days, C3aR-/- = 20 days (Figure 4.25). This was initially a somewhat unexpected 
finding as it suggests that C3a-C3aR signalling protects against progression of AML,  
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Figure 4.23: Survival of WT mice treated with C5a receptor antagonist. 5 x 106 
C1498 cells injected IV into a total of 16 WT mice treated with the C5a receptor 
antagonist (C5aRA) PMX-53 along with 16 age and sex-matched WT controls. Kaplan 
Meier survival curve; P = 0.3958 (Log-rank (Mantel-cox) test). Median survival WT = 
25.5 days, WT + C5aRA = 24 days. It was however noted that approximately 20% 
C5aRA treated mice failed to develop detectable disease.  
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Figure 4.24: Phenotype of C3aR deficient (C3aR-/-) mice. C3aR-/- mice are still able 
to produce C3a but are unable to respond via the C3a receptor. They can still form 
MAC and hence maintain their capacity for complement-mediated lysis. They also 
retain the ability to produce both the anaphylatoxin C5a and the opsonising protein 
C3b.    
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Figure 4.25: Survival of C3aR-/- vs WT mice. 5 x 106 C1498 cells injected IV into a 
total of 16 WT and C3aR-/- mice. Kaplan Meier survival curve; P < 0.0064** (Log-
rank (Mantel-cox) test). Median survival WT = 25.5 days, C3aR-/- = 20 days.  
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and therefore could not account for the protective phenotype observed in C3-/- 
mice. 
 
A review of the literature revealed that C3a has been shown to have an opposing 
role to C5a in both sepsis and an acute inflammatory response (Hollmann, Mueller-
Ortiz et al. 2008; Wu, Brennan et al. 2013). During the acute inflammatory response 
C3a has a potent anti-inflammatory role acting in direct opposition to C5a via 
inhibiting the mobilization of neutrophils into inflamed tissues (Wu, Brennan et al. 
2013). In sepsis, whilst C5aR signalling is deleterious, C3aR signalling is protective 
(Hollmann, Mueller-Ortiz et al. 2008). These findings suggest that C3a might 
regulate C5a generated inflammatory responses. Signalling via the C3a receptor 
could thus have a protective role in AML contrary to the deleterious role for C5a 
described in other malignancies. An alternative explanation would be that C3a 
produced by the host is signalling via an alternative receptor such as C5aR2 or 
driving proliferation of malignant cells via interactions with their C3aR (discussed in 
depth later).  
 
As no protection against the progression of AML was observed via impinging on 
either the C5a-C5aR or C3a-C3aR signalling pathways, I postulated that the 
pathways compensate for each other thus should be blocked concurrently. To 
achieve this, C3aR-/- mice were treated with the C5aR antagonist described above. 
Treatment with C5aRA had no impact on the phenotype of C3aR-/- mice (Figure 
4.26). P = 0.2378, median survival: C3aR-/- = 24 days, C3aR-/- + C5aRA = 25.5 days. 
This is in line with the absence of effect observed when C5aRA was administered to 
WT mice. However, as this was only investigated in one experiment (8 vs 8) this 
finding needs to be confirmed.  
 
Whilst the use of genetically modified C3aR-/- mice impinges C3a-C3aR signalling via 
host cells, it has no effect on C3a production. In addition, the absence of the C3aR 
on host tissue might result in higher plasma levels of C3a in C3aR-/- mice. Hence 
C3a produced by the host mice could still have significant biological effects. The C3a 
cleavage product C3a desArg binds to and mediates its effect via the  
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Figure 4.26: Survival of C3aR-/- mice +/- treatment with C5aRA. 5 x 106 C1498 cells 
injected IV into a total of 8 C3aR-/- mice treated with the C5aRA compared to 8 age 
and sex-matched C3aR-/- controls. Kaplan Meier survival curve; P = 0.2378 (Log-
rank (Mantel-cox) test). Median survival C3aR-/- = 24 days, C3aR-/- + C5aRA = 25.5 
days.  
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alternative C5aR C5aR2 (Kalant, Cain et al. 2003; Li, Coulthard et al. 2013). However, 
as C3aR-/- mice do not express C5aR2 (unpublished data, private correspondence 
with Prof Craig Gerard) this rules out an effect of downstream C3a cleavage 
products on this receptor. However it is possible that C3a might signal via either 
C3aR or C5aR2 expressed on the administered AML cells and hence impact on their 
survival and proliferation. 
 
In contrast to the use of a genetically modified animal, treatment of WT mice with 
C5aRA will impinge on both host and malignant cell receptors. It will however have 
no effect on C5a signalling via the alternative C5a receptors C5aR2.  Hence, any  
effects mediated through C5a signalling via C5aR2 would be unaffected (discussed 
in detail later in this chapter).     
 
4.2.5.2 Complement-induced protection could be an in vivo phenomenon  
 
A longstanding assumption that complement facilitates the elimination of cancer 
cells (Rutkowski, Sughrue et al. 2010) has been reinforced by early promising results 
in studies using monoclonal antibodies against cell-associated complement 
inhibitors in order to enhance anti-tumour complement dependent cytotoxicity 
(Gelderman, Kuppen et al. 2002; Sier, Gelderman et al. 2004; Allendorf, Yan et al. 
2005). This longstanding dogma suggesting that activation of the complement 
system is protective against progression of cancer has been challenged by recent 
publications demonstrating that complement actually impinges on the immune 
response to cancer via the release of the anaphylatoxin C5a (Markiewski, DeAngelis 
et al. 2008). Despite a profound survival advantage being observed in C3-/- mice, no 
effect of C5a or C5aR manipulation has been observed in the C1498 AML model.  
Mice genetically deficient for C3aR also failed to provide an explanation for the 
protective phenotype observed in C3-/- mice.    
 
Whether the production of MAC itself had any effect on progression of AML was 
next explored. If the longstanding dogma of MAC being able to clear malignant cells 
and thus protecting against development/progression of tumours is true, then a 
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more aggressive phenotype would be observed. However, it is also possible that 
complement-induced protection could play a role in vivo. Sub-lytic doses of MAC 
could thus protect malignant cells in vivo against lytic doses of not only complement 
but also other pore-formers including perforin the cytolytic mechanism utilised by 
both NK and CD8+ T cells. If this is the case, then the presence of MAC would 
promote tumour growth and conversely an inability to produce MAC would result in 
protection from progression of AML.   
 
C6-/- mice 
  
C6 knock-out (C6-/-) mice, which had been back crossed onto a B6 background ten 
times, were used to assess the role of MAC in development of AML. The C6-/-mouse 
is unable to produce C6 and hence MAC, and therefore lacks any capacity for 
complement-mediated lysis. However, they have a fully functioning C1 – C5 
complement system and therefore producing both C5a and C3a anaphylatoxins and  
the opsonising protein C3b (Figure 4.27).  If MAC is effective at eliminating tumour 
cells in vivo, a more rapid progression of leukaemia would be expected. If 
complement-induced protection plays a role in vivo, then a lower incidence of 
leukaemia would be observed.  
    
The development on AML was assessed in a total of 38 C6-/- mice, 14 male and 24 
female, over the course of 4 separate experiments. Compared to age and sex-
matched controls, C6-/- mice exhibited a significant survival advantage, P= <0.0001. 
Median survival: WT = 27 days, C6-/- = 35.5 days. Approximately 25% of C6-/- mice 
remained free from AML (Figure 4.28). It should be noted that though the absence 
of MAC appears to be protective, this does not fully account for the protective 
phenotype observed in C3-/- mice as 75% of C6-/- mice did develop AML (compared 
to just 9% of C3-/- mice).  
 
It is somewhat surprising that the protective phenotype observed in C6-/- mice was 
not observed in WT mice treated with anti-C5 mAb, which should also be unable to 
form MAC. This could be the result of an incomplete blockade of MAC at the tissue  
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Figure 4.27: Phenotype of C6 deficient (C6-/-) mice. C6-/- mice are unable to form 
MAC and therefore lack any capacity for complement-mediated lysis. They retain 
the ability to produce both C3a and C5a anaphylatoxins and the opsonising protein 
C3b.    
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Figure 4.28: Survival of C6-/- vs WT and C3-/- mice. 5 x 106 C1498 cells injected IV 
into a total of 48 WT and 38 C6-/- mice. Kaplan Meier survival curve; P < 0.0001*** 
(Log-rank (Mantel-cox) test). Median survival WT = 27 days, C6-/- = 35.5 days. 
Approximately 25% of C6-/- mice failed to develop detectable disease.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
190 
 
level due to either incomplete tissue penetration of the antibody or to constant 
local production of complement proteins in the tumour microenvironment. This 
requires further investigation. Though not affecting survival, the use of the anti-C5 
mAb did appear to lead to an altered disease distribution in line with C6-/- mice 
which will be discussed in detail later.    
 
C6 antisense oligonucleotide 
 
In order to confirm the finding in C6-/- mice, an antisense oligonucleotide which 
targets C6 mRNA in order to prevent the synthesis of C6 in the liver and hence the 
production of MAC was used to reduce C6 synthesis in WT mice. The C6 antisense 
along with a control oligonucleotide was kindly provided by Professor Kees Fluiter 
(Fluiter, Opperhuizen et al. 2014). A dose of 5mg/kg subcutaneously (SC) three 
times a week was used, in line with his recommendation. This was commenced the 
day prior to administration of 5 x 106 C1498 cells IV. 
  
No survival advantage was observed in mice treated with the C6 antisense vs the 
control oligonucleotide. P = 0.6688, median survival: WT + control oligonucleotide = 
28.5 days, WT + C6 antisense oligonucleotide = 24 days (Figure 4.29).  
 
Plasma samples harvested from mice treated with either the C6 antisense or control 
oligonucleotide were sent to Professor Fluiters laboratory for measurement of C6 
levels. This showed that C6 levels were successfully suppressed to a level of 
between 0.3-1.5μg/ml (mean 0. μg/ml) in treated mice compared to 4.5- 9.4μg/ml 
(mean 6.5μg/ml) in control animals (Figure 4.30). Though the inhibition of C6 
production was successful, it is not complete and might mean that a sub-lytic level 
of MAC could still be achieved in C6 low mice. It is also possible that reducing C6 in 
this way results in tumour cells being even more prone to sub-lytic MAC.  
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Figure 4.29: Survival of WT mice treated with C6 antisense oligonucleotide. 5 x 106 
C1498 cells injected IV into a total of 8 WT mice treated with a C6 antisense 
oligonucleotide along with 8 age and sex-matched WT controls. Kaplan Meier 
survival curve; P = 0.6688 (Log-rank (Mantel-cox) test). Median survival WT = 28.5 
days, WT + C6 antisense oligonucleotide = 24 days. 
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Figure 4.30: Plasma C6 levels (μg/ml). Plasma harvested from mice at the end of 
the protocol was sent to Professor Fluiters laboratory for measurement of C6 
plasma levels. C6 levels from WT mice treated with either control (top) or C6 
antisense (bottom) oligonucleotide are shown.    
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C5a receptor antagonism in C6-/- mice 
 
Approximately 20% of C5aRA treated mice remained tumour-free. Although not 
statistically significant, this is similar to 25% tumour-free C6-/- mice. It is also 
possible that progression of AML in a WT mouse might be too aggressive for any 
protective effect conferred by treatment with C5aRA to be detected. C5aRA might 
therefore be more effective in the setting of less aggressive disease. An additive or  
even synergistic effect might also be observed in the absence of MAC. The effect of 
C5aRA on disease progression in C6-/- mice was therefore explored. 
 
In two separate experiments with a total of 16 mice, no differential survival was 
observed between C6-/- mice treated or not with the C5aRA using either thrice 
weekly or daily dosing schedules. P= 0.4958, median survival: C6-/- = 34 days, C6-/- 
+ C5aRA = 34 days (figure 4.31). This supports previous findings in both WT and 
C3aR-/- mice, which demonstrated that C5a receptor antagonism also had no 
impact on disease progression in this model.     
 
4.2.5.3 Tumour distribution 
 
Aside from survival, illustrated using Kaplan Meier survival curves and statistical 
significance, assessed by log-rank (Mantel-Cox) tests, manipulation of the 
complement system also appeared to alter disease distribution. This was explored  
by comparing tumour distribution from 3 experiments which included WT and C6-/- 
mice +/- treatment with C5aRA or anti-C5 mAb.  
 
The classical tumour distribution observed when C1498 AML is administered IV to 
WT mice is the development of central tumours affecting sites such as the liver, 
spleen and ovaries with only occasional mice developing peripheral lesions on their 
back or limbs- most of these in conjunction with central tumours. It was noted that 
in contrast to this, mice that are unable to produce MAC, either due to C6 
deficiency or through neutralisation of C5 by anti-C5 mAb, developed less central  
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Figure 4.31: Survival of C6-/- mice treated with the C5a receptor antagonist. 5 x 
106 C1498 cells injected IV into a total of 16 C6-/- mice treated with C5aRA along 
with 16 age and sex-matched C6-/- controls. Kaplan Meier survival curve; P = 0.4958 
(Log-rank (Mantel-cox) test). Median survival C6-/- = 34 days, C6-/- + C5aRA = 34 
days. 
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but more peripheral tumours. In the case of C6-/ mice, approximately 40% failed to 
develop central tumours whilst most of these went on to develop peripheral 
tumours, in some C6-/- mice AML failed to progress at any sites. In anti-C5 mAb 
treated mice, whilst only around 1/3 developed central tumours, all remaining mice 
went on to develop peripheral tumours on their back or limbs. It was therefore 
concluded that the absence of MAC, conferred protection from the development of 
central but not peripheral tumours.  
 
In contrast to this, it was noted that although approximately 80% of WT mice 
treated with C5aRA developed central tumours, none of the mice developed 
peripheral tumours, leading to 20% surviving long-term. Though isolated peripheral 
tumours are a rarity in WT mice, they are seen in combination with central tumours 
in approximately 20% of cases, making the observation observed in C5aRA treated 
mice potentially significant, however more studies are necessary in order to confirm 
this finding. Unfortunately, the potential protection conferred centrally, by the 
absence of MAC, and peripherally, by treatment with the C5aRA, do not appear to 
be cumulative with C5aRA treated C6-/- mice displaying an intermediate rather than 
additive phenotype (Figure 4.32).    
 
4.2.5.4 Cell adherence and migration 
 
When tumour cells enter the bloodstream they bind to and activate platelets and 
leukocytes which facilitate tumour cell arrest at the vessel wall and extravasation 
into tissues (reviewed in (Gay and Felding-Habermann 2011)). C3 activation can 
enable tethering between activated platelets and polymorphonuclear leukocytes via 
iC3b and the complement receptor CR3 (CD11b/CD18, Mac-1) (Hamad, Mitroulis et 
al. 2015). The murine AML cell line C1498 has been shown to express several 
adhesion molecules including CD11b (Barrett and Jiang 2000). CD11b expression 
also predicts poor prognosis in human AML (reviewed in (Xu, Li et al. 2015)). It was 
therefore possible that complement, specifically iC3b, may play a role in the ability 
of C1498 cells to tether and migrate. If this was the case then C1498 might be  
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Figure 4.32: Tumour distribution in mice lacking various complement components. 
It was noted that along with effects on survival, manipulation of complement also 
altered disease distribution. When mice were unable to produce MAC either due to 
a genetic deficiency or use of anti-C5 mAb, they developed less central but more 
peripheral tumours. In contrast, mice receiving C5aRA developed a similar 
proportion of central tumours but no peripheral tumours. Administering C5aRA to 
C6-/- mice resulted in an intermediate (rather than additive) phenotype. The 
phenotype displayed by C5aRA treated C6-/- mice was also not analogous to WT 
mice treated with anti-C5 mAb.    
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unable to enter tissues in complement deficient mice, remaining within the 
vasculature and giving the immune system a better opportunity to clear tumour 
cells. Thus, the role of the immune system demonstrated thus far though still 
important, may be secondary to the influence of complement on tumour take. 
 
In order to remove the need for the tumour cells to leave the blood stream and 
establish themselves within tissues, C1498 AML cells were administered to WT and 
C3-/- mice via subcutaneous (SC) injection. Tumour growth was then measured via 
calliper measurement alongside in vivo imaging.  
 
Results of this study revealed that when the need for tumours to seed was 
removed, C1498 cells were able to grow at a similar rate in C3-/- and WT controls. 
However, tumour volume peaked at around day 7 before tumours in both C3-/- and 
WT mice began to regress. This timescale is consistent with the development of an 
effective T-cell response with an adaptive immune response generally being 
mounted after 4-7 days (Mandell, Bennett et al. 2000). Interestingly, whilst tumours 
then re-grew in the majority of WT mice, C3-/- mice cleared their tumours and 
remained tumour-free (Figure 4.33).   
 
4.3 Discussion  
 
4.3.1 T Cells are required to control growth of AML in C3-/- mice  
 
The most significant finding is that AML fails to progress in a complement deficient 
environment (Figure 4.7). T cell depletion studies suggest that C3-/- mice are able to 
clear AML through a CD8+ T cell mediated mechanism (Figure 4.14). However, C3-/- 
mice do not appear to mount a superior memory T cell response as measured by 
IFN-γ response to exposure to irradiated tumour cells following vaccination (Figure 
4.16). In fact, in line with other vaccination studies, C3-/- mice mounted a slightly 
inferior response to tumour cell vaccination than WT controls (Pishko, 
Kirimanjeswara et al. 2004; Fernandez Gonzalez, Jayasekera et al. 2008). 
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Figure 4.33: Growth of subcutaneous (SC) C1498 tumours in C3-/- vs WT mice. 106 
C1498 cells were injected SC and tumour growth monitored. In contrast to IV 
inoculation both WT and C3-/- mice developed tumours at the injection site with 
initially comparable tumour growth. At around day 10 tumours began to recede in 
all mice, consistent with development of an anti-tumour T-cell response. 
Interestingly, whilst tumours re-grew in the majority of WT mice, all C3-/- mice 
cleared their tumours and remained tumour-free. WT n= 15, C3-/- n = 12. 
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4.3.1.1 Dose of C1498 
 
Previous studies in WT mice have demonstrated that both NK and CD8+ CTLs are 
able to lyse C1498 however, only NK cells were shown to be effective in vivo (Boyer, 
Orchard et al. 1995). Data from other groups demonstrate a trend towards 
enhanced AML progression following combined depletion of CD8+ and CD4+ T cells, 
however this did not reach statistical significance (P= 0.1, n = 16). A very low dose of 
C1498 (104) was used in these studies meaning that the threshold level of antigen 
required in order to trigger an adaptive immune response may not have been 
reached with the innate immune system effectively clearing low doses of tumour 
cells without triggering an adaptive immune response(Boyer, Orchard et al. 1995).  
Experiments described in this thesis show that CD8+ T cell depleted WT mice 
receiving 5 x 106 C1498 cells IV had a significantly worse survival than WT controls 
(P<0.0001, n= 8, Figure 4.13). This suggests that a large exposure to C1498 is 
capable of inducing a CTL response.  This response is however ineffective at clearing 
AML in a complement sufficient environment. In contrast the CTL response in 
complement deficient mice is capable of clearing AML and preventing disease 
progression.    
 
4.3.1.2 Route of administration 
 
It has previously been demonstrated that T cell responses are different when AML 
cells are delivered via a SC vs IV route. SC or IP but not IV immunization with 
irradiated C1498 cells resulted in immune resistance to subsequent live C1498 
innoculation (Boyer, Orchard et al. 1995). In addition, IV inoculation has been 
shown to result in the development of immune tolerance, preventing functional T 
cell activation following a subsequent SC AML cell challenge (Zhang, Chen et al. 
2013). This T cell tolerance was antigen specific and independent of Tregs and 
MDSCs (Zhang, Chen et al. 2013). Despite the lack of immunogenic response 
observed when C1498 is administered IV, the high dose of C1498 cells used in my 
studies appears to have been sufficient to trigger a CD8 mediated immune response 
demonstrated by the significantly worse survival seen in CD8-depleted vs control 
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WT mice. Contrary to the inefficient immune responses demonstrated in WT 
animals, who almost universally succumbed to the progression of AML, in 
complement deficient animals the immune response was sufficient, even in the face 
of a large and highly aggressive tumour load, to prevent the progression of AML.  
 
Injection of the tumour cells SC also appears to induce an immune response against 
C1498 tumours in both C3-/- and WT mice. Yet, whilst the tumours in the majority 
of WT mice escaped from this immune control, C3-/- mice successfully cleared 
tumours and remained disease free (Figure 4.32). This demonstrates the primary 
CD8 T cell response to be a critical time-point at which complement impacts on 
immune control of AML. It also implies that complement is involved in immune 
escape.   
 
ELISpot analysis of IFN-γ responses generated following injection of mice with 
irradiated tumour cells demonstrated that memory T cell responses in C3-/- mice 
were not superior to those observed in WT mice (Figure 4.16). In fact C3-/- mice 
appeared to mount a slightly inferior response to tumour vaccination than WT 
controls, a finding supported by other studies of the efficacy of vaccination in C3-/- 
mice (Pishko, Kirimanjeswara et al. 2004; Fernandez Gonzalez, Jayasekera et al. 
2008). As the number of splenocytes was standardised in these assays it is unknown 
whether C3-/- mice had a higher number or proportion of CD8+ T cells following 
vaccination than WT controls. It is therefore conceivable that C3-/- mice produce 
higher numbers rather than more effective CD8+ T cells which could account for the 
more effective CD8+ T cell mediated immune response.   
 
4.3.1.3 IFN-γ independent CD8+ T cell killing  
 
Whilst ELISpot assays have thus far have failed to demonstrate any effect, this assay 
did not investigate other readouts of T cell activity such as killing or production of 
cytokines such as IL-2 or TNF-α. Therefore it is possible that complement suppresses 
these functions of CD8+ T cells which would not be revealed in an IFN-γ- based 
ELISpot. Fluorospot assays which differ from ELISpots in that they use multiple 
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fluorescent labelled anti-cytokine detection antibodies to allow optimal 
measurements of multiple cytokines or granzymes, could be used. As well as 
allowing fuller characterisation of T cell responses in C3-/- vs WT mice, these studies 
could also be extended to investigate T cell responses in other genetically altered 
mouse models such as C6-/- and C3aR-/- mice.  
 
4.3.1.4 Immune response to irradiated vs live cells 
 
Observed effects could also be a result of differences between immune responses 
to vaccination with irradiated tumour cells vs inoculation with live cells. Apoptotic 
tumour vaccination, induced by using γ-irradiation prior to injection, has been 
shown to result in potent immune responses in vivo with strong CD4+ and CD8+ T 
cell responses observed at tumour sites (Scheffer, Nave et al. 2003). In my studies, 
following vaccination with irradiated tumour cells, both WT and C3-/- mice 
mounted a tumour specific IFN-γ response. Somewhat surprisingly, given the results 
of my T cell depletion studies, the immune response to vaccination was no superior 
in C3-/- vs WT mice.  
 
Prophylactic tumour vaccination against subsequent live tumour challenge depends 
on the ability of professional APCs such as dendritic cells (DCs) to process tumour 
antigens from whole cells and present them to CD4+ and CD8+ T cells. Exposure to 
live cells has been demonstrated to be significantly better at inducing immune 
responses than immunization with irradiated cells (Matheoud, Perie et al. 2010; 
Volovitz, Marmor et al. 2011). Cross-presentation by DCs of antigens from live cells 
was demonstrated to induce stronger natural CD8+ T-cell responses against lethal 
tumour challenge than those induced by irradiated tumour cells resulting in 
stronger IFN-γ responses and complete protection against tumours (Matheoud, 
Perie et al. 2010). Hence the better immune response observed in C3-/- mice 
following exposure to live inoculums of leukaemia could be due to critical 
differences in immune responses following exposure to apoptotic (irradiated) vs live 
cells.   
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4.3.1.5 The effect of complement on primary CD8+ T cell response 
 
It is also possible that complement may impinge on T cell responses to live cell 
inoculation whilst not affecting memory responses induced by vaccination with 
irradiated cells. This could be seen as analogous, but opposite, to the effect of CD4+ 
T cells on CD8+ memory T cell responses. CD4+ T cells, whilst not critical to 
successful primary CD8+ T cell responses, are essential in order to generate memory 
CD8+ T cell response (Bourgeois and Tanchot 2003; Janssen, Lemmens et al. 2003; 
Shedlock and Shen 2003). Conversely, complement might be critical to the primary 
T cell response but fail to play a role in the generation of a memory response.  
 
Further experiments are required to address whether complement impinges 
broadly on CD8+ T cell responses or whether the effect is limited to the primary 
response. Previous studies using in vitro generated CTLs have failed to control 
established AML in vivo (Zhou, Bucher et al. 2009). An investigation of the role of 
complement on tumour-specific CD8+ T-cells might offer an explanation for the 
disparities observed between in vitro vs in vivo studies. These studies would 
determine whether AML-specific CTLs stimulated in a complement sufficient 
environment are inferior to those stimulated in a complement deficient 
environment by generating AML-specific CTL lines from C3-/- and WT mice for 
reinfusion into complement–deficient and sufficient CD8-depleted mice injected IV 
with AML cells. These experiments would confirm whether memory T cell responses 
against AML were any different when raised in a complement deficient vs sufficient 
environment in vivo. It could also offer insight into whether complement could have 
a specific effect on primary T cell responses. If CTL therapy is both ineffective and is 
impinging on a more robust primary response in C3-/- mice, then increased 
progression of AML might be observed in C3-/- mice following vaccination.  
 
T cell-tolerance leading to inefficient clearance of AML cells has been shown to be 
dependent on a lack of CD40 mediated activation of host antigen presenting cells 
(APCs) (Zhang, Chen et al. 2013). Administration of agonistic anti-CD40 Ab, to 
leukaemia-bearing mice, activated host APCs, enhanced accumulation of functional 
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T cells and prolonged survival (Zhang, Chen et al. 2013). However, this is unlikely to 
be a mechanism through which complement  impinges on primary T cells responses 
to leukaemia as both C3a and C5a have been demonstrated to enhance the function 
of dendritic cells (DCs) during T cell priming (Sacks and Zhou 2012).  
 
Tregs alter their phenotype depending on the concomitant inflammatory response 
(Yamaguchi, Wing et al. 2011)- an environment which will be substantially altered in 
the absence of complement. A role for complement in negatively regulating 
immune response has however been demonstrated via induction of Treg responses. 
Stimulation of the C3 regulator MCP (CD46) steers human CD4+ T cells towards an 
immunosuppressive role characterised by the production of interleukin-10 (IL-
10)(Kemper, Chan et al. 2003). This finding is supported by the low numbers of 
Tregs observed in human C3 deficiency (Ghannam, Pernollet et al. 2008). Despite a 
recognised key role for complement in promoting graft rejection responses to both 
major and minor histocompatibility antigens, a contradictory role exists whereby 
complement inhibits rejection and thus promotes graft tolerance in the setting of 
minor histocompatibilty antigen mismatch (Sacks and Zhou 2012). Increased 
rejection in C3-/- female mice receiving skin grafts from male donors is coupled with 
an increase in antigen specific CD8+ IFNγ T cells (Baruah, Simpson et al. 2010). In a 
mouse model of graft tolerance induction, transplant tolerance was shown to be 
dependent on C3, with FOXP3 + Tregs failing to suppress the immune response in 
the absence of complement (Sacks and Zhou 2012). It might therefore be most 
likely that complement is impinging on adequate immune responses to AML via the 
induction and/or activation of Tregs.   
 
4.3.1.6 Immunosuppressive mechanisms induced by AML 
  
Failed vaccination attempts in mice with established leukaemia have led to the 
identification of several mechanisms by which C1498 leukaemia suppresses immune 
responses including increasing Treg and MDSC activity. Interestingly, although the 
proportion of MDSCs is increased in spleens from leukaemic animals where they 
suppress the activity of CD4+ T cells, they do not appear to suppress CD8+ T cells 
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(Gibbins, Ancelet et al. 2014). Recruitment of MDSC may therefore be irrelevant in 
the AML model described herein explaining why neutralising C5 failed to prevent 
progression of the disease.  
 
Progression of C1498 AML leads to an accumulation of regulatory T-cells (Treg) at 
disease sites (Zhou, Bucher et al. 2009). Treg depletion alone is ineffective at 
clearing tumours, requiring concurrent transfer of anti-AML CTLs (Zhou, Bucher et 
al. 2009). Based on the data described herein, it is tempting to speculate that 
combining Treg- and complement-depletion might prove an effective way of 
optimising both natural and induced CTL responses.  
 
The SC model could be used in order to further explore immune escape, observed in 
WT but not C3-/- mice. Immunohistochemistry could first be used to investigate 
tumour infiltration by immune cells. This would identify significant differences in 
the immune cell infiltrates between receding vs re-growing tumours in WT mice and 
between receding tumours in WT vs C3-/- mice in order to identify which cell sub-
types are key to successful immune mediated clearance and the avoidance of 
immune escape (tissue samples already stored). Fluorospot assays to measure AML-
specific T-cell responses in mice could be used alongside immunophenotyping by 
multiparameter flow cytometry, in order to compare kinetics, quality and 
magnitude of T-cell responses in complement sufficient versus deficient mice. 
Adoptive transfer of cells identified to play a key role, between C3-/- and WT mice 
would confirm key mechanisms at play.  
 
Whilst the experiments discussed above point to a role for the immune system in 
controlling AML, particularly in C3-/- mice, the experiments did not convincingly 
reveal that more efficient CD8+ T cell responses were generated in the absence of 
complement. Indeed, the entire dataset accumulated thus far is compatible with 
the hypothesis that whilst a CD8 T cell response is required for clearing the AML 
cells in C3-/- mice, another mechanism also contributes to the lack of tumour 
growth in these animals.  This led us to investigate whether C3 has a role in seeding 
and tumour invasion.  
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4.3.2 The Role of complement in seeding of AML cells 
 
Tumour cells need to bind and activate platelets and leukocytes in order to adhere 
to vessel walls and extravasate into tissues (Gay and Felding-Habermann 2011). C3 
activation is required for  tethering between activated platelets and 
polymorphonuclear leukocytes (Hamad, Mitroulis et al. 2015). It was therefore 
possible that complement activation has a key role in the ability of C1498 cells to 
tether and migrate. In a complement deficient environment AML cells might thus be 
unable to leave the circulation, create a favourable niche and proliferate leaving 
them in a vulnerable position. A prolonged presence within the circulation might 
provide circulating immune cells with an antigen load capable of triggering a more 
robust immune response. The absence of pro-survival signals provided by a tumour 
niches might also result in cell death independent of immune response. Hence, the 
role of the immune system may be secondary to the influence of complement on 
tumour take.  
 
The main receptor for inactive C3b (iC3b) is complement receptor 3 (CR3) also 
known as CD11b/CD18 and Mac-1. It is binding via this receptor, following 
complement activation, which is essential for tethering between activated platelets 
and polymorphonuclear leukocytes (Hamad, Mitroulis et al. 2015). In the absence of 
C3, C1498 might be unable to tether to platelets, adhere to vessel walls and migrate 
into tissues. When injected IV, C1498 may thus remain circulating in the blood 
stream potentially giving the immune system a better chance of tumour clearance.  
 
In order to remove the need for cells to leave the circulation and seed in tissues, 
C1498 cells were administered subcutaneously (SC). This resulted in comparable 
tumour growth in C3-/- and WT mice (Figure 4.32) suggesting that complement is 
required in order for C1498 AML cells to seed from blood vessels into tissue.  
 
AML-niche interactions have a key role in development, progression, chemotherapy 
resistance and relapse in AML (Rashidi and DiPersio 2016). Myeloid blasts express a 
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range of adherence receptors that could be influenced by the presence of 
complement in the microenvironment. AML cells utilise the CXCR4/ CXCL12 axis in 
order to migrate, mobilise and home to disease sites (Kremer, Dudakovic et al. 
2014). CXCL12 stimulation also results in enhanced adhesion of immature 
haematopoietic cells to endothelial cells and transendothelial migration(Peled, 
Kollet et al. 2000). E-selectin (ES) is involved in leukocyte rolling along luminal 
endothelial surfaces and the ES ligand, expressed on myeloid blasts, also mediates 
cell proliferation (Winkler, Barbier et al. 2012). The survival of myeloid blasts is also 
enhanced by their ability to bind to the vascular niche via ES ligands and activate 
pathways such as Wnt (Chien 2013). Blasts from relapsed or refractory AML have 
increased E-selectin expression indicating a possible role for vascular adhesion in 
resistant disease (Chien 2013). A role for complement in mediating the adherence 
and migration of leukaemia cells would thus be of critical importance.  
 
It is possible that between IV inoculation with the cell line on day 0 and the 
induction of the immune response around day 10, C1498 cells might be readily 
detectable in the blood stream. Identification of cells circulating following IV 
injection, before they are cleared would support the seeding hypothesis. The 
seeding hypothesis could be further explored using the IV C1498 model via 
exploring the relative roles of complement, platelets and adherence molecules. 
Staining for platelets bound to the surface of circulating AML cells following IV 
administration to WT vs C3-/- mice would clarify whether platelets have a key role. 
Anti-platelet agents such as clopidogrel could be used to confirm the role of platelet 
aggregation on tumour cell take following IV administration. Small molecule 
inhibitors of adherence molecules such as E-selectin (GMI-1271) could also be 
utilised in my studies (Chien 2013).    
 
4.3.3 C3 reconstitution/ depletion 
 
I have demonstrated no evidence that C1498 cells produce C3 in vitro or in vivo. 
However, it remains important to address the possibility that C3 (whilst at 
undetectable levels) acts as an immunogen in C3-/- mice. An important next 
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experiment in order to confirm my findings would be to reconstitute the 
complement system in C3-/- mice using purified C3. C3 injected in vivo into C3-/- 
mice is only active for a limited time due to anti-C3 immune reactivity. Patterns of 
tumour growth following subcutaneous injection of cells clearly illustrates two key 
time-points at which C3 reconstitution in the IV model could be used to explore the 
relative importance of tumour cell seeding (day 0-7) and immune clearance (day 7-
14).  
 
Provisional attempts to reconstitute C3 in C3-/- mice using serum from WT mice 
administered daily to C3-/- recipients who had received C1498 cells IV, failed to 
result in any detectable disease. However significant limitations to this experiment 
included the availability of fresh serum and the permissible volume for injection. In 
future experiments, purified C3 should be prepared and used to determine whether 
reconstitution of C3 enables tumour growth in C3-/- mice.  
 
Another method of determining the impact of complement on tumour growth is to 
deplete complement in WT animals. There are several methods of inhibiting 
complement in vivo though they all have limitations. The most widely used, cobra 
venom factor (CVF), is a structural and functional analogue of C3b which on contact 
with serum results in the formation of a long-lived C3/C5 convertase which 
activates C3 and C5 leading to soluble C5b-C9 formation and resulting in the 
depletion of serum complement activity (Vogel, Smith et al. 1984). CVF is short 
acting and highly antigenic, leading to a burst of C3a and C5a,  making data 
interpretation challenging however it is widely used to assess the inhibitory effects 
of experimental anti-complement agents (Morgan and Harris 2003). The transient 
generalised complement inhibition achieved by this method has been 
demonstrated to impair tumour growth in a range of models (Janelle, Langlois et al. 
2014; Downs-Canner, Magge et al. 2015). 
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4.3.4 Complement components key to the protective C3-/- phenotype  
 
In order to determine the mechanism through which C3 deficiency promotes 
resistance to tumour growth the impact of various complement components was 
assessed (Figure 4.17). Complement deficient or therapeutically depleted mice were 
used in order to systematically investigate the role of complement in the 
progression of AML.  
 
4.3.4.1 C5a 
 
Results demonstrate no impact on survival in mice treated with either anti-C5 
antibody or C5a receptor antagonist (Figures 4.21 and 4.23). Several studies have 
supported a role for complement in promoting tumour growth, via a range of 
mechanisms but often implicating C5a (Wang, Veeramani et al. 2009; Corrales, 
Ajona et al. 2012; Gunn, Ding et al. 2012; Nunez-Cruz, Gimotty et al. 2012; Janelle, 
Langlois et al. 2014; Vadrevu, Chintala et al. 2014; Downs-Canner, Magge et al. 
2015; Imamura, Yamamoto-Ibusuki et al. 2015). Generation of C5a in the tumour 
microenvironment has been shown to promote the development of cancer by 
suppressing the anti-tumour CD8+ T cell-mediated response via the recruitment and 
augmentation of myeloid derived suppressor cells (MDSCs) (Markiewski, DeAngelis 
et al. 2008). Further work by the group has shown that the C5a receptor facilitates 
metastasis in breast cancer, though no effect on the primary tumour was observed. 
Metastasis was promoted via C5aR mediated suppression of both CD8+ and CD4+ T 
cell responses in the lungs via recruitment of MDSCs and regulation of their TGFβ 
and IL10 production (Vadrevu, Chintala et al. 2014). A separate group also 
demonstrated that C5a creates a favourable microenvironment for progression in 
lung cancer via both promoting angiogenesis and increasing MDSCs (Corrales, Ajona 
et al. 2012). Indeed, C5aR expression is more often seen on malignant cells at sites 
of metastasis than at the primary tumour site supporting a role in tumour 
progression (Imamura, Yamamoto-Ibusuki et al. 2015). 
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As discussed earlier, whilst MDSCs are increased in leukaemic animals and suppress 
the activity of CD4+ T cells, they did not appear to have a suppressive effect on 
CD8+ T cells (Gibbins, Ancelet et al. 2014). The protective effect of impinging on the 
C5aR in other disease models was mediated via suppressing MDSC activity against 
CD8+ T cells. If MDSCs present in leukaemic animals are truly unable to suppress 
CD8+ T cell activity, this mechanism might not be relevant in this setting.  
 
There might be a more straightforward explanation for the absence of effect of 
impinging on C5a observed in my model. The same group which demonstrated the 
role of C5a in promoting tumour growth in an ovarian model, failed to demonstrate 
any effect on primary tumour growth in a breast cancer model, though an effect on 
priming the metastatic niche was observed (Markiewski, DeAngelis et al. 2008; 
Vadrevu, Chintala et al. 2014).  They accounted this finding to a disparity in the rate 
of tumour growth between the models with harvested tumours in the breast cancer 
model being approximately 3 times bigger than observed in the TC1 ovarian model 
(Vadrevu, Chintala et al. 2014).   
 
The absence of any impact on survival observed in my studies may therefore be due 
to the aggressive phenotype of the AML cells used. C1498 cells exhibit an 
exceptionally high ability to grow and migrate (Goldie, Butler et al. 1953). Tumour 
growth observed following the administration of C1498 leukaemia IV was rapid, 
diffuse and bulky and could therefore be beyond the capacity of any boost to CD8 
function achieved by C5a inhibition. An exploration of the efficacy of the C5aRA in 
the setting of C1498 cells administered via a SC route, which might prompt a more 
efficient CD8+ T cell response, could be informative. The administration of lower 
doses of C1498 resulting in a smaller volume of tumour at the time of a CD8+ T cell 
mediated immune response might also reveal a role for C5a in the setting of a less 
insurmountable tumour load, though as discussed earlier, lowering the cell dose 
might result in the failure to trigger an adequate immune response.     
 
The lack of an effect on tumour growth in mice treated with anti-C5 mAb may be 
due to failure to completely abrogate local production of C5a (even though 
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complete inhibition of complement mediated lysis was confirmed in the plasma of 
anti-C5 mAb treated mice (Figure 4.20)) or, in the case of the C5aRA, failure to block 
C5aR at the tumour site. Whilst other studies have used similar methods in order to 
demonstrate a role for C5a in tumour progression, the production of C5a at a local 
level, could have a more critical role in this disseminated leukaemic model (Lalli, 
Strainic et al. 2008; Strainic, Liu et al. 2008).     
 
In addition to this, the role for C5a in tumour progression is still controversial. 
Whilst some studies indicate that C5a promotes progression through recruitment of 
MDSCs, C5a over-expression in tumour cells has been shown to result in tumour 
regression in a mouse model of breast cancer (Kim, Martin et al. 2005). 
Translational research also supports a positive role for C5a in anti-tumour 
monoclonal antibody therapy (Allendorf, Yan et al. 2005; Li, Allendorf et al. 2007; 
Fuenmayor, Perez-Vazquez et al. 2010). Hence the role for C5a in tumour 
progression remains controversial and my findings might not be surprising.  
 
4.3.4.2 C3a 
 
A role for C3a was also investigated. Mice deficient in the C3a receptor (C3aR-/-) 
were used in order to explore the role of C3a-C3aR signalling on progression of 
AML. Somewhat surprisingly, AML progressed more rapidly in mice lacking a C3a 
receptor (Figure 4.25).  
 
This rapid progression of AML observed in C3aR-/- mice suggests a role for C3a 
signalling in limiting disease progression; a finding that seems to be at odds with the 
protective phenotype observed in C3-/- mice. Several explanations might account 
for this finding. 
 
In contrast to C5a, in addition to its pro-inflammatory role, C3a also has an anti-
inflammatory properties (Coulthard and Woodruff 2015). In the settings of both 
sepsis and an acute inflammatory response C3a has been shown to act in direct 
opposition to C5a (Hollmann, Mueller-Ortiz et al. 2008; Wu, Brennan et al. 2013). It 
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is therefore possible that C3a might have a protective role in the setting of 
malignancy. Recent studies have however found that contrary to this, C3a appears 
to have a deleterious role in malignancy (Guglietta, Chiavelli et al. 2016; Nabizadeh, 
Manthey et al. 2016).  
 
Another possibility is that levels of C3a are elevated in C3aR-/- mice, due to absence 
of the receptor. As C3a both activates a range of haematopoietic cells and enhances 
their survival (Strainic, Liu et al. 2008; Markiewski, DeAngelis et al. 2009), it might 
also bind to leukaemia cells, promoting their growth. The actions of C3a might also 
not be solely mediated through C3aR as C3a has also been shown to signal through 
the alternative C5a receptor C5aR2 (Boos, Campbell et al. 2004; Boos, Szalai et al. 
2005). This theory could be explored by assessing plasma C3a levels in tumour 
bearing WT and C3aR-/- mice and determining whether C3aR and/or C5aR2 are 
expressed on C1498 cells in vitro and in vivo. C3aR antagonists and C5aR2 knock-out 
mice could subsequently be used alongside C1498 cells, genetically modified to 
silence receptor expression, to test the hypothesis. This series of experiments could 
identify a novel mechanism by which complement promotes tumour growth.   
 
4.3.4.3 MAC 
 
Whilst complement is believed by some to facilitate lysis of cancer cells (Rutkowski, 
Sughrue et al. 2010), MAC has never been demonstrated to clear malignant cells 
and hence protect against the development of tumours in vivo. Earlier in this thesis I 
discussed the potential role for sub-lytic MAC in protecting malignant cells from 
immune clearance. In order to explore these opposing theories I used C6-/- mice, 
which are unable to form MAC, to investigate whether MAC affected the 
progression of AML. Increased AML progression would support a role for 
complement-mediated lysis in clearing malignant cells. A reduction in disease 
progression would support a role for complement-induced protection.   
 
Studies demonstrated that C6-/- mice were partially protected against the 
progression of C1498 AML (Figure 4.28). This suggests that the ability to produce 
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MAC results in a favourable environment for the progression of AML. This supports 
the hypothesis that sub-lytic MAC on the surface of malignant cells might be 
protecting against elimination by the immune system in vivo.  
 
Protection against AML was not observed in mice treated with C6 antisense 
oligonucleotide, despite its use achieving an almost 90% reduction in plasma C6 
levels (Figures 4.29 and 4.30). As this reagent functions by preventing the 
production of C6 by the liver, it is possible that it is less effective at the tissue level 
which might result in inadequate impingement on local C6 production in the 
tumour microenvironment. Hence, sub-lytic levels of MAC could still be being 
produced in these C6 depleted (as opposed to fully deficient) animals. These data 
do not therefore weaken the case for complement-induced protection being an in 
vivo mechanism by which elimination of malignant cells is prevented. 
 
Figure 4.34 summarises components of the complement system where 
impingement results in a significant survival effect in the IV C1498 cell model of 
AML. 
 
4.3.5 Tumour distribution 
 
During the course of the experiments described, I noted that mice treated with anti-
C5 mAb, developed far more peripheral soft tissue masses (75%) than WT mice in 
whom isolated peripheral tumours were a rare event (approx 5%). Anti-C5 MAb 
treated mice were also noted to have a far lower incidence of liver and ovarian 
lesions (<40%) than WT controls (>90%). A review of tumour distribution in C6-/- 
mice revealed that they also had approximately half the incidence of liver masses 
than WT controls and twice as many soft tissue masses. WT mice do occasionally 
develop soft-tissue tumours but these are generally in addition to central tumours 
and even then occur at a far lower incidence than seen in mice that lack MAC. 
 
 
213 
 
0 20 40 60 80 100
0
20
40
60
80
100
WT mice
C6-/-
C3-/-
C3aR-/-
***
**
**
Days
P
er
ce
n
t 
su
rv
iv
al
 
 
 
Figure 4.34: Summary of significant phenotypes. Following an IV inoculum of 5 x 
106 C1498 murine AML failed to progress in the majority of C3-/- mice. C6-/- mice 
had a mildly protective phenotype resulting in approximately 25% long-term 
survivors. Contrary to this, AML progressed more rapidly in C3aR-/- mice.       
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In the absence of MAC, mice appear to be protected from the progression of AML at 
central sites, such as the liver and ovaries, generally the first places that tumours 
develop in WT mice, however mice then go on to develop tumours at peripheral 
sites. As complement is primarily produced in the liver, tumour distribution might 
reflect a gradient effect in local complement activity. Hence, the absence of MAC 
might facilitate the clearance of tumours from central sites but might fail to have an 
effect at peripheral sites where complement might have a less active role. 
Alternatively, peripheral tumours might simply be unusual in WT mice because AML 
progression in the livers and ovaries leads them to be killed before peripheral 
tumours become detectable.  
 
The potential role for complement in influencing the location of leukaemic deposits 
led me to review the tumour distribution across all experiments. I noticed that no 
WT mice treated with C5aRA developed peripheral soft tissue masses. Whilst AML 
progressed in the liver and ovaries of C5aRA treated mice at a similar frequency to 
WT mice, those that failed to develop early lesions, did not go on to develop soft 
tissue tumours and became long-term survivors. Power calculations suggest that 
this finding may be statistically significant if more mice (approx. 10) were analysed.  
 
C5a is crucial in order for granulocytes and monocytes to egress from the BM 
(Borkowska, Suszynska et al. 2014). C5aR stimulation might therefore also facilitate 
the movement of C1498 AML cells from the vasculature into peripheral tissues. 
However, the high incidence of soft-tissue masses observed in mice treated with 
anti-C5 mAb, who are unable to produce C5a, is contradictory to this hypothesis. 
Blocking the C5aR appears to results in less peripheral tumours whereas preventing 
production of C5a results in far more. This discrepancy led me to speculate as to 
whether an alternative mechanism other than signalling via the main C5aR could be 
involved. The key difference between mice unable to produce C5a and treated with 
the C5aRA would be their plasma levels of C5a, leading me to postulate that the 
phenotype could be the result of C5a signalling via an alternative receptor.   
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Whilst the vast majority of C5a’s effects are thought to be mediated through C5aR, 
a second C5a receptor, C5aR2 (formerly known as C5L2), also exists, the role of 
which is rather contentious. C5aR2 is often referred to as a ‘decoy’ receptor which, 
by binding and removing active complement fragments from the extracellular 
environment, suppresses the inflammatory nature of C5aR stimulation (Scola, 
Johswich et al. 2009). However other studies have suggested that C5aR2 has a 
functional role in sepsis (Rittirsch, Flierl et al. 2008) and in inflammation (Huber-
Lang, Sarma et al. 2005). The reduction in peripheral tumours observed in C5aRA 
treated mice could thus not be due to the absence of signalling via the C5aR but to 
an increased level of signalling via C5aR2.  
 
Experiments designed to look at tumour distribution are required in order to further 
investigate my findings. An exploration of signalling via the C5aR2 in my model and 
its effect on tumour distribution might then also be warranted. C5a levels in plasma 
from tumour bearing mice will indicate whether there is any clear correlation with 
tumour distribution. Analysis of the expression of C5aR and C5aR2 on various 
murine tissue types including vasculature, liver and soft tissue along with the C1498 
AML cells themselves would also be informative.  
 
It should be noted that all statistically significant survival advantages observed 
herein have been seen in genetically modified animals. This may be due to the need 
for complete ablation as opposed to blockade of complement components or to the 
tissue penetration of reagents which may not be sufficiently thereby limiting their 
efficacy at tumour sites. It could also suggest that my findings are the result of 
inconsistencies with the genetically modified mouse model system. Whilst 
genetically modified mice are powerful tools they have significant limitations. The 
mouse and human genomes are extremely similar- 97.5% of functional human 
genes are conserved in the mouse (Mural, Adams et al. 2002). However, even small 
genetic disparities, in combination with subtle differences in function between 
human and mouse versions of the same gene, can translate into major distinctions. 
Modification of a given gene does not always result in the predicted phenotype with 
outcome also being influenced by epigenetic and environmental factors (Tarantino, 
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Sullivan et al. 2011). This results in significant inter-strain variation in the phenotype 
of mice with the same genome making interpretation of results from studies of 
genetically modified mice more challenging. Unless findings are extremely robust, 
results described in mice have proved extremely unlikely to translate into humans 
(Mak, Evaniew et al. 2014).  
 
The restriction of my findings to genetically modified animals, whether due to 
incomplete efficacy of the therapeutic agents explored or limitations in the genetic 
models used, has implications on the potential for complement therapeutics to 
impact on human disease.  
 
4.4 Concluding remarks 
 
In vivo studies using a C1498 murine model of AML have resulted in several exciting 
discoveries. I have discussed potential mechanisms that could underpin these 
findings including complement-induced protection, C3a mediated stimulation of 
tumour cells, iC3b mediated tumour seeding and migration and C5a mediated 
metastasis. Further studies are warranted in order to fully characterise the role of 
complement in mouse AML and the relevance of these findings to human disease.           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
217 
 
Chapter 5: Final Discussion 
 
The work presented in this thesis explored the role of complement in the setting of 
AML. It investigated both complement-induced protection in vitro and the role of 
complement in the progression of AML in vivo.  
 
In Chapter 3, I explored whether sub-lytic complement attack protected against NK 
cell lysis in vitro then went on to explore the genetic signature of complement-
induced protection. Results of these studies demonstrated that whilst sub-lytic 
complement offers convincing protection against a subsequent lytic complement 
attack, no convincing protection against NK cell killing is seen. Despite a strongly 
protective phenotype, no genetic signature for complement-induced protection was 
observed. This was despite the ability to identify a genetic signature for other 
experimental variables such as exposure to serum. This strongly suggests that an 
alternative mechanism such as actin re-modelling or depletion of lipid rafts could be 
involved. 
  
In Chapter 4, I investigated the role of the complement system on the progression 
of AML in vivo. A combination of mice deficient in various complement components 
and complement inhibitors were used to study the role of various complement 
components in AML. The role of three complement-mediated processes and their 
underlying mechanisms were explored in the context of AML. These were: 
 
i) C5a and C3a anaphylatoxins,  
ii) Complement-induced protection and iii)  
iii) iC3b mediated cell adherence and migration,  
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Key Finding Potential Implication 
AML fails to progress in C3-/- mice. The complement system is critical to the 
progression of AML. 
The protective effect in C3-/- mice is 
overcome by CD8+ and to a lesser 
extent CD4+ T cell depletion. 
Complement impinges on the efficacy of 
CTLs in AML. 
AML cells administered SC to C3-/- 
mice grow at the same rate as in WT 
mice. 
Complement is critical to seeding of AML 
cells. 
Administering anti-C5 mAb or C5aRA to 
WT mice had no impact on survival   
Impinging on C5a had no impact on 
progression of AML 
AML progressed more rapidly in C3aR-
/- mice. 
Either i) C3aR signalling protects against 
AML or ii) C3a signalling via C3aR 
expressed by AML promotes progression. 
C6-/- mice had reduced progression of 
AML. 
Complement-induced protection could be 
an in vivo phenomenon.   
C6-/- and WT mice treated with anti-C5 
mAb had fewer central tumours (ns). 
MAC promotes progression of AML at 
central sites 
WT mice treated with C5aRA had fewer 
peripheral tumours (ns).  
C5a signalling promotes progression of 
AML at peripheral sites 
  
Table 5.1: Key Findings of In Vivo Studies of the Role of Complement in the 
Progression of AML and their Potential Implications.  
 
5.1: Complement-induced protection in vitro  
 
5.1.1: Sub-lytic complement offers no convincing protection against NK cell killing 
 
Despite investigating multiple variations to my experimental protocol including 
timescale analysis, altering effector:target (E:T) ratio, using alternative PBMC 
donors and developing an alternative combination assay, no convincing evidence of 
in vitro complement-induced protection from NK cell attack was observed during 
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my studies. This could be the result of the extreme susceptibility of K562 cells to NK 
mediated lysis meaning that sub-lytic complement attack is not sufficiently 
protective in this setting. As K562 was used in the original studies describing CIP and 
is widely used in the study of NK biology, it was the obvious choice of cell line to be 
used in these studies. However, a cell line less susceptible to NK cell lysis might 
offer more insight into the role of CIP in this setting.  
 
Previous studies used purified perforin to demonstrate a cross-protective effect 
between sub-lytic complement and other pore-formers (Reiter, Ciobotariu et al. 
1995). In contrast to complement, which relies purely on MAC to disrupt cell 
homeostasis and lyse cells, NK cells mediate cytotoxicity via a range of distinct 
mechanisms. Whilst the most studied mechanism is via perforin mediated 
degranulation, this is reliant on the formation of an immunological synapse which is 
the result of a complex interaction between activating cell surface receptors 
counteracted by signals from inhibitory receptors, most of which bind to MHC class 
1 molecules (Bryceson and Long 2008). A sub-lytic complement attack will result in 
cellular stress which can lead cells to down-regulate MHC class 1 and up-regulate 
ligands for NK activating receptors, thus making cells more susceptible to NK attack 
(reviewed in (Chan, Smyth et al. 2014)). This stress response could compensate for 
protection provided by CIP against the insertion of perforin into the cell membrane. 
Increased numbers of activated NK cells forming immunological synapses could 
compensate for a hampered ability to form cytolytic pores thus explaining why CIP 
was not observed in a whole cell assay.   
 
NK cells degranulation releases both pore-forming perforin and granzyme which 
enters target cells via the pore and induces apoptosis. The presence of granzyme in 
the whole cell assay, which might be able to enter sub-lytically attacked cells, might 
trigger apoptosis independently of direct cell lysis. In addition to this, NK cells also 
exert their cytotoxic effects on target cells through death receptor pathways such as 
TRAIL and Fas which induce apoptosis independently of NK cell degranulation. Thus 
the whole cell assay offers a far more complex environment which is likely to be 
why a protective effect was not observed.   
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5.1.2: Complement-induced protection does not have a unique genetic signature  
 
A comprehensive microarray analysis revealed no significant gene expression 
changes an unusual finding in this setting. The strong ‘protected’ phenotype was 
confirmed in each test condition included in the analysis. This, along with our ability 
to clearly observe a ‘serum effect’, implies that if the protected phenotype was due 
to alterations in gene transcription, it would have been detected. I therefore 
concluded that CIP was dependent on an alternative mechanism. 
 
The insertion or shedding of membrane attack complexes could result in structural 
or compositional change to the cell membrane, or underlying scaffolding elements, 
preventing MAC or other pore-formers from being inserted into the cell membrane. 
Mechanisms such as the preferential loss of cholesterol-rich regions of the cell 
plasma membrane, termed lipid rafts, could impinge on subsequent attack. If MAC 
is preferentially inserted into these lipid rich areas, a sub-lytic complement attack 
would not only lead to shedding of membrane vesicles containing MAC, but could 
also result in the loss of lipid rafts. Loss of these cholesterol rich areas could thus 
impinge on the ability of MAC or other pore-formers to insert into the cell 
membrane until lipid rich areas are replenished.   
 
An alternative mechanism for CIP could be re-configuration of the actin skeleton, a 
mechanism utilised by pathogens such as cytomegalovirus (CMV). Despite a clear 
role for actin reconfiguration by cytotoxic cells in the development of the immune 
synapse, there is surprisingly little data regarding the role of the actin cytoskeleton 
in target cells. Their ability to reorganise actin could affect the ability of pore-
formers to insert into the cell membrane. This could therefore be a potential 
mechanism through which sub-lytic complement attack results in resistance from 
further pore-forming attack.  
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5.2: Complement is critical to the progression of AML 
 
The over-reaching effects of the complement system were investigated using C3-/- 
mice which lack the ability to produce MAC, C3a and C3b. C3-/- mice were resistant 
to progression of AML with 29/32 failing to develop detectable disease (P 
<0.0001***) (Figure 4.7).  
 
5.2.1: Complement impinges on the efficacy of CTLs in AML 
 
T cell depletion studies suggest that C3-/- mice are able to clear AML through a 
CD8+ T cell mediated mechanism (Figure 4.14). However, C3-/- mice do not appear 
to mount a superior memory T cell response as measured by IFN-γ response to 
exposure to irradiated tumour cells following vaccination (Figure 4.16).  
 
The dose of C1498 used in these studies was sufficient to trigger an adaptive 
immune response, with even WT mice having more aggressive disease following 
CD8+ T cell depletion (P<0.0001, n= 8, Figure 4.13).  The CTL response, whilst 
ineffective at clearing AML in a complement sufficient environment, successfully 
prevented the progression of AML in a complement deficient environment. 
Injection of the tumour cells SC also induced a visible immune response in both C3-
/- and WT mice. Yet, whilst the tumours in the majority of WT mice escaped from 
this immune control, C3-/- mice successfully cleared tumours and remained disease 
free (Figure 4.32). This supports a role for complement impinging on the efficacy of 
primary CD8+ T cell response and leading to immune escape.  
 
ELISpot analysis of IFN-γ responses generated following injection of mice with 
irradiated tumour cells however, demonstrated that memory T cell responses in C3-
/- mice were not superior to those observed in WT mice (Figure 4.16). As the 
number of splenocytes was standardised in these assays, it is conceivable that C3-/- 
mice produce higher numbers rather than more effective CD8+ T cells thus 
accounting for the more effective immune response observed in vivo.  
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It is also the case that Fluorospot assays, which use multiple fluorescent labelled 
anti-cytokine detection antibodies to allow measurements of multiple cytokines or 
granzymes might offer a better measure of CTL response.  
 
Observed effects could also be the result of critical differences in immune responses 
generated by vaccination with apoptotic (irradiated) vs inoculation with live cells. In 
vivo exposure to live cells leads to more effective cross-presentation by DCs 
resulting in more effective CTL responses than observed following immunization 
with irradiated cells (Matheoud, Perie et al. 2010; Volovitz, Marmor et al. 2011). 
Thus, exposure to irradiated cells may fail to trigger the full CTL response observed 
in C3-/- mice following exposure to live inoculums of leukaemia.   
 
It is also possible that complement may selectively impinge on primary CTL 
responses whilst not having a role in the generation of a memory response. In vitro 
generated CTLs often fail to control established AML in vivo (Zhou, Bucher et al. 
2009). This could be addressed by investigating the efficacy of CTLs generated in a 
complement sufficient vs deficient environment when reinfused into complement–
deficient and sufficient CD8-depleted mice prior to exposure to live AML cells.  
 
This would help to address whether memory T cell responses against AML are 
different when raised in a complement deficient vs sufficient environment in vivo 
and might also reveal whether complement has a selective effect on primary T cell 
responses. If CTL therapy is both ineffective and is impinging on a more robust 
primary response in C3-/- mice, then increased progression of AML might be 
observed in C3-/- mice following vaccination.  
 
Uncontrolled complement activation, mediated by fH suppression by PTX53, is an 
essential component of tumour-promoting inflammation (Bonavita, Gentile et al. 
2015). Tregs alter their phenotype depending on the concomitant inflammatory 
response (Yamaguchi, Wing et al. 2011). Complement can impinge on immune 
responses via induction of Treg responses with MCP stimulation steering human 
CD4+ T cells towards an immunosuppressive role (Kemper, Chan et al. 2003), a 
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finding also supported by the low numbers of Tregs observed in human C3 
deficiency (Ghannam, Pernollet et al. 2008). Transplant tolerance is also dependent 
on C3, with FOXP3 + Tregs failing to suppress the immune response in the absence 
of complement (Sacks and Zhou 2012). Progression of C1498 AML leads to an 
accumulation of regulatory T-cells (Treg) at disease sites (Zhou, Bucher et al. 2009). 
Treg depletion alone is ineffective at clearing tumours, requiring concurrent 
transfer of anti-AML CTLs (Zhou, Bucher et al. 2009). It therefore perhaps most 
likely that complement is impinging on adequate immune responses to AML via the 
induction and/or activation of Tregs. Thus combining Treg- and complement-
depletion might prove an effective way of optimising both natural and induced CTL 
responses.  
 
The C1498 model of AML has also been shown to induce MDSCs. Interestingly, 
whilst these are both increased in numbers and able to suppress the activity of 
CD4+ T cells, they do not appear to suppress the activity of CD8+ T cells (Gibbins, 
Ancelet et al. 2014). This could explain why neutralising C5a, an intervention that 
resulted in MDSC mediated suppression of CD8+ T cell responses in other disease 
models, failed to prevent progression in this model.  
 
The SC model offers an excellent opportunity to explore the mechanism of immune 
escape, observed in WT but not C3-/- mice. Immunohistochemistry, Fluorospot 
assays and immunophenotyping could be used to compare kinetics, quality and 
magnitude of T-cell responses in complement sufficient versus deficient mice. 
Adoptive transfer of cells identified to play a key role, between C3-/- and WT mice 
would confirm key mechanisms at play.  
 
5.2.2: Complement is critical to seeding of AML  
 
In order to infiltrate tissues, tumour cells must bind to and activate platelets and 
leukocytes allowing them to adhere to vessel walls and extravasate (Gay and 
Felding-Habermann 2011). Complement activation results in iC3b binding to CR3 
(CD11b/CD18) which is essential for tethering between activated platelets and 
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polymorphonuclear leukocytes (PMN) (Hamad, Mitroulis et al. 2015). As a 
malignant form of PMN, C1498 also expresses CD11b (Barrett and Jiang 2000), CR3 
expression on the surface of leukaemia cells could thus be critical to its ability to 
seed. Alternatively iC3b deposition on malignant cells might result in its tethering to 
the platelet/PMN complex. In a complement deficient environment, the absence of 
iC3b might thus prevent tethering between C1498 and platelets or a platelet/ PMN 
complex, preventing them from adhering to vessel walls and migrating into tissues. 
We therefore postulated that the lack of progression observed in complement 
deficient mice, when leukaemia was administered IV, was secondary to this inability 
to tether and migrate.  
 
When C1498 cells were administered SC, thus removing the need for cells to adhere 
and seed, comparable tumour growth was observed in C3-/- and WT mice (Figure 
4.32). This supports the hypothesis that complement is required in order for C1498 
AML cells to seed from blood vessels into tissue.  
 
The prolonged presence of leukaemia cells within the circulation, following IV 
injection, might provide an antigen load capable of triggering a more robust 
immune response in C3-/- mice. An inability to seed might also starve cells of pro-
survival signals, provided by a tumour niche, essential to cell survival and 
proliferation. Thus cell death could be independent of immune response making the 
role of the immune system secondary to the influence of complement on tumour 
take.  
 
AML-niche interactions have a key role in development, progression, chemotherapy 
resistance and relapse in AML (Rashidi and DiPersio 2016). Myeloid blasts express a 
range of adherence receptors including CXCR4 and the ES ligand modulate 
adherence, migration, survival and proliferation (Peled, Kollet et al. 2000; Winkler, 
Barbier et al. 2012; Chien 2013; Kremer, Dudakovic et al. 2014). A role for 
complement in mediating the adherence and migration of leukaemia cells would 
thus be of critical importance.  
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Identification and quantification of leukaemia cells in the circulation following IV 
injection might support the seeding hypothesis. Staining for platelets bound to the 
surface of circulating AML cells following IV administration to WT vs C3-/- mice 
would clarify whether platelets play a key role. Anti-platelet agents such as 
clopidogrel could be used to confirm the role of platelet aggregation on tumour cell 
take following IV administration. Small molecule inhibitors of adherence molecules 
such as E-selectin (GMI-1271) could also be utilised in my studies (Chien 2013).    
 
Although I demonstrated no evidence that C1498 cells produce C3 in vitro or in vivo, 
it remains important to address the possibility that C3 (whilst at undetectable 
levels) acts as an immunogen in C3-/- mice. Reconstituting the complement system 
in C3-/- mice using purified C3 would confirm that the presence of C3 is critical to 
AML progression. C3 reconstitution at a range of time points in the IV model could 
be used to explore the relative importance of C3 on tumour cell seeding, induction 
of both CTL and Treg responses.  Transient complement depletion with CVF could 
also be used to explore my findings in WT mice. This would also allow me to explore 
the role of NK cells on AML progression in a complement deficient environment as 
NK cells could be depleted in complement sufficient mice ahead of 
decomplementation with CVF.  
 
5.2.3 C5a has no impact on progression of AML 
 
Results fail to demonstrate any impact on survival in mice treated with either anti-
C5 antibody or C5aRA (Figures 4.21 and 4.23) despite other reports indicating that 
C5a is the most widely cited complement component thought to play a role in 
promotion of tumour growth (Wang, Veeramani et al. 2009; Corrales, Ajona et al. 
2012; Gunn, Ding et al. 2012; Nunez-Cruz, Gimotty et al. 2012; Janelle, Langlois et 
al. 2014; Vadrevu, Chintala et al. 2014; Downs-Canner, Magge et al. 2015; Imamura, 
Yamamoto-Ibusuki et al. 2015). Whilst this is most widely attributed to C5a 
promoting the development of cancer by suppressing the anti-tumour CD8+ T cell-
mediated response via the recruitment and augmentation of MDSCs (Markiewski, 
DeAngelis et al. 2008; Corrales, Ajona et al. 2012; Vadrevu, Chintala et al. 2014), C5a 
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has also been shown to support tumour progression by promoting angiogenesis 
(Corrales, Ajona et al. 2012; Nunez-Cruz, Gimotty et al. 2012). Some studies suggest 
that the level of C5a expression might be critical to the malignant phenotype (Kim, 
Martin et al. 2005; Gunn, Ding et al. 2012). C5a might also be particularly important 
in the setting of metastasis (Vadrevu, Chintala et al. 2014; Imamura, Yamamoto-
Ibusuki et al. 2015).  
 
As discussed earlier, whilst MDSCs are increased in leukaemic animals and suppress 
the activity of CD4+ T cells, they did not appear to have a suppressive effect on 
CD8+ T cells (Gibbins, Ancelet et al. 2014). The protective effect of impinging on 
C5aR in other disease models is often mediated via suppressing MDSC activity 
against CD8+ T cells. If MDSCs present in leukaemic animals are truly unable to 
suppress CD8+ T cell activity, this mechanism might be irrelevant in this setting.  
 
The lack of observed effect observed could simply be due to the aggressive 
phenotype of C1498. This is the explanation offered by other groups for disparities 
observed between tumour models (Markiewski, DeAngelis et al. 2008; Vadrevu, 
Chintala et al. 2014).  The rapid tumour growth observed following the 
administration of C1498 leukaemia IV could therefore be beyond the capacity of 
any boost to CD8 function achieved by C5a inhibition. An exploration of the efficacy 
of the C5aRA in the setting of C1498 cells administered via a SC route, which might 
prompt a more efficient CD8+ T cell response, would be informative.  
 
The lack of survival advantage observed in mice treated with anti-C5 mAb or C5aRA 
might be due to failure to completely abrogate local production of C5a or block 
C5aR at the tumour site.  
 
Despite multiple studies supporting a role for C5a in tumour progression, this is still 
controversial as C5a over-expression in tumour cells has also resulted in tumour 
regression in a mouse model of breast cancer (Kim, Martin et al. 2005). 
Translational research also supports a positive role for C5a in anti-tumour 
monoclonal antibody therapy (Allendorf, Yan et al. 2005; Li, Allendorf et al. 2007; 
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Fuenmayor, Perez-Vazquez et al. 2010). Hence the role for C5a in tumour 
progression remains controversial.  
 
It is also the case that the profoundly protective phenotype observed in C3-/- mice 
is unlikely to be mediated via C5a, as C3-/- mice are widely accepted to produce 
C5a. Even in the absence of complement generated C5 convertase, C5 can be 
cleaved into its active forms by a range of other proteolytic enzymes, such as 
thrombin and plasmin (Huber-Lang, Sarma et al. 2006; Borkowska, Suszynska et al. 
2014). With this in mind, it is unlikely that C5a is completely absent in C3-/- mice, 
further supporting the conclusion that C5a does not play a key role in the 
progression of AML in the model described herein.       
 
5.2.4: C3a has a role in AML progression  
 
C3aR-/- mice were used to explore the role of C3a-C3aR signalling on progression of 
AML. Somewhat surprisingly, AML progressed more rapidly in mice lacking a C3a 
receptor (Figure 4.25). This rapid progression of AML observed in C3aR-/- mice 
might suggest a role for C3a signalling in limiting disease progression; a finding 
somewhat at odds with the protective phenotype observed in C3-/- mice, in which 
C3a signalling would also be absent.  
 
A protective role for C3a could be explained by the fact that, in addition to its pro-
inflammatory role, C3a also has anti-inflammatory properties (Coulthard and 
Woodruff 2015). Thus, in the settings of both sepsis and an acute inflammatory 
response C3a can act in direct opposition to C5a (Hollmann, Mueller-Ortiz et al. 
2008; Wu, Brennan et al. 2013). It is therefore feasible that C3a could have a 
protective role in the setting of malignancy.  
 
This is challenged by other studies which have conversely demonstrated a role for 
C3a-C3aR signalling in promoting tumour growth (Guglietta, Chiavelli et al. 2016; 
Nabizadeh, Manthey et al. 2016). Using a B16 model of melanoma, C3aR-/- mice 
exhibited retarded tumour growth and treatment with a C3aR antagonist (C3aRA) 
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inhibited growth of established tumours (Nabizadeh, Manthey et al. 2016). C3aR 
deficiency/ inhibition affected tumour-infiltrating leukocyte populations leading to 
increased neutrophil and CD4+ T cell infiltration but reduced infiltration by 
macrophages (Nabizadeh, Manthey et al. 2016). Neutrophil depletion reversed the 
tumour inhibitory effects observed in C3aR-/- mice (Nabizadeh, Manthey et al. 
2016). C3aR deficiency/ inhibition also resulted in reduced tumour growth in murine 
models of BRAFV600E mutant melanoma, colon and breast cancer (Nabizadeh, 
Manthey et al. 2016). In the second study, using an APCmin/+ model of colorectal 
cancer, tumourigenesis resulted in an upregulation of C3aR on neutrophils which 
led to activation of the complement cascade and promoted tumour progression. 
Tumour suppression observed in APCmin/+/C3aR-/- mice, was mediated via a 
reduction in pro-tumorigenic neutrophils (Guglietta, Chiavelli et al. 2016). The fact 
that both of these studies found C3a’s role to be mediated via neutrophils might 
explain the disparate effects observed in the setting of leukaemia, where 
neutropenia is a key feature.   
 
Another possibility is that C3a does not actually impede the progression of AML but 
that the observed phenotype is the result of C3a signalling via receptors on the 
malignant cells. C3a levels are elevated in C3aR-/- mice, due to absence of the 
receptor. As C3a both activates a range of haematopoietic cells and enhances their 
survival (Strainic, Liu et al. 2008; Markiewski, DeAngelis et al. 2009), it might also 
bind to leukaemia cells, promoting their growth. The actions of C3a might also not 
be solely mediated through C3aR as C3a can also signal through the alternative C5a 
receptor C5aR2 (Boos, Campbell et al. 2004; Boos, Szalai et al. 2005). This theory 
has the advantage of also partially explaining the phenotype observed in C3-/- mice 
which are unable to produce C3a and would thus be unable to promote leukaemic 
growth.  
 
This could be further explored by assessing plasma C3a levels in tumour bearing WT 
and C3aR-/- mice, determining whether C3aR and/or C5aR2 are expressed on C1498 
cells in vitro and in vivo and exploring whether C3a influenced proliferation of 
C1498 in vitro. C3aR antagonists, C3aR-/- and C5aR2-/- mice could subsequently be 
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investigated in combination with C1498 cells, genetically modified to silence 
receptor expression, in order to test the hypothesis. This series of experiments 
could identify a novel mechanism by which complement promotes tumour growth.   
 
5.2.5: Complement-induced protection could be an in vivo phenomenon   
 
C6-/- mice, which are unable to form MAC, were used to investigate whether the 
presence of MAC affected the progression of AML. In the absence of MAC, mice 
were protected against the progression of C1498 AML (Figure 4.28). The presence 
of MAC resulted in a favourable environment for the progression of AML, thus 
supporting the hypothesis that sub-lytic MAC protects malignant cells against 
elimination by the immune system in vivo. The observed effect was however 
insufficient to explain the almost complete protection observed in C3-/- mice. 
 
The 90% reduction in C6 levels achieved by treatment with C6 antisense 
oligonucleotide did not result in any survival advantage. This is perhaps not 
surprising as this incomplete ablation might result in a sub-lytic level of MAC being 
produced in the tumour microenvironment. These data do not therefore weaken 
the case for complement-induced protection being an in vivo mechanism by which 
elimination of malignant cells is prevented. 
 
It is concerning that all statistically significant survival advantages observed in these 
studies are observed in genetically modified animals. Although this may be due to 
an inability of reagents to result in completely ablation at the tissue level it might 
also suggest that my findings are the result of inconsistencies with the genetically 
modified mouse model system. Whilst genetically modified mice are powerful tools 
they have significant limitations. Whilst mouse and human genomes are extremely 
similar, even small genetic disparities, in combination with subtle differences in 
function, can translate into major distinctions. Modification of a given gene does 
not always result in the predicted phenotype with outcome also being influenced by 
epigenetic and environmental factors (Tarantino, Sullivan et al. 2011). Unless 
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findings are extremely robust, results described in mice have proved extremely 
unlikely to translate into humans (Mak, Evaniew et al. 2014).  
 
It is perhaps more concerning that the protective effect observed in the C6-/- mice 
was not seen in mice treated with the anti-C5 mAb, who were also unable to form 
MAC. Despite no observed survival advantages I did note some profound 
differences in tumour location in the anti-C5 mAb treated mice which led me to 
explore the effect of complement on tumour distribution.     
 
5.2.6: Complement has a potential role in tumour distribution 
 
As studies performed in this thesis were not performed in order to explore an effect 
of complement on tumour distribution the observations made regarding this are 
provisional, but none-the less interesting. The observation that mice treated with 
anti-C5 mAb had an extremely high incidence (75%) of peripheral tumours led me to 
review tumour distribution across my studies.  This led me to observe that mice 
lacking MAC, either due to genetic knock-out (C6-/-) or administration of anti-C5 
mAb developed fewer central (liver, ovary) tumours but more peripheral (limbs or 
back) tumours. Central sites were generally the earliest sites of disease progression 
with mice developing peripheral tumours at a later stage. Complement is primarily 
produced in the liver, meaning there could be a gradient of complement activation.  
The absence of MAC might thus facilitate the clearance of tumours from central 
sites but fail to have an effect at peripheral sites where complement might have a 
less active role. Peripheral tumours might only be unusual in WT mice as AML 
progression in the livers and ovaries leads them to be killed before peripheral 
tumours become detectable.  
 
It was also noted that no WT mice treated with C5aRA developed peripheral 
tumours. C5aRA treated mice had a similar frequency of central tumours however, 
those that failed to develop early lesions, did not go on to develop peripheral 
tumours and became long-term survivors. Power calculations suggest that this 
finding may be statistically significant if additional mice (approx. 10) were analysed.  
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It is notable that blocking the C5aR appears to results in less peripheral tumours 
whereas preventing production of C5a results in far more. The key difference 
between mice unable to produce C5a and those treated with the C5aRA would be 
their plasma levels of C5a, leading me to postulate that the phenotype could be the 
result of C5a signalling via an alternative receptor.   
 
Whilst the vast majority of the effects of C5a are thought to mediated through 
C5aR, a second C5a receptor, C5aR2, exists, the role of which is rather contentious. 
Whilst previously discounted as being just a ‘decoy’ receptor, other studies have 
suggested that C5aR2 has a functional role in sepsis (Rittirsch, Flierl et al. 2008) and 
in inflammation (Huber-Lang, Sarma et al. 2005). The reduction in peripheral 
tumours observed in C5aRA treated mice could thus not be due to the absence of 
signalling via the C5aR but to an increased level of signalling via C5aR2.  
 
These observations, though interesting, are provisional and additional experiments 
designed to look at tumour distribution, are required in order to further investigate 
my findings. This might lead to further studies such as whether plasma C5a levels 
correlate with tumour distribution, if signalling via C5aR2 affects tumour 
distribution and whether C5aR and C5aR2 are expressed by various murine tissue 
types along with the C1498 AML cells themselves.  
 
5.3 Implications to AML patients 
 
The restriction of my findings to genetically modified animals, whether due to 
incomplete efficacy of the therapeutic agents explored or limitations in the genetic 
models used, has implications on the potential for complement therapeutics to 
impact on human disease.  
 
A major limitation of the mouse studies is the lack of a C3-specific inhibitor which 
would clearly be extremely useful for the studies described herein. Such an 
inhibitor, namely Compstatin, is however available for targeting of human C3. 
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Compstatin is a cyclic peptide which functions by binding C3 and interfering with C3 
cleavage (Mastellos, Yancopoulou et al. 2015). By targeting C3, the hub of the 
complement cascade, this offers a more encouraging method of manipulating 
complement in the human disease setting and has shown promise in a range of 
immune and inflammatory disorders (Ricklin and Lambris 2013). Compstatin has 
demonstrated unparalleled efficacy at improving survival and preventing end organ 
damage in a model of severe sepsis, even when administered at a late stage (Silasi-
Mansat, Zhu et al. 2010). Compstatin analogues have also proved effective in 
haemodialysis- induced inflammation (Reis, DeAngelis et al. 2015).  
 
The anti-C5 monoclonal antibody Eculizumab limits acute graft rejection and 
prolongs graft survival and function in a proportion of renal and pancreatic 
transplant recipients (Biglarnia, Nilsson et al. 2011; Stegall, Diwan et al. 2011). 
Compstatin is currently under investigation in this setting in an attempt to achieve 
more consistent responses (Mastellos, Yancopoulou et al. 2015). Eculizumab is also 
used in the clinical management of paroxysmal nocturnal haemoglobinuria (PNH) in 
order to prevent complement-dependent intravascular haemolysis (Hillmen, Young 
et al. 2006). Responses are however variable due to amplification of C3 activation 
and persistent opsonisation of erythroctyes resulting in C3-mediated extravascular 
haemolysis in some patients (Hill, Rother et al. 2010; Risitano, Notaro et al. 2010). 
The strong therapeutic potential of direct C3 inhibition in PNH has been endorsed 
by both the EMA and US FDA recently granting orphan drug designation to the 
Compstatin derivative AMY-101 (Mastellos, Yancopoulou et al. 2015).     
 
The complement system remains largely unstudied in the context of human AML. 
Historic studies demonstrated that complement was upregulated in active disease 
(Minh, Czink et al. 1983). Interestingly, high CD11b expression predicts poor 
prognosis in human AML (reviewed in (Xu, Li et al. 2015)) suggesting that the role of 
complement in tumour cell adhesion could be relevant to patients with AML. More 
recently, C3f-desArg has been identified as having a potential role in the AML 
diagnosis and MRD assessment (Liang, Wang et al. 2010). C3f derivatives have also 
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been identified in other forms of cancer (Villanueva, Martorella et al. 2006; 
Profumo, Mangerini et al. 2013).  
 
C3f is formed when C3b is converted into iC3b by fI and fH and is rapidly degraded 
into C3fdesArg (Liang, Wang et al. 2010) (Figure 5.1). FH has a significant role in a 
range of malignancies (Junnikkala, Jokiranta et al. 2000; Raitanen, Marttila et al. 
2001; Junnikkala, Hakulinen et al. 2002; Ajona, Castano et al. 2004; Wilczek, Rzepko 
et al. 2008). 
 
Provisional transcriptome analyses of human myeloid blasts carried out in 
conjunction with our AML research group, identified complement dysregulation as 
being key to poor outcome in AML (Dr S. Coles, unpublished data). Further analysis, 
undertaken by myself and Dr Coles, revealed high expression of fH to be associated 
with poor prognosis (Figure 5.2). This finding was confirmed using a German AML 
diagnostic dataset available online (Metzeler, Hummel et al. 2008). FH was also 
identified as one of the most discriminatory genes by an independent group who 
defined a prognostic gene signature in AML (Bullinger, Dohner et al. 2008).  
 
234 
 
- High levels poor prognosis in AML
- Non small cell lung, colon and ovarian cancer
- Increased in acute leukaemia
- Potential new MRD marker
- C3f also↑ in bladder, prostate, 
thyroid and breast cancer 
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Figure 5.1: C3fdesArg and fH in cancer. C3b inactivation by fI and fH results in the 
release of C3f which is rapidly degraded into C3fdesArg. C3fdesArg has been 
identified as a potential new MRD marker in AML and is also elevated in a range of 
other malignancies. FH expression is also dysregulated in AML a finding also 
described in several other cancer types.  
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Figure 5.2:  AML patient survival with respect to FH gene expression levels. Patient 
survival analysed with respect to FH gene expression levels > or < median.  Kaplan 
Meier survival curve; P = 000041 (Log-rank (Mantel-cox) test), n= 131. 
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Figure 5.3: Dysregulation of Factor H levels in plasma from patients with AML.   A. 
Provisional data reveals a trend for higher FH levels in plasma samples taken from 
AML patients at diagnosis conferring a worse prognosis (Kaplan Meier survival 
curve; P = 0.2914 (non-significant) (Log-rank (Mantel-cox) test), n = 42. B. Further 
analysis revealed that FH dysregulation rather than high or low level had a 
significant effect on survival. Patients with plasma FH levels in either the upper or 
lower quartile appear to have significantly worse survival than that observed in 
patients with a FH level within the inter-quartile range at diagnosis. Kaplan Meier 
survival curve; P = 00159 (Log-rank (Mantel-cox) test), n = 42.  
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Over the course of my studies, a bank of >1000 plasma and bone marrow 
supernatant samples from AML patients taken at diagnosis and post-treatment has 
been generated. Multiplexed complement protein ELISAs have been developed in 
our laboratory but were unavailable for use before the end of my studies. 
Provisional results generated using ELISAs to measure levels of fH, iC3b and TCC in 
diagnostic plasma samples from patients with AML support the microarray findings 
of high fH expression being associated with poor prognosis although larger numbers 
of samples need testing in order to determine whether these findings are significant 
(Figure 5.3). Interestingly provisional data suggest that fH dysregulation rather than 
simply a high or low level might be critical to outcome. Patients with plasma FH 
levels in either the upper or lower quartile have significantly worse survival than 
patients where the FH level at diagnosis lies within the inter-quartile range. P= 
0.0159 n = 42 (Figure 5.3). This raises questions about the potential down-stream 
effects of FH expression as well as whether other factors, such as FH polymorphisms 
affecting function, might play a role.  The multiplexed complement protein ELISAs 
are now available and could be used to comprehensively interrogate patient 
complotype in AML. 
 
5.4: Concluding remarks 
 
In vivo studies using a C1498 murine model of AML have resulted in several exciting 
discoveries. I have discussed potential mechanisms that could underpin these 
findings including complement-induced protection, C3a mediated stimulation of 
tumour cells, iC3b mediated tumour seeding and migration and C5a mediated 
metastasis.  
 
Immune therapies are already widely used in the treatment of AML, with novel 
agents constantly being investigated and developed for use. If complement has a 
role in the progression of AML, then complement-targeted therapeutics already 
available for use in humans, may not only have an independent role in improving 
spontaneous immune responses to leukaemia, but may also impact on all therapies 
aimed at controlling AML via immune mediated mechanisms.    
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